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1.1. Gene expression in eukaryotes
Since the first discovery over 70 years ago that DNA is capable of transferring genetic information
between different strains of bacteria (Avery et al. 1944), DNA has been regarded as one of the most
important molecules in cells. Despite the identical genomic information in practically all its cells, an
organism is composed of multiple different cell types and tissues with diverse functions. The difference
between cell types arise from the differences in gene expression between them (Moore et al. 2013).
There are several layers acting in concert to control the expression of genes, which act in concert despite
the difference in their functional mechanism.
One layer of gene expression control lies within the chemical modifications deposited on the
nucleosome, the basic organizational unit of DNA, composed of the DNA wrapped around a protein
complex formed by dimers of four different histones (H2A, H2B, H3 and H4). These histones contain a N-
terminal that protrude from the nucleosome and can undergo a plethora of modifications such as
methylation, acetylation and phosphorylation. Histone modifications are associated with activation or
repression of the modified genomic regions. Thus, acetylation of the residue lysine 7 of H3 (H3K27ac)
promotes a more permissive chromatin state, which allows transcription to occur. Histone modifications
associated with active transcription are usually restricted to gene regulatory regions and active gene
bodies (Shogren-Knaak et al. 2006). On the other, hand regions of highly condensed chromatin
(heterochromatin) with suppressed transcription are often associated with trimethylation of lysine 27 of
H3 (H3K27me3), a histone modification deposited by Polycomb repressor complex 2 (PRC2) (Boyer et al.
2006, Pauler et al. 2009).
The enrichment of certain histone modification in the genome can be used to identify regions with
different condensation degrees. Euchromatin, which is less condensed and more permissive to gene
expression is enriched in H3K27me3, while heterochromatin, more condensed and where transcription is
repressed, is associated with higher levels of H3K9me3 (Becker et al. 2017). Some of the most
extensively studied histone modifications and their association with a gene transcriptional status are
summarized in Figure 1 (Iglesias-Platas et al. 2016).
The DNA can also be directly modified by addition of a methyl group at the 5’ position of cytosine
residues, which predominantly occurs at cytosine-guanine dinucleotides (CpG). DNA methylation is
associated with a higher condensation of chromatin and transcriptional repression, playing an important
role in processes such as gene imprinting and silencing of repetitive DNA sequences (Suzuki et al. 2008).
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Three different DNA methyl transferases (DNMTs) are responsible for the deposition and maintenance of
DNA methylation: DNMT1, DNMT3A and DNMT3B (Lyko 2018).
Transcription factors (TFs) are proteins capable of binding DNA in a sequence-specific manner. They
can bind to both proximal promoters of genes and more distal regulatory regions such as enhancers. TFs
act mainly by promoting the recruitment of the transcription initiation machinery to the promoter of
their target genes. In addition, these factors guide histone modifiers, which are complexes capable of
adding and removing modifications in histone residues and chromatin remodelling complexes, thereby
regulating target gene expression.
Many TFs are expressed in a tissue-specific manner and are key regulators in establishing tissue
identity. For example, T-cell acute lymphocytic leukemia protein 1 (Tal1) is a key hematopoietic TF
essential for the generation of hematopoietic precursors cells in the mouse (Robb et al. 1995). Sal-like 1
(Sall1) is another key regulator and depletion of this protein leads to mice born without kidneys or with
severe defects of these organs (Nishinakamura et al. 2005).
Deletion of Lung Kruppel-like factor (Lklf) in mice leads to major defects in lung development, not
affecting remaining organs formation (Wani et al. 1999). The vast majority of TFs act in combination with
other TFs and other regulators of transcription, such as the above mentioned histone modifiers. This
Figure 1- Histone modifications found at gene locus
Histone marks that are associated with a) active genes and enhancers and b) repressed genes (Iglesias-
Platas et al. 2016)
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mode of action allows TFs to have different roles depending on their interaction partners and the
chromatin status. Serum response factor (SRF), for example, is a ubiquitously expressed TF which
interaction with Nuclear factor of activated T-cells (NAFT) and Homocysteine-responsive endoplasmic
reticulum-resident (HERP1) is important for the proper differentiation of smooth muscle, while its
interaction with NK3 Homeobox 1 (NKX3-1) plays a role in proper differentiation and function of the
prostate (Doi et al. 2005, Gonzalez Bosc et al. 2005, Zhang et al. 2008).
1.1.1. Transcription initiation mechanism
One of the major processes regulating spatial and temporal gene expression is the recruitment of
RNA polymerase to the transcription start site (TSS) of genes and the subsequent gene transcription. In
eukaryotes, three distinct polymerases have been identified, each involved in the transcription of specific
classes of genes (Roeder et al. 1969). RNA polymerase I (Pol I) produces the vast majority of cellular RNAs,
which consist of ribosomal RNA (rRNA). Pol III specializes in the transcription of small RNAs like transfer
RNAs (tRNAs) and 5S rRNA. All messenger RNAs (mRNAs) and other non-coding RNAs (ncRNAs) are
transcribed by Pol II (Khatter et al. 2017).
Purified Pol II is capable of melting double-stranded DNA, transcribe it and proofreading the
synthesized RNA. However, this purified enzyme does not recognize promoter sequences nor does it
respond to regulatory signals. These additional functions are performed by general transcription factors
(GTFs) that associate with Pol II, namely TFIIA, TFIIB, TFIID, TFIIF, TFIIE and TFIIH. Together with Pol II, the
GTFs form the pre-initiation complex (PIC), which is assembled near a gene TSS (Cramer et al. 2000).
This assembly is a process that occurs in a stepwise manner, involving the recruiting of additional co-
activators, as depicted in Figure 2. Binding of the core promoter by TFIID comprises the first step in PIC
assembly (Orphanides et al. 1996). The core promoter consists of the minimal DNA sequence necessary
to specify basal transcription and can contain elements such as TATA-box, B recognition element (BRE),
initiator element (Inr) and downstream promoter element (DPE). TFIID, one of the GTFs, is composed of
the TATA-binding protein (TBP) and 14 TBP-associated factors (TAFs) and is able to identify and bind the
different elements present at the promoter. The TBP subunit recognizes and binds the TATA-box
sequence and is sufficient to drive expression from promoters that contain this sequence.
However, most metazoan promoters lack TATA-box and as such other elements are recognized by
different subunits of TFIID. TAF1 and TAF2 subunits bind Inr elements, while DPE are recognized by TAF6
and TAF9 (Burke et al. 1997, Chalkley et al. 1999). TFIIA and TFIIB interact specifically with TBP bound to
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DNA. TFIIA stabilizes the TBP-DNA interaction and protects it from negative regulators (Weideman et al.
1997). Apart from binding to BRE, TFIIB also promotes selective binding of Pol II to TFIID at the promoter
by interacting with Pol II and TBP (Leuther et al. 1996). Binding of Pol II and TFIIF to the assembled GTFs
stabilizes the whole complex. With Pol II bound to the promoter region, the DNA strand is guided to the
cleft of Pol II which results in recruitment of TFIIE by TFIIF, a crucial step for binding of TFIIH (Kornberg
2001). TFIIH is composed of 10 subunits, including a Pol II carboxyl-terminal domain (CTD) kinase-cyclin
pair (Kin28-Cyclin H) and two DNA helicases (xeroderma pigmentosum type B (XPB) and XPD) (Schultz et
al. 2000) that facilitate promotor melting, leading to transcription initiation (Douziech et al. 2000).
Although Pol II and GTFs complex assembly is sufficient for proper transcription initiation in vivo, this
complex fails to respond to activators bound at distal regulatory regions. This responsiveness is
conferred by a macromolecular complex termed Mediator. The Mediator complex integrates regulatory
signals from a single or multiple TFs bound to enhancers and transduces the information to Pol II and the
remaining GTFs.
Figure 2 – Schematic summary of PIC
Core elements are present at -35, -25 and +1 bp from TSS. PIC assembly near the TSS is initiated by
binding of TBP to the TATA box, which is then followed by step wise bind of TFIIB, Pol II/TFIIF, TFIIE and
TFIIH. PIC assembly can be initiated without a TATA box, by binding of TAFs from the TFIID to other
promoter elements. PIC assembly is stimulated by TFs bound to distal enhancer, which recruit different
coactivators, like Mediator, that in turn bridges TFs at enhancers and the general Pol II machinery.
(Krishnamurthy et al. 2009).
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With the advent of Cryogenic electron microscopy (cryo-EM), it became possible to generate atomic
models of complex structures. Using this method, it was possible to confirm the composition and
interactions between GTFS and Pol II that had been described in a series of previous studies (Hantsche et
al. 2017). Additionally, new aspects of the interactions were observed. Within the factors, mobile
domains were identified that adopt a specific location within the core Mediator. Essential regions for cell
viability were observed in fixed structures while non-essential, non-conserved regions were often mobile.
The position of TFIID at the promoter was determined to be located on the side of Pol II lobe and
protrusion, allowing contacts between this GTF and the downstream DNA, which explains the
contribution of TFIID in promoter recognition. TFIIH, a GTF not included in previous crystalized structures
of the PIC, was analysed by cryo-EM as well. Consistent with its role in DNA melting, it was shown to be
located on the downstream DNA.
1.1.2. Enhancers in gene activation
Enhancers were originally described as small sequences of DNA capable of driving target gene
expression regardless of distance and orientation. Additional features are characteristic of these
elements, such as an open state of the surrounding chromatin, the presence of TF binding motifs and
enrichment of bound co-activators (Bulger et al. 2011). With the development of genome-wide methods,
such as chromatin immunoprecipitation sequencing (ChIP-seq), these techniques have permitted a
systematic annotation and prediction of enhancers. They rely on the combination of multiple features,
such as accessible chromatin (as assessed by DNase hypersensitivity assay (DNase-seq)), the presence of
different histone marks such as H3K27ac, a higher ratio of H3K4me1 compared to H3K4me3, binding of
co-activators such as p300 and clustered binding of multiple TFs (assessed by Chip-seq) (Calo et al. 2013).
These methods have allowed the prediction of a high number of enhancers through the genome
(400,000 to ~1 million in human cells) (Shlyueva et al. 2014). Enhancer activity has been linked to
transcription from these elements by early reports (Tuan et al. 1992). More recently, conclusive evidence
has demonstrated the transcription of non-polyadenylated, non-coding transcripts originating from




1.2. The Mediator complex
Mediator was first discovered in the yeast S. cerevisiae in two independent studies. While the Young
laboratory was studying extragenic suppressors of a pol II CTD mutation (Thompson et al. 1993), the
Kornberg laboratory was identifying factors necessary for the response to activator proteins in a Pol II
and GTFs reconstituted system (Flanagan et al. 1991). Although these studies demonstrated that yeast
Mediator is essential for TF-dependent gene activation in vitro, there was no evidence for conservation
of the complex in other species. However, several activating cofactors that were described based on a
variety of functional assays were later identified as homologs of Mediator subunits.
The Positive cofactor complex (PC2), isolated in Hela cells as a complex capable of stimulating
transcription upon addition of synthetic activator GAL4-AH (Kretzschmar et al. 1994), was further
characterized in a later study and shown to consist of Mediator subunits (Malik et al. 2000). Likewise, the
TRAP complex (thyroid hormone receptor-associated proteins), described as a group of nuclear proteins
that associate with human thyroid hormone receptor alpha in the presence of thyroid hormone (Fondell
et al. 1996), was also identified as a Mediator related complex. Due to the different assays used to
identify these complexes, diverse nomenclatures were used to name the subunits of Mediator, such as
Med14, which is also known as TRAP170, ARC150 (Activator-recruited cofactor), CRSP2 (Cofactor
required for Sp1 transcriptional activation) in humans and as Rgr1 in S. cerevisiae. A common
nomenclature was created in 2004 in order to facilitate communication between researchers and to
unify description of homologous proteins between different species (Bourbon et al. 2004).
Mediator is a highly conserved structure, present in all eukaryotes. Despite the conservation in
structure and general function of Mediator, the conservation of the individual subunits between species
is poor. Similarity in subunit sequence between human and yeast ranges between 12-42%, while eight
subunits are not present in yeast (Poss et al. 2013). The divergence observed for orthologous subunits
can be explained by the computational prediction of at least one intrinsically disordered region (IDR) in
over 70% of the yeast and human subunits. These IDR evolve more rapidly than structured sequences
and contribute to Mediator interaction with a vast number of TFs and to its intrinsic flexibility (Toth-
Petroczy et al. 2008).
In yeast, Mediator contains 25 subunits (30 in mammals) that are organized in four different modules,
designated as head, middle, tail and kinase modules (Tsai et al. 2013, Tsai et al. 2014). One of the first
applications of mass spectrometry (MS) in the study of Mediator revealed two stable forms in yeast. The
smaller one, which consists of a 21 subunit complex (26 in mammals) composed by the head, middle and
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tail modules, is called the core Mediator (matching the PC2 complex previously identified). The larger
form (previously characterized as the TRAP complex) is constituted of 25 subunits (29 in mammals),
including the kinase module in addition to the core Mediator (Liu et al. 2001). Early immunoprecipitation
and fractionation studies indicated that MED26 (CRSP70), part of the core Mediator, dissociates the
complex upon kinase module binding (Taatjes et al. 2002). However, more recent evidence obtained
using MS-based multidimensional protein identification technology (MudPIT) suggests that a smaller
fraction of Mediator contains both MED26 and the kinase module (Sato et al. 2004).
Due to the large size of the whole complex most structural studies on Mediator relied on portions of
the complex. However, developments in cryo-EM allowed the analysis of the complete Mediator-PIC
complex (Robinson et al. 2016). This work allowed to complement the structures previously described, to
position the Mediator in relation to the PIC complex and to determine the position of the tail module,
which had so far only been predicted (Figure 3). Chemical cross-linking applied to Mediator-PIC complex
revealed 71 cross-links between the two complexes. As demonstrated by the surface map, the













Figure 3 - Cryo-EM Structure of the Mediator-PIC Complex
Surface representation of Mediator-PIC cryo-EM data. Adapted from (Robinson et al. 2016)
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1.2.1. Functions of the Mediator complex
The structure of Mediator reflects a functional organization. The head and middle modules are
necessary for Mediator function in regulating transcription. When these two modules are complemented
with MED14, they reconstituted a functional basal Mediator in vitro. On the other hand, tail and kinase
modules interact with TFs, which allow Mediator to be responsive to regulatory signals (Cevher et al.
2014).To regulate transcription, Mediator is recruited to enhancers in metazoans and to upstream
activating sequences (UAS) in yeasts via specific TFs. Following recruitment, Mediator can then
coordinate PIC assembly at promoters (Figure 4a), an observation supported by different in vitro studies
(Ebmeier et al. 2010, Lin et al. 2011, Chen et al. 2012). Chromatin immunoprecipitation sequencing
(ChIP-seq) data for diverse Mediator subunits revealed that Mediator occupies predominantly enhancers,
with a low occupancy at promotors (Andrau et al. 2006). Depletion of Kin28, the TFIIH subunit
responsible for phosphorylation of Pol II CTD, results in a promoter escape defect. This results in an
arrest of Pol II at the promoter. When Kin28 was depleted, it was observed that Mediator stabilized at
promoters, confirming that the complex indeed associates with promoters in vivo (Jeronimo et al. 2014).
These data reveal that, despite its important role on PIC assembly, Mediator occupancy at promoters is
transient.
A recent study by the Roeder laboratory has shown that in yeast, Mediator is recruited to UAS with all
Mediator modules detected at these elements (Petrenko et al. 2016). At promoters, however, no kinase
module could be detected, even in Kin28-depleted mutants where Mediator stabilization at promoters
was observed (Jeronimo et al. 2014). The lack of kinase module at promoters is consistent with a
previous model in which the kinase module sterically blocks Mediator interaction with Pol II (Elmlund et
al. 2006). These observations suggest that Mediator undergoes a conformational change during
transcription activation, ejecting the kinase module upon PIC integration, which in turn allows
interaction between Pol II and Mediator (Figure 4b). In contrast, mouse cell ChIP-seq data for Med12
subunit, which is part of the kinase module, obtained from provided evidence that the kinase module
can be found at promoters, although at lower levels than at enhancers (Kagey et al. 2010). Sequential
ChIP experiments have demonstrated that a single Mediator complex connects UAS and core promoters.
This observation links Mediator to DNA looping, a process that brings enhancers and promoters to close
proximity (Reavey et al. 2015). This hypothesis is corroborated by observation of interactions between
Mediator and cohesin in murine embryonic stem cells (mESCs), using co-immunoprecipitation assays.
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Figure 4 - Conformational change of Mediator during transcription activation
a) Activator proteins (Act) bound to enhancers recruit Mediator through interactions with its subunits.
Most of subunits capable of interacting with TFs reside in the tail module. The recruited Mediator
contains the kinase module. b) TFs recruit the GTFs and Pol II to the core promoter, which also includes
the protein Kin28 of the TFIIH. This recruitment leads to the dissociation of the kinase module and
interaction between the head Module and Pol II (blue line indicates CTD of Pol II). Conformational
Change of Mediator leads to the PIC formation and consequent transcription initiation. c)
Phosphorylation of Pol II CTD (red line) by Kin28 leads to dissociation of Mediator, promoter escape from
Pol II and to transcription initiation (Petrenko et al. 2016).
Additionally, ChIP-seq data for Mediator and cohesin revealed both complexes bound at enhancers
and promoters of a variety of active genes. DNA looping between enhancer and promoter of these co-
bound genes was further characterized using chromosome conformation capture (3C), which reveals
interaction frequency between genomic regions. Upon Med12 or Structural maintenance of
chromosomes 1a (Smc1a) depletion, there was a decreased frequency of the interactions between
promotor and enhancer of genes bound by these two proteins, further supporting the role of Mediator
in DNA looping (Kagey et al. 2010).
In order to assess the impact of the kinase module on Mediator occupancy at enhancers and
promoters, Med13-depleted mutants were used for ChIP-seq analysis. These mutants assembled the
Mediator complex without the kinase module (Jeronimo et al. 2016). ChIP-seq data for Med15 (tail) and
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Med7 (middle), obtained from Kin28/Med13-depleted mutants, revealed that, although the middle and
tail module occupancy at promoters was only slightly affected, their occupancy at UAS drastically
increased. These observations support a model were kinase module antagonizes Mediator-UAS
interaction.
Additionally, Cyclin-dependent kinase 8 (Cdk8), the kinase subunit of the kinase module, is capable of
phosphorylating several TFs which often results in their degradation. This degradation further supports
the mentioned model, since - by degrading TFs - the kinase module prevents these factors from
recruiting Mediator to the enhancer of their target genes (Fryer et al. 2004, Poss et al. 2016).
Tailless Mediator, generated in yeast by Med15 and Med3 deletions, was depleted from UAS.
Depletion of Mediator from UAS in these mutants supports the hypothesis of TFs recruiting Mediator
through interactions with subunits of the tail module. On the other hand, in metazoans, several TFs
recruit Mediator through the interaction with modules other than the tail (Ito et al. 1999, Zhou et al.
2006). Although no Mediator was found above background levels at promoters in tailless yeast mutants,
cells were viable and showed only minor gene expression defects. Depletion of Kin28 in Med15/Med3
mutants revealed a smaller occupancy of promoters by Mediator.
These results led to the conclusion that Mediator is capable of binding promoters without being first
recruited to UAS, contrary to the previous model in which Mediator first had to be recruited to UAS. It
also revealed that Mediator’s essential function is to act on promoters by contributing to PIC assembly,
since expression profile was only slightly affected although no Mediator was present at UAS, (Jeronimo
et al. 2016). This function is further supported by the observation of several contacts between Mediator
and PIC components, such as RNA Pol II, TFIIB, TFIIE, TFIIF and TFIIH (Plaschka et al. 2015).
Thus, the Mediator complex plays an important role in PIC assembly, with additional functions in
other steps throughout gene transcription. In order for transcription to initiate, the PIC complex must be
disrupted, a process known as promoter escape. Despite multiple contacts between Pol II and Mediator,
it is the CTD-Mediator interaction that allows the entry of Mediator into the PIC complex, with the
affinity for the other contacts at least two orders of magnitude lower. The importance of this specific
insertion was confirmed by the lack of detectable affinity by Mediator for Pol II without CTD. In yeast, a
seven residue sequence (heptad) is repeated 26 times in the CTD of Pol II (52 repeats in mammals).
Through contacts with TFIIH and the remaining GTFs, Mediator stabilizes TFIIH in the complex.
Additionally, Mediator, upon binding to PIC, creates a path that guides CTD to the TFIIK submodule. The
Kin28 kinase of TFIIK phosphorylates all heptads, disrupting Mediator-CTD contacts, which results in Pol
II release and promoter escape (Robinson et al. 2016).
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For several years, transcription initiation was considered the rate limiting step during transcription.
However, pausing of Pol II after transcription of 30-60 nucleotides was verified in multiple genes (Core et
al. 2008), revealing that for these genes, pause release was the limiting step. This phenomenon can
result from intrinsic factors, such as specific residues in the Pol II protein which mutation increase pause
rate, certain DNA sequences that cause an abrupt reduction of melting temperature, stabilizing RNA-
DNA duplexes, or even the transcribed RNA, which can fold into secondary structures that interfere with
elongation (Herbert et al. 2006, Kaplan et al. 2012, Hein et al. 2014). However, pausing can also be
induced by factors such as DRB-sensitivity-inducing factor (DSIF) and Negative elongation factor (NELF),
which - in a purified system - were sufficient to induce pausing of Pol II (Adelman et al. 2012). In order to
release Pol II, Positive transcription elongation factor b (P-TEFb) phosphorylates DSIF and NELF,
neutralizing their repressive effect. P-TEFb has been shown to be recruited in a CDK8-dependent manner,
inducing gene expression by releasing Pol II into active elongation (Donner et al. 2010). Additionally, by
interaction with Med26 and CDK9, P-TEFb induces expression of target genes in mESCs. In an in vitro
reconstituted system, purified Mediator complex was able to promote expression of genes where DSIF
induced Pol II pausing, even in the absence of P-TEFb. This revealed the possibility of Mediator not only
recruiting this factor to release Pol II pausing, but to act together with P-TEFb in its pausing release
function.
The Mediator complex has been described as a molecular bridge, transducing information from
activators at enhancer to Pol II and GTFs at promoter. More recently, Mediator has been associated with
a new class of enhancers, termed super enhancers (SE). While traditional enhancers typically span a few
hundred base pairs , SEs are clusters of enhancers, spanning up to 50 kb (Whyte et al. 2013). SEs share
many features with typical enhancers, including presence of Mediator and histones modifications, such
as H3K27ac and H3K4me, however, at much higher levels, typically over one order of magnitude. The
same increase was observed for other enhancer associated factors such as TFs, co-factors, chromatin
regulators, Pol II and eRNAS. The high levels of these features are due not only to the size of the domains
but also to the higher density of the enhancers that constitute SEs. These super enhancers are typically
in control of key genes in cell-type-specific processes, such as most genes that control ESCs pluripotency.
Genes under the control of SEs are expressed at higher levels than genes under the control of typical
enhancers. However, SEs are more sensible to loss of co-activators, such as Mediator. Upon Mediator
depletion in ESCs, the genes more affected were the ones associated with SEs, revealing the critical role
of the complex in these clusters. TFs usually contain at least one of each of two different domains: a
DNA-binding domain (DBD) and an activation domain (AD). Although a deep understanding of structure
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and function has been documented for DBDs, ADs are less well understood. These domains contain
intrinsically disordered regions (IDRs), which make their structural characterization difficult. The low
complexity of ADs contributes to the recent observation that GNC4, a yeast master TF, binds to Med15 at
multiple sites and in different conformations (Tuttle et al. 2018). The current “lock and key” model,
according to which two proteins bind in defined complementary conformations, does not explain this
kind of “fuzzy” complexes. Additionally, several observations regarding TFs are not explained by the “lock
and key” model: hundreds of TFs with different ADs interact with a small subsets of coactivators, such as
Mediator. Furthermore, ADs are interchangeable between different TFs and with the IDR present in most
coactivators. Another model consolidating all of these observations was recently suggested (Hnisz et al.
2017). According to this model, transcriptional regulation is impelled by phase-separated condensates
that allow a compartmentalization and concentration of the transcriptional machinery and regulators.
This physical separation explains the high density of molecules detected in SEs, which is further
supported by the observation that enhancer elements within these clusters are in close spatial proximity
with the other enhancers and with the regulated promoters. In eukaryotic cells, membraneless
organelles, such as nucleoli and Cajal bodies, allow concentration of essential reactions through
formation of such phase separated droplets.
This model was recently corroborated by the observation that IRDs of both MED1 and Bromodomain-
containing protein 4 (BRD4) were capable of generating phase separated droplets in an in vitro assay,
which were able to concentrate the transcriptional machinery in a nuclear extract (Sabari et al. 2018).
Another study by the same group revealed that MED1 and MED15 were able to generate phase
separated droplets in vitro (Boija et al. 2018). Additionally, when MED1 was combined with several
known interactors (e.g. NANOG, GATA binding protein 2 (GATA2), SRY-box 2 (SOX2)), the TFs were found
concentrated together with the subunits, despite the capacity of these TFs to form droplets on their own.
Furthermore, residues required for target gene activation for Octamer-binding transcription factor 4
(OCT4) and GCN4 were also required for phase separation with Mediator. These studies demonstrated
that Mediator not only plays an important role in phase separation, but also that this separation is
important for the proper regulation of transcription.
Several TFs have been shown to interact with Mediator and a recent study has increased the binding
repertoire of Mediator by discovering a class of ncRNAs that interact with the complex. While studying
the function of ncRNAs-activating (ncRNA-a), the Shiekhattar laboratory developed a luciferase reporter
assay to analyse the transcriptional control of the genes analysed. Of the tested factors with known
activator or enhancer functions, only Mediator subunits decreased the reporter signal when depleted
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(Lai et al. 2013). Depletion of Mediator subunits in human embryonic kidney 293 cells (HEK293) resulted
in a decreased expression in a subset of the ncRNAs-a and in all of their targets genes. Mediator and Pol
II were detected at the promoter of ncRNAs-a target genes, with a loss of occupancy observed upon
Mediator subunit or ncRNAs-a depletion. By fractionation of affinity-purified Mediator and UV-crosslink
RNA Immunoprecipitation (UV-RIP) the authors could additionally detect a physical interaction between
ncRNAs-a and Mediator (Lai et al. 2013).
1.2.2. Mediator subunit functions
Mediator subunits can be classified into two groups: those that are required for the overall function
of the complex and those that interact with specific TFs and other transcriptional regulators. The first
group is required for the expression of all Pol II transcripts and includes, for instance, subunits with
important structural functions that maintain the structural integrity of the complex. The second group
consists of subunits that act as an interface through which transcription regulators are able to recruit
Mediator to their target genes. Subunits of this group are involved in the transcription of a subset of
genes, namely those under the control of the TFs. One such example are nuclear receptors that interact
with Mediator through Med1. Depletion of this subunit in mouse fibroblasts resulted selective loss of a
subset of nuclear receptor dependent pathways (Chen et al. 2007).
Loss of structural integrity of Mediator results in an impairment of Mediator function. This effect was
observed for several subunits with important structural roles, such as Med17 and Med14. When Med17
(srb4) was depleted in yeast, the head and kinase modules dissociated, ceasing all Pol II transcription
(Linder et al. 2006). Depletion of the Drosophila homolog of Med17 (dTRAP80) resulted in a similar effect
(Boube et al. 2000). In a study where head or middle subunits from yeast Mediator were expressed in
bacteria, the subunits assembled into the respective modules. However, when both modules were
purified and combined, they did not form a bimodular complex and as such were not capable of
stimulating basal transcription in an in vitro assay (Cevher et al. 2014). Only upon addition of Med14 the
two modules were able to associate and strongly induce basal transcription. These data, together with
the observation that deletion of the C-terminus of Med14 leads to a loss of the tail module from the
Mediator complex (Li et al. 1995), highlight the essential role of Med14 in Mediator structure .
Different studies showed that of the 25 subunits in yeast, 10 are essential for cell viability (Med4,
Med6, Med7, Med8, Med10, Med11, Med14, Med17, Med21 and Med22) and depletion of each tested
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subunit in mice resulted in embryonic lethality (Soutourina 2018). Besides the Mediator subunits’
essential role for embryonic development, specific functions of subunits have been identified.
Through Med23, Mediator is recruited to a subset of genes under the control of ELK1. Deletion of this
subunit in mouse embryonic fibroblasts (MEFs) prevents adipogenesis in culture, suggesting Med23 as an
endpoint of the insulin signalling pathway (Wang et al. 2009). Mediator isolated from Med1 (Trap220)
KO MEFs was stable and transcriptionally active, revealing that Med1 is not essential for the complex
integrity. This subunit is the interface through which Mediator is recruited by different nuclear receptors
and its depletion in MEFS affected nuclear receptor-dependent gene expression. The Roeder laboratory
concluded that this was a Med1 specific effect and not a general Mediator defect, since expression
mediated by p53 and VP16, which recruit Mediator through Med25, was not affected (Ito et al. 2000,
Vojnic et al. 2011, Lee et al. 2018).
A subunit of Mediator complex can contain binding sites for different transcriptional regulators, as in
vitro studies in yeast have demonstrated. VP16 and Gal4 bind Med15 (Gall11) and while both bind the
same region in this subunit, Gal4 is capable of binding to an additional site. Med15 mutants lacking these
binding regions showed no interaction with the mentioned activators, which affected expression of VP16
and Gal4 target genes (Park et al. 2000). Although certain TFs bind to a specific subunit like mentioned
above, others can interact with multiple subunits. One example of the latter is RE1 Silence TF (REST), a
key TF in neuronal gene repression in non-neuronal cells, which recruits repressors such as G9a histone
methyl transferase to its target genes. Co-immunoprecipitations assays in human cells revealed
independent interactions between REST and two different Mediator subunits: Med9 and Med26 (Ding et
al. 2009). While depletion of either subunit with small interfering RNA (siRNA) did not affect REST-
Mediator association, a double depletion did. Quantification of REST repressed genes expression in HeLa
cells revealed that only upon depletion of both subunits was the repressive effect disrupted. These data
suggest a synergetic effect of both subunits in modulating REST repression.
Another cooperative effect, between Med15 and Med16, during heat shock response in yeast has
been observed (Kim et al. 2013). When yeasts were subjected to above optimal temperatures, different
heat shock genes (HSG) started to be expressed. Expression of these genes was induced by Hsf1
recruitment of Mediator to the promoter of HSG. Deletion of either Med15 or Med16 decreases
recruitment of Mediator while a double deletion completely prevents it.
Introduction
25
1.2.3. The Kinase module
The kinase module is reversibly coupled to Mediator and it is its presence that distinguishes the two
main stable forms of Mediator. In yeast, the kinase module is composed of 4 subunits: Med13, Med12,
Cdk8 and Cyclin C (CycC). In vertebrates, due to duplication events, three of the subunits acquired
paralog pairs, namely Med13-like (Med13L), Med12L and Cdk19. The kinase module is always composed
of 4 subunits, including CycC and one paralog of each pair. By expressing and capturing kinase subunits
with a HaloTag in human cells followed by MS, it was possible to determine the composition of the
kinase module and its interaction with the core Mediator (Daniels et al. 2013). It was observed that
paralogs were mutually exclusive, but would interact with any of the other pairs, which allows for up to 8
different kinase module compositions. As mentioned before, while in yeast the Med26 subunit is not
found in Mediator with kinase module, in vertebrates, a small fraction of Mediator contains both kinase
and Med26. Interestingly, the inclusion of Med26 was only observed when Med13L was present in the
kinase module. The small fraction of Mediator-kinase-Med26 complexes observed in vertebrates arises
from the Med13L subunit present in these. This observation correlates with the lack of such complexes
in yeast, since no Med13L homolog exists.
Multiple studies led to the initial characterization of the kinase module as a negative regulator of
Mediator functions. It was observed that only upon dislocation of the kinase module Mediator was able
to interact with Pol II (Elmlund et al. 2006). Additionally, the kinase module subunit Cdk8 phosphorylates
several substrates, including Cyclin H, part of TFIIH, preventing transcription activation (Akoulitchev et al.
2000). Cdk8 also phosphorylates a variety of TFs, targeting them to degradation and preventing their
target genes induction (Fryer et al. 2004). In fruit flies, Med12 (kohtalo) and Med13 (skuld) suppress a
subset of Hedgehog target genes, which are important for normal differentiation in the eye (Janody et al.
2003), while in C. elegans both play a role in the repression of Wnt target genes involved in asymmetric
cell division (Yoda et al. 2005).Med12 (dpy-22) is additionally involved in the repression of Ras target
genes, which play a crucial role during vulval fate specification in C. elegans (Moghal et al. 2003).
However, more recent studies revealed the involvement of kinase module in transcription activation.
In mESC, Cdk8 phosphorylates receptor-activated Smads, which leads to recruitment of Yes associated
protein 1 (YAP). Recruitment of YAP results in expression of canonical Bone morphogenetic protein (BMP)
pathway genes involved in repression of neuronal differentiation (Alarcon et al. 2009). More evidence on
the activating role of the kinase module comes from the Drosophila TF Pygopus, which recruits Mediator
through interactions with Med12 and Med13, activating Wnt targets (Carrera et al. 2008). Using a
genome-wide RNA interference (RNAi) screen, it was observed that Med12 and Med13 act as co-
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activators of the TFs RUNX and GATA during crystal cell differentiation in Drosophila blood cells. This TF
activation is independent of Cdk8 and CycC, although all four subunits are involved in the emergence and
proliferation of this cell lineage (Gobert et al. 2010).
As mentioned before, the kinase module is able to dissociate from Mediator. A study from the group
of Dylan Taatjes provided evidences that the kinase module exists as a stable and active complex in
human cells and performs regulatory functions independent of Mediator (Knuesel et al. 2009). The stable
kinase module was isolated from Hela nuclear extracts and confirmed by MS to be constituted by all
expected four subunits without representation of core subunits. Recombinant expression of kinase
subunits assembled in a complex with a 1:1:1:1 stoichiometry. Cdk8, as part of this recombinant kinase
module, phosphorylated H3 in vitro in a histone octamer core. However, when DNA was wrapped
around the histone core CDK8 was not able to modify H3. Only upon kinase association with the core,
Mediator did Cdk8 phosphorylate H3 in the chromatin context. These data confirmed that the kinase
module can have functions independent of Mediator, but that the Mediator complex modulates its
activity. It could additionally be shown that Med12, but not Med13, is important for Cdk8 activity. This
fact was evidenced by the lack of activity when the kinase module was assembled without Med12, while
a kinase module lacking Med13 showed kinase activity comparable to the four subunit complex (Knuesel
et al. 2009). This role of Med12 is not observed in yeast since the Cdk8/CycC pair maintains its activity
independently of both Med12 and Med13 (Myer et al. 1998).
1.2.4. The MED12 subunit
MED12 is one of the most interesting subunits of Mediator, being the one of the largest subunits and
the only one described as a genetic hub due to its role in a variety of cell regulatory processes (Lehner et
al. 2006). In all mammals, the MED12 gene is located on the X chromosome and contains 45 exons
spanning over 25 kb and coding for a protein of around 230 kDa (Knuesel et al. 2009). Although
expressed in all tissues, expression levels are tissue and age-dependent, reaching a peak at embryonic
day 7 (E7.0) in mice and decreasing until birth to low but stable levels (Philibert et al. 1999). The role of
MED12 in the overall function of Mediator has not been widely investigated, but a number of studies
have demonstrated several gene-specific roles for this subunit.
Its role in early mouse development was described for the first time in a study by the Schrewe
laboratory using embryos generated from mESCs, expressing either 5% of Med12 (Med12hypo) or
completely devoid of Med12 (Med12null ) (Rocha et al. 2010). The developmental defects observed in
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these embryos together with the analysis of target gene expression, allowed determining the essential
role of Med12 in both the canonical Wnt and Wnt/PCP (Planar cell polarity) pathways. While Med12null
embryos failed to complete gastrulation and to activate T, a direct Wnt/β-catenin target and died at E7.5.
The residual subunit in the Med12hypo allowed the activation of the early processes under Wnt control,
but not latter processes. Different phenotypes observed in the Med12hypo embryos, such as neural tube
closure, linked Med12 to the Wnt/PCP pathways. And in fact, loss of asymmetric distribution of Pricle1, a
key factor in PCP, was detected in neural plate cells in Med12hypo (Rocha et al. 2010).
In order to clarify MED12 function in general transcription control, the Boyer laboratory, using an in
vitro yeast two-hybrid screen, identified G9a as a binding partner of MED12 (Ding et al. 2008). G9a is a
histone methyl transferase which, together with REST, represses neuronal genes in terminal
differentiated non-neuronal cells by depositing repressive H3K9 mono- and demethylation. MED12 and
G9a co-immunoprecipitated in cellular extracts and serial immunoprecipitations revealed that, together
with REST, they form a trimeric complex in mammals. Depletion of MED12 by RNAi decreased G9a
expression and Mediator associated H3 methyl transferase activity, culminating in de-repression of REST
target genes. On the other hand, none of these effects was observed upon deletion of other subunits of
the Mediator complex, such as CDK8 or MED23. In addition, MED12 depletion did not affect expression
of REST or any of its corepressors, supporting a specific role for MED12 in G9a dependent REST targeted
repression. Med12 interaction with Sox10 in mouse glia cells was identified. Glia-specific deletion of
Med12 led to defects in glia terminal differentiation, since Sox10 failed to recruit Mediator to its target
genes and induce their expression (Vogl et al. 2013).
The same study also observed an interaction between Sox10 and Med12L. This paralog is poorly
characterized due to a lower expression than MED12 but also to a lack of available tools such as specific
anti-MED12L antibodies. Thus, Med12l and Sox10 interaction was not further investigated. In human
cells, MED12 binds GLI Family Zinc Finger 3 (GLI3), a target of Sonic Hedgehog (SHH) pathway and acts as
a repressor of GLI3 transactivation activity (Zhou et al. 2006). Another MED12 binding partner is β-
Catenin, the canonical Wnt signaling effector protein. This subunit is an essential interface for targeted
recruitment of the Mediator and thus for proper expression of β-catenin targets genes (Kim et al. 2006).
The interaction of GLI3 and β-Catenin with MED12 and their respective role in SHH and Wnt signaling
has been shown to be conserved in other organisms (Boube et al. 2000, Rocha et al. 2010).
Using zebrafish mutants, it was possible to observe a role for Med12 in several different
developmental processes. Med12 mutants showed defects in neuronal and endoderm development
including defects on formation of a subset of neuronal types, chondrogenesis, normal neural crest cell
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development, organogenesis of the liver, kidney and pancreas. Most of these defects can be explained
by the inability of TFs like Sox9, Sox32 and Foxa2 to induce expression of their target genes (Hong et al.
2005, Rau et al. 2006, Wang et al. 2006).
Hematopoietic-specific Med12 deletion in mice resulted in reduction of bone marrow and of
hematopoietic stem and progenitor cells (HSPC), which led to the animals death within four days after
deletion. Depletion of Med12 reduced H3K27ac in lineage specific enhancers, to which Med12 strongly
binds and their consequent de-activation (Aranda-Orgilles et al. 2016). Depletion of other kinase
subunits did not affect HSPC function. Furthermore, in these mutants all of the cellular Med12 was found
in association with Mediator, revealing a role for Med12 within the core Mediator that is independent of
the kinase module. In the same study, several phenotypes observed in murine cells were also observed
in human cells, suggesting a conserved Med12 function in hematopoiesis. This observation is in
agreement with a previous report where a single point missense mutation in zebrafish med12 resulted in
myelopoiesis and late hematopoiesis defects (Keightley et al. 2011). MED12 can function in Mediator
independently of the kinase module and new studies additionally support Mediator-independent
functions. A fraction of MED12 was found to reside in the cytosol in different human tumorous lines,
where it inhibits glycosylation of TGF-β2R (Huang et al. 2012). Upon MED12 depletion, TGF-β was
strongly activated conferring resistance to several anti-cancer drugs.
As described above, MED12 plays a crucial role in various processes and pathways and in fact, in a
study performed in C. elegans, where 65.000 pairs of genes were evaluated in their ability to genetically
interact, Med12 has been described as one of the six hub genes, due to its genetic link to multiple
different developmental pathways (Lehner et al. 2006). Several studies mentioned before support a
conservation of MED12 genetic hub activity in additional species.
1.2.5. MED12 in human pathologies
MED12 has been associated with different human pathologies including tumours. Mutations in
MED12 have also been associated with different X chromosome linked intellectual disability syndromes
(XLID), specifically Opitz-Kavegia (FG), Lujan-Fryns and Ohdo Maat-Kievit-Brunner (MKB) type (Risheg et
al. 2007, Schwartz et al. 2007, Vulto-van Silfhout et al. 2013). The mutations associated with FG (R961W
and G958E) and with Lujan syndromes (N1007S) are in close proximity, situated in exon 21 and 22 of
MED12, respectively. In turn, Ohdo mutations (G1148H, S1165P and H1729N) are more spread through
the gene, located in exons 24, 25 and 37. While there are defects common in all of these syndromes,
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such as intellectual disability, neonatal hypotonia and craniofacial defects (including prominent forehead,
down slanting palpebral, high narrow palate and micrognathia), others are more specific. Agenesis of the
corpus callosum is found in FG and Lujan syndromes, anal defects are present in the FG patients,
hypernasal voice is a characteristic of Lujan syndrome and blepharophimosis arises from Ohdo mutations.
Although the etiology of these syndromes is known, there is a lack of information regarding their
pathogenesis. However, recent studies have highlighted the impact of these mutations in the normal
function of MED12. MED12 missense mutations associated with FG and Lujan syndromes do not disrupt
its interaction with G9a but prevent REST repression rescue in a reporter assay. These data, together
with the observation that these mutants support β-catenin transactivation, suggest that the mutations
described specifically disrupt MED12-REST corepressor function (Ding et al. 2008). Another study
demonstrated that FG and Lujan mutations disrupt MED12 mediated repression of GLI3-dependent SHH
(Zhou et al. 2012). These mutations resulted in a disruption of CDK8 recruitment through Mediator to
GLI3 target genes promoters, leading to their over activation in response to SHH signalling.
Whole genome analyses have identified mutations on MED12 with a low frequency in colorectal,
breast and ovarian carcinomas (<1%). A more pronounced frequency was found in hormone-associated
cancers, such as prostate cancer and adrenocortical carcinoma, with 5% of analysed tumours containing
MED12 mutations (Barbieri et al. 2012, Assie et al. 2014) and up to 7% in uterine leiomyosarcomas and
chronic lymphocytic leukemia (Kampjarvi et al. 2012, Wu et al. 2017).
Strikingly, mutations in exon 2 were found in 70% of the studied benign uterine leiomyomas
(Makinen et al. 2011) and in almost 60% of benign breast fibroadenoma (Lim et al. 2014). Interestingly,
all of the found mutations were in frame, with the vast majority consisting of missense mutations. This
observation supports Med12 as an essential protein, since the lack of frameshift mutations is very likely
due to the embryonic lethality caused by this type of mutations.
Additionally, Mediator has been implied in activation of ncRNAs target genes and, although it could
be shown that Mediator and ncRNAs-a interact, the subunits involved in this interaction were not
identified. FG associated mutations did not affect MED12 association with Mediator, however, through
UV-RNA Immunoprecipitation (UV-RIP) data, a decreased interaction between Mediator and ncRNA-a
was observed. Therefore, MED12 has been suggested as the main interface between the Mediator




Despite the known existence of genes that generate functional RNAs without the need to be
translated into proteins, such as the classical tRNAs and rRNAs, for several years most of the genome had
been considered as “junk DNA” without any functional role. However, the completion of the Human
Genome Project revealed that only 2% of the genome encode for proteins, revealing that the vast
majority of the genome was not translated into proteins.
With the development of next generation sequencing and gene prediction algorithms, it was shown
that more than 70% of the genome can be transcribed into RNA, with estimates that up to 93% of the
genome can be transcribed (Djebali et al. 2012). In fact, the number of ncRNA genes exceeds the number
of protein coding genes. However, despite the evidence that these genes are transcribed, for the vast
majority their function is still unknown.
Genes described as ncRNAs can be classified by their length as small ncRNAs (sncRNAs) or long
ncRNAs (lncRNAs), based on an arbitrary cut-off of 200 nt (Djebali et al. 2012). Micro RNAs (miRNAs) are
the most studied class of sncRNAs. They originate from a pre-miRNA that is cleaved by Drosha and Dicer
to form a mature miRNA of approximately 22 nt. They regulate gene expression post-transcriptionally,
usually by recruiting the RNA-induced silencing complex (RISC) and, through base pairing, direct this
complex to their target genes, resulting in their degradation (Ha et al. 2014). One miRNA can bind
multiple targets either by perfect or imperfect base pairing. Conversely, the transcripts of one gene can
be targeted by multiple miRNAs.
Other known classes of sncRNAs include small nuclear RNAs (snRNAs), which are part of the
spliceosome (Yean et al. 2000), small nucleolar RNAs (snoRNAs), that target mainly rRNA for methylation
or pseudouridylation (Kiss 2001) and piwi-interacting RNAs (piRNAs), which interact with PIWI proteins,
guiding them to transposable elements locus in order induce a repressive state and prevent their
expression (Le Thomas et al. 2013).
1.3.1. Long Non-coding RNAs
The most diverse class of ncRNAs are lncRNAs, with thousands of genes identified. Similarly to mRNAs,
lncRNAs are transcribed by Pol II, most are 5’ capped, polyadenylated and spliced. The epigenetics marks
associated with coding genes (such as H3K4me3 enrichment at TSS and H3K36me3 along gene body of
active genes) are also found in lncRNA loci, although usually less prominent. Despite being expressed at
lower levels than mRNAs, lncRNAs show an even higher tissue specificity than coding genes (Cabili et al.
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2011). This specificity makes lncRNAs suited to act as fine-tuners of individual genes in very specific
developmental processes. Although usually tissue specific, spatial conservation is lower than mRNAs and
changes in specificity between species are common. One such example is the lncRNA H19 X-linked
(H19X), which in humans and mice is expressed mainly in placental tissues, while in the opossum its
expression is restricted to the testis (Necsulea et al. 2014) .
As the cost of sequencing decreases, it becomes feasible to sequence more deeply, which allows the
detection of lowly expressed lncRNAs. As such, over 16,000 human lncRNAs are already part of gene
databases such as Gencode, with studies indicating the existence of over 60,000 lncRNAs among
different human tumours, tissues and cells lines (Iyer et al. 2015). Despite the evolution of methods and
algorithms that allow identifying new lncRNAs, their functional characterization as proven to be far more
difficult. Therefore, their genomic location is often used as criteria to describe them. lncRNAs can
originate from intergenic regions (termed long intergenic ncRNAS (lincRNAS)) or regions near known
genes, from which they can be either exonic or intronic, convergent or divergent, in a sense or antisense
orientation (Djebali et al. 2012).
A common method to characterize protein coding genes is identification of sequence conservation
between different species. However, the majority of lncRNAs are poorly conversed even in close
relatives. Nonetheless, there are lncRNAs that show a striking conservation, such as MALAT, one of the
most conserved lncRNAs. This gene is conserved throughout the jawed vertebrates with functions in
gene splicing and transcriptional regulation of a small subset of genes (Gutschner et al. 2013).
Another example of conservation is TUNA, a gene involved in normal brain development that shows
outstanding high exonic conservation across vertebrates. It contains an element of almost 200 bp that
shows conservation above 80% between zebrafish, mouse and humans, even exceeding conservation of
most coding genes (Lin et al. 2014). In turn, HOTAIR and GAS5 are two lncRNAs with functions in
repressing HoxD genes and other imprinted genes and in maintenance of mESC pluripotency network
and induced pluripotent stem cells (iPSCs) reprogramming, respectively (Li et al. 2013, Tu et al. 2018).
Despite their conserved function, their sequence is not conserved. These observations demonstrate
that sequence conservation is not sufficient to defined lncRNAs conservation and that other dimensions
are necessary. One such dimension is secondary structure, with studies showing conserved secondary
structures among characterized lncRNAs. However most methods for resolving lncRNAs secondary
structures are base on in silico predictions, which are limited to regions that are already moderately
conserved (Gorodkin et al. 2011). Additionally, random RNA sequences can also fold into stable
structures, demonstrating that presence of a complex and stable secondary structure cannot be used as
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evidence for a functional role (Schultes et al. 2005). A recent study, where a new statistical test for RNAs
secondary structure was developed, concluded that there was no evidence of conservation for the
proposed structures for several known lncRNAs such as X-Inactive Specific Transcript (XIST) or HOX
Transcript Antisense RNA (HOTAIR) (Rivas et al. 2016).
Development of biochemical assays capable of elucidating the RNA complex folding pattern such as
SHAPE-MaP (Selective 2′-hydroxyl acylation analysed by primer extension and mutational profiling) or
icSHAPE (in vivo click selective 2′-hydroxyl acylation and profiling experiment) allow to confirm the
predictions of the current in silico methods. These experimentally validated structures can then be used
as training sets to further improve reliability of computed predictions (Smola et al. 2015, Spitale et al.
2015).
One of the criteria used to define the coding potential of a gene is the presence of a long open
reading frame (ORF), with small ORFs (sORFs) being usually discarded as non-significant. However, in
multiple lncRNAs sORFs were detected, leading to protein products shorter than 100 amino acids. Due to
the presence of these sORFs, dozens of lncRNAs have been re-annotated as protein coding (Olexiouk et
al. 2018). This information reveals that lack of long ORFs is not sufficient to discard any coding potential
and further criteria must be used.
1.3.1.1. lncRNAs functions
Due to their size and flexibility, lncRNAs can fold into complex structures capable of interacting with
proteins. Through base pairing, lncRNAs can additionally interact with DNA and other RNAs, allowing
formation of complexes containing RNA, DNA and proteins. Due to their versatility, lncRNAs have been
discovered to affect, either positively or negatively, gene expression at epigenetic, transcriptional, post-
transcriptional and translational levels (Figure 5).
One of the first and most widely studied lncRNA is XIST. This lncRNA is the main organizer of X-
chromosome inactivation (XCI), a crucial process through which mammalian females, who possess two X-
chromosomes, can prevent double dosage of genes transcribed from this chromosome (Penny et al.
1996). This lncRNA coats the chromosome from which it is transcribed, acting is cis and through
recruitment of different repressor complexes that induce a chromosome-wide inactivation. Interestingly,
when Xist was ectopically expressed from autosomal chromosomes, a chromosome wide repression was
observed. This demonstrated that Xist-mediated chromosome-wide repression is not restricted to the X-
chromosome and that Xist expression was sufficient to induce repression in cis (Wutz et al. 2000).
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A number of other lncRNAs play a role during XCI, mainly by modulating Xist expression, such as Jpx
and Ftx, which are two activators of Xist. Jpx acts as an indirect activator by binding the Xist repressor
CTCF, a factor with important functions in 3D genome structure regulation and enhancer insulation, and
preventing its repressor activity (Sun et al. 2013). In turn, Ftx transcript does not act on Xist, but it is the
transcription from its locus that leads to Xist expression in cis (Furlan et al. 2018). In order to ensure that
Xist is only transcribed from the inactivated chromosome, Tsix, a lncRNA antisense of Xist, is expressed
from the active chromosome and represses Xist in cis (Lee et al. 1999). XCI is an essential process that
reveals the importance of lncRNAs and the different functions performed by these transcripts. Additional
lncRNAs have been proposed to exert their functions through multiple mechanisms.
ecCEBPA (extra coding CCAAT enhancer binding protein alpha) is a non-polyadenylated lncRNAwhich
is transcribed in the sense orientation of its coding neighbour CEBPA, encompassing the full CEPBPA
mRNA (Di Ruscio et al. 2013). It has been proposed that this lncRNA prevents the binding of DNMT1
(DNA methyl transferase 1) to ecCEBPA locus, which in turn allows the expression of CEBPA by keeping
its promoter free of methylation (Figure 5a). In fact, ecCEBPA interacts with DNMT1 and depletion of the
lncRNA with short hairpin RNAs (shRNAs) led to an increased methylation at CEBPA promoter. This
increase led to down-regulation CEBPA, while the opposite effect was observed upon ecCEBPA
overexpression (Di Ruscio et al. 2013).
Enhancer RNAs (eRNAs) are a class of ncRNAs that can be further categorized in 2 classes: 1D, that are
transcribed unidirectionally and are indistinguishable from other lncRNAs and 2D, shorter ncRNAs that
are non-polyadenylated and non-spliced (Schmitz et al. 2016). Together with the already mentioned
ncRNA-a, which have enhancer-like functions, eRNAs are described as acting in the formation of DNA
loops (Figure 5b). As an example, depletion of either ncRNA-7 or ncRNA-3 led to a decreased DNA
looping between their locus and the target promoters (Lai et al. 2013). However, another study
concluded that depletion of Arc and Gadd45b associated eRNAs did not affect the DNA looping at these
loci (Schaukowitch et al. 2014). These data suggest that not all eRNAS are involved in stabilization of DNA
lopping. Due to the complex structures that lncRNAs are capable of folding into, they can act as scaffolds,
allowing the assembly of different protein complexes. PRC2 is a repressive complex that deposits the
repressive H3K27me3 mark and Lysine-specific histone demethylase 1A (LSD1) is a demethylase that
mediates H3K4me2 demethylation. HOTAIR, a lincRNA involved in HOXD genes silencing, has been
shown to act as a scaffold, bringing both PRC2 and LSD1 to the loci of target genes (Figure 5 d-e) (Tsai et
al. 2010). RNase treatment abrogated the interaction between these two complexes. Additionally,
HOTAIR knockdown led to a loss of occupancy of PRC2 and LSD1 from HOXD promoters and consequent
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gain of H3K4me2 and loss of H3K27me3. Although the lncRNAs described so far were mostly nuclear, as
further evidenced by their function, a large portion of lncRNAs are exported to the cytoplasm by
mechanisms which remain unclear. Outside of the nucleus, lncRNAs can mediate post-transcriptional
regulation, such as competing endogenous RNAs (ceRNAs). This class of transcripts competes with other
RNAs, mainly mRNAs, for miRNAs binding sites (Figure 5f). One example is linc-MD1, a muscle specific
lncRNA that sequesters mir133, preventing repression of MAML1 and MEF2C (Cesana et al. 2011).
Another example is the cytoplasmic circular RNA (circRNA) CDR1as, which contains 63 binding sites of
mir7. (Memczak et al. 2013) This circRNA acts as a sponge, removing mir7 from solution, which prevents
degradation of the miRNA target mRNAS. Through splicing mediation lncRNAs also play a role in gene
regulation, a mechanism observed for MIAT, a lncRNA which overexpression or depletion changed the
ratio of Wnt7b isoforms 201 and 202 (Aprea et al. 2013). TINCR is a cytoplasmic lncRNA and one of the
most upregulated lncRNAs during epidermal differentiation. Consistent with its cellular location, it binds
several mRNAs containing a “TINCR box”, leading to its target mRNAs’ stabilization. On the other hand,
the half-STAU1 lncRNA decreases stability of its target genes (Figure 5h). Despite being STAU1-mediated,
TINCR and half-SRAU1 mechanism of action have opposite effects on their target mRNAS (Kretz et al.
2013, Wang et al. 2013).
Multiple lncRNAs have also been reported to have a role in different pathological settings. By far the
highest association is with cancer. Analysis of thousands of tumor samples has revealed that despite the
same number of protein coding genes and lncRNAS are found misregulated in different tumour samples,
more than half the lncRNAs showed specificity for only one type of tumor (Yan et al. 2015). A large
number of lncRNAs has been associated with cancer due to their misregulation in tumour compared to
healthy tissues and due to their tissue specificity. However, for multiple lncRNAs, their role in cancers
was analysed in more detail. The TF p53 is one of the best studied tumour suppressors that acts by
activating genes responsible for cell cycle arrest and apoptosis upon oncogenic signalling (Real 2007).
The lncRNA lincRNA activator of enhancer domain (LED) is activated by p53 and induces expression of
p53 target genes. Accordingly, this lncRNA was found downregulated in different cancers (Leveille et al.
2015). The gene lincRNA-p21 is another lncRNA activated by p53. Depletion of this lncRNA leads to de-
repression of Polycomb repressed genes, increasing the rate of cell proliferation (Dimitrova et al. 2014).
High rates of survival are associated with high expression of this gene. While the mentioned lncRNAs act
as tumour suppressors, others have been associated with proliferation of cancer. MALAT1 depletion in
breast cancer cells led to a reduction of cell proliferation. Together with HuR, a RNA-binding protein with
known roles in cancer progression, this lncRNA controls the dedifferentiation process of breast cancer
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cells (Jadaliha et al. 2016, Latorre et al. 2016). High levels of MYC, a gene involved in tumorigenesis, are
not sufficient to promote tumour development and the lncRNA PVT1 is also necessary. This was shown
by depleting PVT1 in colorectal cancer cells, which failed to induce xenograft tumours (Tseng et al. 2014).
Although the majority of pathologies-associated lncRNAs has been linked to cancer, multiple others
Figure 5 - lncRNA mechanisms of actions
These transcripts able to a) evict repressor proteins from target locus; b) stabilize loop formation,
resulting in the target gene expression; c) repress formation of enhancer and promoter loop; d) guide
proteins to target locations by interaction with both proteins and target DNA sequences; e) bind
different protein complexes and acts as a scaffold, which allows a concert action of these complexes; f)
bind miRNA or proteins, reducing their concentration and attenuating or preventing their function; g)
bind a target mRNA and affect its splicing pattern; h) target mRNAs and through recruitment of proteins
such as STAU1 , prevent mRNA degradation (Schmitz et al. 2016).
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are associated with different diseases, such as autism. Autism spectrum disorder (ASD) is caused by
diverse genetic factors. Two different studies, analysing patient and control cortices samples, revealed
dozens of lncRNAs misregulated in disease samples, most of which were enriched in brain compared to
other tissues. Additionally, a subset of these lncRNAs was co-expressed with protein coding genes with
known roles in this disorder. Several of these lncRNAs were also in close proximity of genes with a
characterized function in ASD (Parikshak et al. 2016, Gudenas et al. 2017).
Alzheimer’s disease (AD) is caused by accumulation of extracellular plaques in brain tissues. These
plaques are composed of amyloid beta (Aβ), which is formed upon cleavage of amyloid precursor protein
(APP), a process performed by β-site APP cleaving enzyme 1 (BACE1) (Faghihi et al. 2008). Multiple
lncRNAs have been implicated in AD. BACE1 antisense (BACE1-AS) transcript is a conserved lncRNA that
induces BACE1 expression, enhancing Aβ production. It also binds BACE1 mRNA in order to increase its
stability, further increasing BACE1 levels (Mulder et al. 2010, Dash et al. 2014, Liu et al. 2014).
Neuroblastoma differentiation marker 29 (NDM29) is another lncRNA that also promotes BACE1 function
and Aβ production (Massone et al. 2012). The lncRNA 51A is also associated with AD, with its
overexpression resulting in increased Aβ formation.
LncRNAs have also been associated with other less common pathologies. Prader Willi Syndrome (PWS)
is caused by a loss of genes activity from a 5-6 Mb from the paternally driven chromosome 15. This
syndrome is caused by either deletion of this region from the chromosome inherited from the father
(70%) or by inheriting two copies of chromosome 15 from the mother (25%) (Cassidy et al. 2012). From
this region, five lncRNAs are expressed, part of a new class designated sno-lncRNAs, which include a
snoRNA at their 3’ and 5’ end. These sno-lncRNAs contain multiple binding sites for Fox2, a gene that
regulates the splicing pattern of a number of target genes. By binding Fox2, the sno-lncRNA titrate the
coding gene levels, maintaining the proper splicing patterns that allow a normal development (Yin et al.
2012).
1.3.1.2.Methods for functional characterization of lncRNAs
Despite the diverse functions already attributed to a number of lncRNAs, their functional
characterization is not a trivial undertaking. Depending on their genomic position but also gene structure,
different methods routinely applied for characterization of protein coding genes may or not be suitable.
As mentioned before, certain lncRNAs are transcribed and exert their function in trans, affecting their
targets regardless of their genomic location. In turn, genes with function in cis act on their neighbouring
Introduction
37
genes. Function can also be attributed to transcription of the and not to the transcript itself, which
makes it possible that transcription of a lncRNA has a cis effect while the transcript has a different
function in trans. Although some lncRNAs have a very specific expression pattern, this doesn’t
necessarily translate into important biological function (Oliver et al. 2015). Additionally, certain lncRNAs
overlap protein coding genes, which complicate genomic manipulations without affecting the neighbour
gene. All of these features make functionally characterization of lncRNAs a challenging undertaking.
Nonetheless, different methods have been successfully used to identify lncRNA functions.
On lncRNAs distant from other genes or regulatory elements, direct deletion of the full gene can be a
viable option to perturb its normal expression. Additionally, CRISPR-Cas9 mediated editing is faster and
more precise than through classical methods such Talen or Zinc finger mediated edition. In a previous
study, mutants for 18 lncRNAs were generated by replacing their locus with a lacZ reporter cassette,
while keeping the regulatory region intact. This strategy allowed a simultaneous deletion of the lncRNA
and assessment of its expression pattern in vivo (Sauvageau et al. 2013). However, this kind of approach
might result in the disruption of local regulatory elements, especially in long deletions.
Another approach is the insertion of a stop cassette near the lncRNA transcription start site (TSS).
This method reduces the risk of unintentional disruption of regulatory elements and has been
successfully used characterize lncRNAs, such as Fendrr, an essential lncRNA for normal embryonic
development (Grote et al. 2013). Although usually effective, there are reports of this approach resulting
only in moderate downregulation of the targeted gene (Kraus et al. 2013). Overexpression of a lncRNA,
which can be achieved by different methods, also allows studying its function. Injection of either viral
vectors or in vitro transcribed lncRNAs, as well as insertion of BAC constructs that overexpress a specific
lncRNA, have been used in functional studies (Ulitsky et al. 2011, Grote et al. 2013, Lv et al. 2018).
However, these approaches are only suitable to study lncRNAs with effects in trans. Overexpression from
the endogenous locus by insertion of a stronger promoter can be used to assess cis effects. Nevertheless,
this method comes with the same risks as already described for direct genomic editing.
Methods that do not rely on genomic modification have also been used to study lncRNAs. Through
RISC, siRNAs mediate target RNA degradation by base pairing, affecting both mRNA and lncRNAs. It’s an
effective method for lncRNA depletion and most of a transcript of interested can be targeted by the
siRNAs. In turn, this method has shown a high risk of false positives due to off target effects, since
specificity depends on a “seed” sequence of only 7-8 nt (Birmingham et al. 2006). Antisense
oligonucleotides (ASOs) are a more reliable alternative to the use of siRNAs. These single stranded DNA
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oligos of usually 15-20 nt are frequently chemically modified in order to increase efficiency or nuclease
resistance (Meng et al. 2015).
Engineering of the Cas9 protein has led to the development of additional methods such as CRIPSR
interference (CRISPRi). Mutation on both nuclease domains of Cas9 results in a dead Cas9 (dCas9), which
can still target genomic regions, yet is not able to cleave DNA. Positioning of dCas9 near a gene TSS can
prevent Pol II elongation and TFs binding by physical blockade. Additionally, fusion of dCas9 with
repressor domains further contributes to gene repression. The Krüppel associated box (KRAB) domain
has been successfully fused with dCas9 and results in deposition of the repressor mark H3K9me3. This
method efficiency is restricted to a window of -50 to +300bp of the gene TSS, which limits the risk of
affecting expression of neighbouring genes (Qi et al. 2013). The engineered dCas9 can also be fused to
activator domains such as VP64, p65 or even multiple domains in tandem, which can induce an
overexpression of the endogenous gene by several orders of magnitude (Chavez et al. 2016).
As mentioned before, different methods have different advantages and disadvantages, so care must
be taken when selecting the most appropriate for the lncRNAs of interest.
1.4. High-throughput RNA sequencing
The thousands of described lncRNAs have been discovered by analysing transcriptome data obtained
through high-throughput RNA sequencing (RNA-seq). Since first described over a decade ago (Emrich et
al. 2007), RNA-seq has become a cornerstone of molecular biology, with its main application being
genome-wide differential gene expression (DGE) analysis. Incredible technological advances have
allowed sequencing of millions of fragments simultaneously, however, the workflow for DGE has not
substantially changed. First, RNA is extracted, followed by rRNA depletion or poly-A RNA enrichment.
cDNA is then synthesized and a sequencing library is generated by ligation of a specific adapter to the
cDNA. The library is then sequenced and obtained reads aligned to the genome. Reads overlapping the
transcripts are quantified and normalized between samples. Finally, statistical tests are performed in
order to detect significant changes on gene expression between different groups.
Short read sequencing represents the most common method to generate RNA-seq data. Before cDNA
generation, RNA is fragmented, resulting in a library with fragments of 150-400 nt. These are then
sequenced from one end (single-end reads) or from both ends (paired-end reads). When using Illumina
technology, sequencing of these fragments results in reads as small as 50 nt. With this approach, robust
results are obtained, with high intra- and inter-platform correlation (Li et al. 2014). However, this
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method shows limitations especially in assigning reads to a specific isoform in genes with multiple splice
variants, which is critical in longer transcripts or highly variable isoforms (Djebali et al. 2012). Long-read
sequencing overcomes these limitations by sequencing complete transcript sequences. With these
methods, ambiguity of reds mapping is reduced, longer transcripts can be identified, leading to a more
complete index of different transcripts and increases accuracy of splice-junction identification. The use of
long-read sequencing has allowed discovering a number of novel transcripts and detecting full length
homologs (Thomas et al. 2014). For both short and long read sequencing, RNA must be reversed
transcribed to cDNA. However, it has been recently demonstrated that using Oxford Nanopore
sequencing, it was possible to sequence RNA directly in a method termed direct RNA-seq (dRNA-seq),
removing the bias generated by the reverse transcriptases and polymerases used on other methods
(Garalde et al. 2018).
Long-read methods present clear advantages, such as allowing full transcript sequencing from the
poly-A tail to the 5’ cap and direct detection of isoforms with the need to re-construct them. However,
these methods also display several limitations. They show a lower throughout (around three order of
magnitude lower compared to short-read methods) which complicate the analysis of lowly expressed
genes, as is the case for most lncRNAs. Additionally, long-read sequencing technologies produce reads
with one or two orders of magnitude higher error rates (Weirather et al. 2017). Since longer reads are
obtained, it is necessary to obtain intact RNA and cDNA from it. However, due to shearing from handling
samples and due to RNA degradation, such full size transcripts are not always present.
The processing of samples and methods to generate sequencing libraries have also evolved
throughout the years (Cartolano et al. 2016). RNA-seq was initially developed for analysis of
polyadenylated transcripts. However, not only is this kind of approach biased for the 3’ end of transcripts,
it also does not allow to study the many transcripts without a poly-A tail, such as miRNAs and some
eRNAs. In order to overcome this limitation, rRNA depletion removes this highly expressed class of
ncRNAS (up to 95% off total RNA in a cell), allowing also to study all transcripts in a samples, including
ncRNAs not polyadenylated (Morlan et al. 2012)T. he sequencing library can additionally be prepared in a
stranded or unstranded fashion. Using stranded libraries, information about the strand of origin of the
sequenced reads is retained. This strand information allows detecting antisense transcripts and correctly
quantifying gene expression of overlapping genes (Zhao et al. 2015). How the reads are generated for
each fragment can also be varied. The cDNA fragments can be sequenced from one or both of their ends,
without any changes necessary to the library preparation method. For DGE analysis, single-end
sequencing is enough to obtain robust results. However, paired-end reads help to disambiguate read
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mappings and is preferred for alternative exons quantification and for de novo transcript assembly for
identification of new genes (Alamancos et al. 2014).
Having sequenced the cDNA fragments it is necessary to use computational tools for the next steps of
the analysis. The first step is to align the generated reads to a reference genome. Since the sequences
are derived from RNA, they may span exons. Besides mapping, most used tools also perform spliced
alignment by allowing gaps in reads (Dobin et al. 2013, Kim et al. 2015). The vast majority of reads will be
equally mapped using any of the splice aligner available. However, for a subset of the reads, the available
tools will handle them differently, an effect more noticeable for reads with multiple possible genomic
locations. The most common practice is to exclude these reads from the analysis, which can cause bias in
the results. Some methods consider all possible locations as valid or only the ones with higher score,
discarding all others. In case of multiple alignments with the same score, some tools keep them all while
others randomly select among them. Other tools calculate an estimate of uncertainty, which are used in
the next steps of the analysis (McDermaid et al. 2018).
The mapped reads are attributed to transcripts in order to determine transcripts abundance. Due to
the different approaches available to perform this task, the choice of used tool during this step is the one
that has a great impact on the final results (Robert et al. 2015). Assigned reads need to be normalized
due to differences in read depth in different samples or to technical variability (Risso et al. 2014) but also
to transcript size , since longer transcripts will have more reads mapped to them even if there are
expressed at a similar level as a shorter transcript. For this normalization step, most computational
approaches rely on two assumptions: that most genes remain unchanged between samples and that
mRNA level is the same in all samples. The final step consists on modelling differential expression in
order to identify genes with a significantly altered expression between groups. Despite the number of




1.5. Aim of the project
Previous work has shown that Med12 is essential for canonical Wnt and Wnt/PCP pathways. Embryos
generated from Med12 depleted mutant cells died during early gastrulation and revealed loss of
expression of β-catenin target genes. Additionally, embryos generated from a hypomorfic mutant
showed striking defects in neural tube closure, heart development, axis truncation and malformations of
the branchial arches. Another study has revealed that MED12 depletion affected the expression of a
subset of lncRNAs in human cells, linking Med12 to activation of expression of lncRNAs.
The aim of this project was to evaluate the impact of Med12 depletion on embryonic stem cells by
analysing their transcriptome and to identify misregulated genes important for the processes disrupted
in embryos generated with these cells. For this, previously generated transcriptome data for Med12
mutant cells was used to evaluate the expression changes caused by variations of Med12 expression
levels. Furthermore, expression of ncRNAs was evaluated in the different mutant cells in order to identify
lncRNAs whose expression was dependent of Med12. Besides annotated genes, putative novel genes
were additionally assembled and studied. Finally, having identified lncRNAs that were dependent of





2. Material and Methods
2.1. Constructs generation
2.1.1. CRISPR-Cas9 vector guide sequence cloning
To generate double strand breaks (DSB) at targeted locations in the genome of ES cells, the CRISPR-
Cas9 method was used. This method relies on the Cas9 nuclease that generates DSB in regions
complementary to the associated single guide RNA (sgRNA). By changing the sequence of the sgRNA, the
Cas9 can be guided to the desired locus, where it will generate a DSB. In this study, the CRISPR-Cas9
vector px459, a generous gift from Dr. Dario Lupianez (Max-Delbrück-Centrum für Molekulare Medizin,
Berlin), was used. Guide sequences were designed using Benchling online tool (www.benching.com) and
selected for the ones with least change of off-target effects (off-target score < 1.0 for individual genomic
locations). For each sequence a forward and reverse primer were ligated in order to generate a double
strand guide sequence with overhangs compatible with px459 vector digested with BbsI (Supplementary
Table 1). Briefly, for primer pair ligation, 1 µl of 100 µM of each primer, 1 µl 10x T4 ligase buffer
(Promega) in a 10µl volume were heated up to 95°C for 5 min followed by a slow cooldown to 4°C (1%
ramp decrease) in a Master Cycler Pro S (Eppendorf). 1 µl of 1:250 dilution of annealed primer pairs were
ligated to 50ng of BbsI digested px459 vector using 2 µl 10x T4 ligase buffer and 1 µl T4 Ligase (Promega)
in a total volume of 20 µl and incubated at RT for 30 min. Insertion was confirmed by Sanger sequencing.
2.1.2. β-galactosidase donor vector generation
In order to generate the vector donor for insertion of a β-galactosidase (β-gal) cassette into LN-BP18
locus, a double strand gene block was ordered (Integrated DNA Technologies) consisting of the guide
sequence and respective protospacer adjacent motif (PAM) that the Cas9 targeted on LN-BP18, a 120
base pairs (bp) homology arm matching the sequence immediately before the induced double strand
break (DSB), a spacer region with restriction sites for cassette insertion, another 120 bp homology arm
matching the sequencing immediately after the induced DSB and again the guide sequence and the
respective PAM. Flanking the whole construct with the same guide sequences used to target LN-BP18
allowed Cas9 to also target the donor vector and excise the donor sequence from vector backbone. This
gene block was cloned into pBluescript SK vector (Stratagene). A β-gal mouse codon optimized cassette,
a generous gift from Dr. Frederic Koch (Max Planck Institute for Molecular Genetics) and the 3x
polyadenylation (pA) signal from pCCALL vector were amplified by polymerase chain reaction (PCR). The
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resulting amplicons were digested with restriction enzymes which sites were included in the primers
used for PCR amplification. Digested fragments were inserted into pBluescript-gene-block vector
linearized with proper enzyme. The whole construct sequence was confirmed by Sanger sequencing.
2.2. Mouse strains and animal husbandry
The mouse strains used for this study were purchased from the Harlan Laboratories (Harlan
Winkelmann GmbH, Borchen, Germany). The outbred strain CD1® was derived from the Swiss-Webster
mice at the beginning of the 20th century and a stock established at the Institute for Cancer Research
(ICR) in Philadelphia, PA (USA). Offspring from this strain were transferred to the Charles River Breeding
Laboratories, in Willington, MA (USA), from which a breeding stock was obtained by the Harlan Sprague
Dawley, Inc. (Hsd:ICR(CD-1®)). The mice were housed at specific pathogen free conditions at the animal
facility of the Max Planck Institute for Molecular Genetics and kept under a 12h cycle of light and dark at
22°C and a relative humidity of 55 ± 10%. They were fed a pelleted, irradiated diet (ssniff M-Z®, Soest,
Germany) composed of 22% raw protein, 4.5% raw fat, 3.9% raw fibre and 6.8% raw ashes. For timed
mattings, day of plug was assumed to be E0.5. All animal experiments were approved by the Berlin State
Office for Safety at Work, Health protection and Technical Safety (Landesamt für Gesundheit und
Soziales, LAGeSo) and carried out in accordance with the German animal welfare act (Tierschutzgesetz,
TSchG).
2.3. Whole mount in situ hybridization
Whole-mount in situ hybridization (WISH) was performed following the protocol described in the
MAMEP website (http://mamep.molgen.mpg.de/index.php) with slight changes.
2.3.1. Fixation of mouse embryos
Timed-pregnant mice were euthanized via cervical dislocation. The uterus was removed and the
embryos were dissected in cold PBS and fixed overnight at 4°C in 4% PFA/PBS solution on a roller mixer.
The next day, the fixative was removed by two washes with cold PBS for 10 min and the embryos were
dehydrated through a graded methanol series (25% MetOH/PBS, 50% MetOH/PBS, 75% MetOH/PBS, 1x
for 10 min each, 100% MetOH 2x for 10 min). All steps were performed at 4°C on a roller mixer with pre-
cooled solutions. The fixed embryos were stored in 100% MetOH at -20°C until used.
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2.3.2. Preparation of labelled probes
All probes were prepared by PCR amplification following the protocol described in the MAMEP
database. Probes templates for Cufflinks predicted genes were generated by PCR amplification using
complementary DNA (cDNA) from mouse embryonic stem cells (mESC) and subcloned into pPCRII-TOPO
(Invitrogen). Antisense in situ probes were generated as described on the MAMEP website using either
T7 or SP6 RNA polymerase (Promega) and labelled with Digoxigenin11dUTP (DIG). Using an anti-DIG
antibody coupled to alkaline phosphatase (AP), the location of the probes can be determined. Sall1
probe was generated from vector UH010 of the MAMEP database. Probes against predicted genes
corresponded to the total transcript length isolated, described in Figure 9. Probe against Sall1 probe was
complementary to nucleotides 3741-4418 of Sall1 mRNA.
2.3.3. Processing of mouse embryos
The desired number of fixed embryos of the same stage was pooled into 2 ml microtubes (Sarstedt). If
not stated otherwise, all subsequent steps comprised a 10 min incubation at 4°C on a roller mixer. The
embryos were rehydrated (1x 75% MetOH/PBST, 1x 50% MetOH/PBST, 1x 25% MetOH/PBST, 2x PBST),
bleached in a 6% H2O2/PBST solution (30 min for E10.5, 45 min for E11.5) and washed 3x in PBST. The
specimens were digested with 10 µg/ml proteinase K/PBST (13 min for E10.5, 17 min for E11.5) in order
to allow for better penetration of the labelled probe. The digestion process was stopped by incubation
with 2 mg/ml glycine/PBST solution followed by two washes with PBST.
The embryos were refixed in 0.2% glutaraldehyde/4% PFA/PBST for 30 min at room temperature (RT)
while rolling, washed twice with PBST at RT and preincubated with hybridization solution (50%
formamide, 5x SSC pH 5.0, 1% SDS, 0.05 µg/ml yeast RNA (Sigma-Aldrich), 0.05 µg/ml heparin (Sigma-
Aldrich), in RNase-free H2O) for 15 min at RT.
Embryos were sorted according to the probe used and prehybridized for 2h at 68°C to reduce
unspecific background staining. 2 ml of preheated hybridization solution (68°C) was added to the
embryos together with 10 µl of denatured probe (5min at 95°C) per ml of hybridization solution and





Hybridization solution was discarded and embryos washed twice at 68°C for 30 min with preheated
Solution 1 (50% formamide, 5x SSC pH 5.0, 1% SDS) followed by two washes for 30 min at 68°C with
Solution 3T (50% formamide, 2× SSC pH 5.0, 0.1% Tween-20). Embryos were then incubated for 20 min
at RT with 50% solution 3T: 50% MABT pre-heated to 68°C, followed by a 15 min wash in MABT + 2mM
Levamisole. Embryos were incubated in blocking solution (2% blocking reagent (Roche), 20% Serum
(Gibco), 2mM levamisole, in MABT) for 1h at RT. 0.5 µl of anti-DIG antibody (Roche) was added and
embryos incubated overnight at 4°C.
The next day, the embryos were washed twice for 15 min, twice for 30 min and at least six times for
1h at RT in the dark in MABT. To reduce background staining, the specimens were incubated overnight at
4°C in MABT in the dark. .
2.3.5. Staining
The next day, the embryos were washed 2 times for 15 min and 1 time for 40 min at RT with freshly
prepared NTMT (100 mM Tris-HCl pH 9.5, 100 mM NaCl, 50 mM MgCl2, 0.1% Tween-20, 1 µM
levamisole). Embryos were then stained with BM-Purple (Roche) and incubated at RT, rocking in the dark.
The staining intensity was monitored periodically under a binocular. Once an appropriate staining was
obtained, the reaction was stopped by washing the embryos once in NTT (100 mM Tris-HCl pH 9.5, 100
mM NaCl, 0.1% Tween-20) and several times in PBST at RT. The stained embryos were postfixed in 4%
PFA/PBST and stored in the dark at 4°C.
2.3.6. Imaging
Whole-mount specimens were photographed with a SteREO Discovery.V12 microscope (Zeiss) and an
AxioCam Color camera (Zeiss) using the AxioVision 4.6 software (Zeiss).
2.4. ES cell culture
2.4.1. Culture procedure
All the ESCs used in this study were male. They were derived from JM8A1.N3 with a C57BL/6N genetic
background (Pettitt et al. 2009) or from a G4 hybrid line (129S6/C57BL6) (George et al. 2007). The
procedures were performed under sterile conditions in a laminar flow hood (HERAsafe; Heraeus). ES cells
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were seeded onto a monolayer of mitotically inactivated primary embryonic fibroblasts, i.e., feeder cells,
in a gelatine-coated 6 cm cell culture dish (Corning) and incubated at 37°C in a humidified 7.5% CO2
incubator (HERAcell 150; Heraeus). The cells were grown in ES cell medium composed of Dulbecco’s
Modified Eagle’s Medium (DMEM containing 4,500 mg/ml glucose, without sodium pyruvate; Sigma-
Aldrich), 15% (v/v) ES cell-qualified, heat-inactivated fetal bovine serum (FBS; Gibco), 2 mM L-glutamine
(Sigma-Aldrich), 50 U/ml penicillin (Sigma-Aldrich), 50 µg/ml streptomycin (Sigma-Aldrich), 1% 100× non-
essential amino acids (Sigma-Aldrich), 0.1 mM β-mercaptoethanol (Sigma-Aldrich), 1% 100x nucleosides
(Sigma-Aldrich). 1000 U/ml murine leukemia inhibitory factor (LIF; Chemicon) were added to keep the ES
cells in an undifferentiated state. The medium was exchanged daily for 3 days or until plate was 90%
confluent. At this point cells were splitted by trypsinization. Before trypsinization, the ES cells were
grown in fresh medium for at least 2 h. The medium was aspirated and the cells were carefully washed
twice with cell-culture grade D-PBS (Lonza). 1 ml trypsin/EDTA solution (Gibco) was added and the cells
were incubated at 37°C for 10 min in order to disrupt cell-cell contacts. The enzyme was inactivated by
the addition of 2 ml ES cell medium before pipetting vigorously up and down to produce a single cell
suspension. To determine cell density, 10 µl of cell culture and 10µl of 0.4% Trypan Blue Stain were
mixed then 10 µl were loaded into a LUNA Cell Counting Slide and viable cells counted in LUNA
Automated Cell Counter (Logos Biosystems). Cells were either platted in a fresh gelatinized plate with a
monolayer of feeders or aliquots were prepared by freezing cells in ES medium with 20% FCS and 10%
DMSO.
2.4.2. ES cells transformation
In order to generate the different mutant ESCs, 3.0x105 ESC were seeded onto with a monolayer of
4.0x105 feeder cells in a gelatine-coated 6well plate (Corning) and incubated for 24h at 37°C. To
transform ESC, Lipofectamine 2000 (Invitrogen) was used according to the manufacturer’s instructions.
Briefly 8 µg of DNA were mixed with 125ul OptiMEM and incubated with 125 µl of a 1:4
lipofectamine/OptiMEM solution for 15 min at RT. Afterwards, the combined solution was added to the
cells, acting for 5 hours at 37°C.
Cells were then splitted as described below into 4x6 cm culture dishes (Corning) containing
puromycin resistant feeders in the following ratios 1/12, 2/12, 4/12 and 5/12. Selection with 2 µg/ml of
puromycin (invivoGen) started the following day for 48h, followed by 24h using 1 µg/ml of puromycin
and then approximately 96h without selection, until colonies were visible. Throughout the whole
procedure ES medium was exchanged daily. For Sall1, LN-BP18 TSS1 and TSS2 excision 4 µg of each
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CRISPR-Cas9 vector was used, while for knock-in of the β-gal-3xpA cassette into LN-BP18, 2 µg of CRISPR-
Cas9 vector and 6 µg of donor vector were used.
2.4.3. Colonies picking
Fresh ES cell medium was added to the cells 3-4h prior to picking. The cells were washed twice with
D-PBS before covering the colonies with a layer of fresh D-PBS. Individual colonies were picked using
disposable 10 µl pipette tips under a stereo microscope (MZ8; Leica) and transferred to the wells of a
round-bottomed 96-well plate (Corning) containing 50 µl cold trypsin/EDTA solution. After all colonies
had been picked, the 96-well plate was placed in the 37°C incubator for 10 min. 100 µl ES cell medium
were added per well to inactivate the trypsin. The colonies were disaggregated with a multi-channel
pipette and transferred to the wells of a gelatinized, flat-bottomed 96-well plate (Corning) containing a
monolayer of feeder cells (1x106 feeder cells/plate) and grown in regular ES cell medium.
2.4.4. Splitting and freezing
After the cells had been grown 2-3 days, they were washed twice with D-PBS before incubating them
at 37°C with 50 µl trypsin/EDTA for 10 min. The trypsinization was stopped by adding 100 µl bicarbonate-
free DMEM (Sigma-Aldrich) supplemented with 10 mM HEPES (Sigma-Aldrich) and 20% FBS (v/v). The
cells in the so-called ‘DNA Original Plate’ were disaggregated and 50 µl of the 150 µl were transferred to
the wells of a round-bottomed 96-well plate containing 50 µl 2x concentrated ES cell freezing medium
(bicarbonate-free DMEM (Sigma-Aldrich), 10 mM HEPES, 20% FBS, 20% DMSO). The contents of this so-
called ‘Master Plate’ were mixed well by pipetting. Another 50 µl of the remaining 100 µl cell suspension
were transferred to the wells of a gelatinized, flat-bottomed 96-well plate (Corning) containing 200 µl ES
cell medium (‘DNA Replica Plate’) and the contents were again mixed. The ‘Master Plate’ was sealed,
placed inside a styrofoam box and frozen at -80°C. 200 µl ES cell medium was added to the remaining 50
µl cell suspension in the ‘DNA Original Plate’ and the contents were mixed.
The cells in the ‘DNA Original Plate’ and the ‘DNA Replica Plate’ were grown to confluency at 37°C.
DNA was isolated and subsequently used for analysis by PCR.
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2.4.5. Screening of ES clones by PCR
In order to identify clones with successful transformation, a PCR screen was used. The procedure
followed the protocol previously described (Ramirez-Solis et al., 1993). ES cells were grown to confluency
in the wells of a 96-well plate (in the so-called ‘DNA Original Plate’ and the ‘DNA Replica Plate’ (2.4.4) in a
humidified incubator at 37°C and 7.5% CO2. The cells were carefully washed twice with D-PBS and 50 µl
prewarmed lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM EDTA pH 8.0, 10 mM NaCl, 0.5% sarcosyl)
containing 1 mg/ml proteinase K (Roche)) were added per well. The plate was placed inside a humidified
chamber and incubated overnight at 60°C. The next day, 100 µl ice-cold 75 mM NaCl/100% EtOH was
added without mixing. The plate was allowed to stand on the bench for 30 min to precipitate the DNA as
a filamentous network on the bottom of the wells. The plate was then carefully inverted to discard the
solution and excess liquid was blotted on a paper towel. The wells were rinsed three times by adding 200
µl 70% EtOH. After the final wash, the precipitated DNA was allowed to dry on the bench. The ‘DNA
Replica Plate’ was sealed and stored at -20°C. The ‘DNA Original Plate’ was used for PCR screen after
resuspending DNA in 50 µl 1xTE buffer. For PCR, PrimeSTAR HS DNA Polymerase (Takara) was used for
primer pairs 3 and 4, while for the remaining pairs Taq DNA polymerase (Invitrogen) was used
(Supplementary Table 2). Amplification mixture was prepared as described in Supplementary Table 3 and
the run followed the conditions in Supplementary Table 4. For primer pairs 3 and 4, since a different
polymerase was used, the denaturation temperature was changed to 98°C. the PCR reactions were then
loaded on a 2% agarose gel (Biozym) using 1:30000 SYBR Safe DNA gel staining (Invitrogen) to visualize
the double strand DNA using a Gel Doc XR+ (BioRad).
2.4.6. Screening of ES clones by Southern blot
PCR screen of JM8A1.N3 (JM8) ESC clones that had successfully integrated the β-gal cassette into the
LN-BP18 locus did not provide clear results. As such, Southern blot analysis was performed. The
procedure followed the protocol described in (Ramirez-Solis et al., 1993). ES cells were grown to
confluency in the wells of a 96-well plate (in the so-called “DNA Original Plate” and the “DNA Replica
Plate” (section 2.4.4) in a humidified incubator at 37°C and 7.5% CO2.
The cells were carefully washed twice with D-PBS and 50 µl prewarmed lysis buffer (10 mM Tris-HCl
pH 7.5, 10 mM EDTA pH 8.0, 10 mM NaCl, 0.5% sarcosyl) containing 1 mg/ml proteinase K (Roche) were
added per well. The plate was placed inside a humidified chamber and incubated o/n at 60°C. The next
day, 100 µl ice-cold 75 mM NaCl/100% EtOH were added without mixing. The plate was allowed to stand
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on the bench for 30 min to precipitate the DNA as a filamentous network on the bottom of the wells. The
plate was then carefully inverted to discard the solution and excess liquid was blotted on a paper towel.
The wells were rinsed 3 times by addition of 200 µl 70% EtOH. After the final wash, the precipitated DNA
was allowed to dry on the bench. The ‘DNA Replica Plate’ was sealed and stored at -20oC. The “DNA
Original Plate” was used for restriction enzyme digestion.
2.4.6.1. DNA digestion and electrophoresis
A restriction digest mix was prepared containing 1 U/µl BamHI (Promega), for identification of correct
integration of β-gal, plus 1xBuffer E (Promega), 1 mM spermidine (Promega), 100 µg/ml BSA (Promega),
100 µg/ml RNase A (Promega). The mix was prewarmed to 37°C and 30 µl were added to each well
without mixing. The reaction was incubated at 37°C for 2-4 h in a humidified chamber before mixing the
content of the wells. The 37°C incubation was continued o/n in a humidified chamber. The next day, 6 µl
of 6x gel loading buffer were added to each well and the DNA was electrophoretically separated in a
0.7% agarose gel in 1x TBE electrophoresis buffer for 3 h at 80 V. The next day, the gel was documented
with the Gel Doc XR+ (BioRad).
2.4.6.2. DNA bloting
After electrophoretic size separation, the gel was pretreated in order to facilitate transfer of large
DNA fragments. First, the DNA was partially depurinated by soaking the gel twice in 0.25 N HCl for 10
min. The gel was washed in ddH2O for 5 min before denaturing the DNA by placing the gel in a bath of
0.5 N NaOH on a moving platform for 40 min at RT. The DNA was then blotted o/n onto a preequilibrated
nylon Zeta-Probe GT membrane (Bio-Rad) by capillary transfer. The DNA was UV-crosslinked to the
membrane using 5000 µJ/cm2 radiation (Stratalinker 2400; Stratagene). The membrane was washed
twice in 2xSSC pH 7.0 and directly hybridized.
2.4.6.3. Probe labelling
For the generation of the radioactively labelled probe, a fragment of 550 bp, downstream of exon 4
was amplified by PCR from WT ESCs using the primers 5’-CTGACCACGATCCCCTCATC and
3’GGCAGGACAATCAGCCATCT. 25 ng of purified PCR product were diluted in 12 µl of ddH2O and
denatured for 5 min at 95°C. After the sample was cooled down on ice for 2 min, dATP, dGTP, dTTP,
Klenow enzyme and random primers were added (Rediprime II Random Prime Labelling System;
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Amersham) and the components mixed. All following procedures were performed in an isotope
laboratory facility according to the manufacturer’s instructions. 5 µl of 50 µCi (α-32P) dCTP (Redivue;
Amersham) were added and the mixture was incubated for 30 min at 37°C to allow for the labeling
reaction catalysed by the Klenow fragment of the DNA polymerase I. The radioactive sample was
pipetted onto a Sephadex G-50 MicroSpin Column (GE) to separate the labelled probe from
unincorporated radioactive nucleotides, according to manufacturers’ instructions. The labelled DNA
probe was denatured for 5 min at 95oC, cooled down on ice for 5min and added to the hybridization
buffer (see below).
2.4.6.4. Hybridization and detection
The DNA-blotted membrane was prehybridized in a glass bottle with 20 ml prewarmed ExpressHyb
Hybridization Solution (Clontech) for 30 min in a hybridization oven (Hybaid Shake’n’Stack; Thermo
Scientific) at 68oC with constant rotation. After prehybridization, the denatured, labelled probe was
added to the solution and the membrane was hybridized o/n at 60oC with constant rotation. The next
day, the membrane was washed in two times for 20 min in 2x SSC 0.1% SDS at 68°C. The membrane was
them sealed inside a plastic bag. The radioactively labelled DNA was exposed in a phosphoimager
(Amersham) for 24h before detection. In case of lower signal, exposure on extended.
2.4.7. Depletion of feeder cells from ESC culture
Before RNA and protein extraction or in vitro differentiation of mutant ESC, feeder cells used to
support ESC growth were removed in order to prevent contamination of results since the feeder cells
used were derived from WT mouse embryonic fibroblasts. As such, ESC were cultured in a 6 cm plate
following procedures described in section 2.4.1. After reaching confluency, feeder cells were remove
with feeder removal microbeads (Macs) following manufacturers’ instruction. Briefly, a single cell
suspension was obtained. The cell suspension was then filtered using a 30 µm filter (Sysmex) and cells
were resuspended in 80 µl of cold ES medium. 20 µl of beads suspension was mixed with cells and
incubated rocking at 4°C for 15min. Afterwards, 400 µl of cold ES medium was added to cells and the
whole cell suspension loaded into equilibrated LS columns (Macs). Cells were eluted by washing columns
with ES medium and used directly.
Chapter 2
52
2.5. In vitro differentiation of ESCs into mesoderm
Since LN-BP18 was lowly expressed in ESCs and was found to also be expressed in the caudal end of
E8.5 mice embryos, ESCs were in vitro differentiated into mesoderm transcriptionally similar to the one
in E8.5 caudal end (Koch et al. 2017). The differentiation protocol was performed as described previously
with slight modifications (Gouti et al. 2014). The procedures were performed under sterile conditions in
a laminar flow hood. Briefly, to 12 well plates, 0.8 ml of 0.025 mg/ml Synthemax II-SC (Corning) were
added per well and incubated at RT for 2h, after which they were aspirate. 2.0x105 ESCs were plated into
each well.
Cells were incubated for 48h cells with N2B27 medium (DMEM/F12 medium (Gibco) and neurobasal
medium (Gibco) (1:1), 1x N2 (Thermo Fisher Scientific), 1x B27 (Thermo Fisher Scientific), 2 mM L-
glutamine, 40 µg/ml BSA, 0.1 mM 2-mercaptoethanol, 50 U/ml penicillin, 50 µg/ml streptomycin)
supplemented with 10ng/ml bFGF (Peprotech), 24h with N2B27 medium supplemented with 10ng/ml
bFGF and 5 µM CHIR99021 (CHI, Calbiochem) and 48h with N2B27 medium with 5 µM Chiron. Medium
was changed daily and cells incubated at 37°C, 7.5% CO2.
For every time point, duplicate samples were prepared in order to extract RNA and perform X-gal
staining. RNA was extracted as described in section 2.7.1.
2.5.1. X-Gal staining for assessing β-gal reporter cassette activity
In order to check β-gal reporter cassette activity in generated mutants, X-Gal staining was done in
ESCs, in vitro differentiated cells and in embryos. Cells were washed twice with cell-culture grade D-PBS
and fixed with cold 4% PFA/PBS at RT for 5 min. Embryos were dissected in PBS and fixed in 4%PFA/PBS
at 4 °C for one hour. Samples were then rinsed three times at RT in rinse buffer (5 mM EGTA, 0.01%
deoxycholate, 0.02% NP40, 2mM MgCl2, in PBS). Meanwhile, the staining buffer was prepared
containing 5 mM potassium ferricyanide (Merck) and 5 mM potassium ferrocyanide (Merck), in rinse
buffer. To this X-gal (40 mg/ml in dimethylformamide) was then added to a final concentration of 1
mg/ml and the prepared staining buffer was then filtered. Staining was done o/n at 37 °C in the dark.
After staining, samples were washed 3 times with PBS and refixed in 4%PFA/PBS. After one final wash
with PBS, samples were imaged with a SteREO Discovery.V12 microscope and an AxioCam Color camera
using the AxioVision 4.6 software.
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2.6. Nuclear and cytoplasmic fractionation
To determine LN-BP18 cellular localization nuclear and cytoplasmic fractions for ESCs were prepared.
1x106 WT ESCs were lysed in Low salt buffer (50 mM TRIS-HCl, 150 mM NaCl, 0.4% Triton X-100, 5%
glycerol, 1x cOmplete (Roche) and 1 U/µl RNasin (Promega)) and mixed for 10min at 4°C. Lysate was
centrifuged and the supernatant constituting the cytoplasmic fraction collected. For RNA extraction,
RNeasy micro kit was used on the nuclear pellet and on cytoplasmic solution as described in section 2.7.1.
For protein, the extraction nuclear pellet was lysed with 150 µl western lysis buffer (1% SDS, 10 mM
TRIS-HCl, 2 mM EDTA) and 50 µl of 4x NuPAGE LDS buffer (Thermo Fisher Scientific) was added to
nuclear lysate and to 150µl of cytoplasmic fraction.
2.7. Real-time quantitative PCR analysis
2.7.1. RNA extraction
Total RNA was isolated from embryonic tissues or cells using the RNeasy Micro Kit (Qiagen) according
to the manufacturers’ instructions with slight modifications. Briefly, cells or tissues were lysed in 1 vol.
RLT Buffer, 1 vol. 70% EtOH was added to the lysate and the contents mixed by pipetting. The sample
was transferred to an RNeasy column placed in a collection tube and centrifuged and the flow-through
discarded. The column was washed with RW1 Buffer. An on-column DNase digestion step was performed,
supplemented with an additional 1µl of DNase I (Roche) and incubated at table top 30 min. The column
was washed with, RW1 Buffer, RPE Buffer and with 80% EtOH. The RNA was eluted with RNase-free
water.
The RNA concentration was measured by UV spectrophotometry (ND-1000 Nanodrop)and the
samples were either used directly or stored at -80°C.
2.7.2. Reverse transcription of RNA
The SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) was used for reverse
transcription of RNA into cDNA. Briefly, 1-5 µg RNA were diluted in a total volume of 8 µl DECP-H2O. 1 µl
of either random hexamers, oligo dT or of a gene specific primer and 1 µl dNTP mix (10 mM) were added
per reaction and the samples were incubated at 65°C for 5 min before placing them on ice for 1 min. A
reaction mixture was prepared containing 2 µl 10× RT Buffer, 4 µl MgCl2 (25 mM), 2 µl 0.1 M DTT, 1 µl
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SuperScript III and 1 µl RNaseOUT per sample. The reaction mixture was added to the RNA and incubated
at 25°C for 10 min, at 50°C for 50 min and at 85°C for 5 min.
The reactions were cooled on ice before adding 1 µl RNase H to each tube and incubating them for 20
min at 37°C. The cDNA samples were used directly or stored at -20°C.
2.7.3. Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was performed with the above yielded cDNA using GoTaq qPCR
master mix (Promega). This mix contains polymerase, dNTPs, buffer and SYBR Green I Dye. For each
reaction, a mixture of 10 µl GoTaq qPCR master mix, 5.0 µl of primer mix (1µM), 4.8 µl DECP-H2O and 0.2
µl cDNA were transferred to the wells of a MicroAmp Fast Optical 96-Well Reaction Plate (Applied
Biosystems).
Each sample was run in technical triplicates in a StepOne Real-Time PCR System according to the
program listed in Supplementary Table 5. The results were analysed using the StepOnePlus Software.
The housekeeping gene Pmm2 was used as internal control for normalization of each cDNA sample and
expression normalized to a control sample using the ΔΔCt method. For data derived from embryonic
tissue, no internal control was used and samples were normalized to the sample “rest” by calculating the
ΔCt.
2.8. Isolation of putative new lncRNAs
To verify putative lncRNAs expression in ESCs, RNA was extracted from wild type (WT) ESCs as
mentioned in section 1.8.1. The cDNA was generated according to the protocol on section 2.7.2 ,using 5
µg of total RNA and random hexamers. Obtained cDNA was used directly as a template for PCR with a
combination of different primers along the identified genes. For PCR, Taq DNA polymerase was used
with the conditions in Supplementary Table 3 and Supplementary Table 4, using an elongation step of 2
minutes instead of 30 seconds. PCR was then loaded on a 2% agarose gel using 1:20000 SYBR Safe DNA
gel staining to visualize the double strand DNA. Amplified fragments were extracted from the gel using a
MinElute PCR Purification Kit (Qiagen) following manufacturers’ instructions. Briefly, 1 vol. of agarose
containing the PCR amplicons was dissolved in 3 vol. of QG buffer. Dissolved agarose was then loaded
into a Minelute column and washed with QG and PE buffer. Finally it was eluted using 25 µl of EB buffer.
The eluted amplicons were cloned into pCR2.1-TOPO vector using TOPO TA cloning kit (Invitrogen)
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according to the manufacturer’s instruction, using 4 µl of DNA. Insertion was confirmed by Sanger
sequencing.
2.9. Rapid Amplification of cDNA Ends (RACE)
To determine LN-BP18 gene structure, its transcription start and end sites (TSS and TES, respectively)
were identified using 5´ RACE System for Rapid Amplification of cDNA Ends and 3´ RACE System for Rapid
Amplification of cDNA Ends (Thermo Fisher Scientific), respectively, following the manufacturer’s
instructions and using the primers in Supplementary Table 6. Briefly, 5 µg of total RNA were used for
cDNA generation using a gene specific primer (GSP) in the 5’ RACE (primers 1, 4 or 7) or oligo dT for 3’
RACE. With the generated cDNA, LN-BP18 transcripts were amplified using a GSP (primer 2, 5, 7 or 9) and
an adapter oligo supplied with the kit. Then a nested PCR was performed using an adjacent GSP (primers
3, 6, 8 or 10) and the same adapter. Obtained amplicons were extracted, cloned and sequenced as
described in section 2.8. Primers 1, 2 and 3 were used to identify TSS1.
Primers 4, 5 and 6 were used to confirm TSS1. Primers 7 and 8 were used to identify TSS2 and primers
9 and 10 for determining the TES of LN-BP18 (Supplementary Table 8 - Primers used during RACE
protocol).
2.10. LN-BP18 Isoforms identification
LN-BP18 initial isolation revealed the presence of two different isoforms. In order to identify additional
isoforms, RNA was extracted from WT and Med12null ESCs, as well as from forelimbs of E11.5 WT
embryos as mentioned in section 2.7.1. cDNA was generated according to the protocol on section
2.7.2 ,using 5 µg of total RNA and a GSP located at the identified TES, random hexamers or oligo dT. PCR
amplification of LN-BP18 isoforms as described in Supplementary Table 3 and Supplementary Table 4,
using different annealing temperature and with an elongation step of 2 min. However, since the
obtained signal was weak and unspecific fragments were also amplified, the obtained solution was used
as a template for a nested PCR. For this additional PCR, 2.5 µl of a 1:100 dilution of the original PCR
reaction was used as a template, using primers adjacent to the ones used in the first round of




Proteins were extracted by lysing cells in western lysis buffer (1% SDS, 10 mM TRIS-HCl, 2 mM EDTA).
After incubation on ice for 10 min, benzonase (Sigma-Aldrich) was added and samples incubate at 37°C
for 30 min in order to degrade DNA and RNA. Protein concentration was calculated using BCAProtein
Assay Kit (Thermo Fisher Scientific). To 3 volumes of volumes of protein lysate, 1 volume of 4x NuPAGE
LDS buffer (Thermo Fisher Scientific) and dithiothreitol to a final concentration of 50mM were added.
Samples were at 95°C and cooled down to RT before being loaded into NuPAGE 4-12% Bis-Tris gel
(Thermo Fisher Scientific) and ran in MOPS buffer (Thermo Fisher Scientific).
After the run proteins were transferred to a PVDF membrane (BioRad) pre-activated with methanol
using a BioRad Minigel Blotting System in transfer buffer (25mM Tris base, 192 mM glycine, 10%
methanol) at 4°C using 100 V, 400 mA for 1 hour. The membrane was then blocked in 5% skim milk
(Sigma-Aldrich) in TBS-T (10mM Tris pH 8, 150mM NaCl, 0.01% Tween-20) at RT, cut into appropriated
pieces and incubated with primary antibody diluted in 1% milk in TBS-T for 1h at RT. After 3 washes of
5min in TBS-T, membranes were incubated 1h at RT with secondary antibodies coupled to HRP diluted
1:5000 in 1% milk in TBS-T. Membranes were washed three times in TBS-T and two times in TBS for 5min
each after which the signal was detected with Amersham ECL substrate (Health Care RPN3243) in a
Fusion SL Advance (Vilber Lourmat).
2.12. RNA-seq analysis
2.12.1. Libraries preparation
RNA was extracted from 2 biological replicates of WT, Med12flox, Med12hypo and Med12null mESC using
RNeasy Micro kits as mentioned in section 2.7.1. The RNA was quantified using the Qubit RNA HS Assay
(Life Technologies) and the integrity was verified using Bioanalyser RNA Pico chips (Agilent) using a
Bioanalyser (Agilent). rRNA was depleted of 500 ng total RNA using Ribo-Zero Magnetic Kit (Ilumina)
according to manufacturer’s instructions with small changes. 90 µl of magnetic beads were used for each
sample and washed in 90 µl of H2O followed by resuspension on 35 µl of resuspension buffer and
addition of 0.5 µl RiboGuard RNase Inhibitor. 2 µl of Ribo-Zero reaction buffer and 4 µl Ribo-Zero rRNA
Removal solution were added to 16 µl of the RNA suspension. rRNA depleted RNA was cleaned using
RNeasy Micro columns (Quiagen) and used to generate strand-specific RNA-seq libraries with ScriptSeq
V2 RNA-Seq Library Preparation Kit (Ilumina) according to manufacturer’s instructions. The cDNA was
purified with MinElute PCR Purification Kit (Qiagen) and indexed using ScriptSeq Index PCR Primer
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(Ilumina) according to manufacturer’s instructions for 15 cycles of amplification. Libraries were then
purified with AMPure XP beads (Beckman Coulter). Quantification of all RNA-seq libraries was performed
using the Qubit high sensitivity DNA assay (Life Technologies) and the size distribution was verified using
the DNA HS Bioanalyser chips (Agilent). Libraries were pulled together and sequenced in a single lane of
the HiSeq 2500 (Ilumina). Approximately 45 million pair end reads of length 75 bp were obtained for
each of sample
2.12.2. Bioinformatics analysis
For differential gene expression analysis performed in section 3.1, reads quality was evaluated with
FastQC and mapped against mouse genome (mm10) with Hisat2 (Kim et al. 2015) with the options -dta-
cufflinks --no-discordant --no-mixed. Resulting .sam files were converted to .bam using samtools and
supplied to Cufflinks (Trapnell et al. 2012). Cufflinks was used with the de novo assembly, instructing the
algorithm to assembled transcripts that were not part of the supplied annotation. The software was used
with options --no-effective-length-correction --library-type fr-firststrand and supplying also a mask file for
rRNA and tRNA genes. Since this assembly step had to be done in separately for each sample Cuffmerge,
part of the Cufflinks package, was used to create a unique non-redundant annotation file containing all
Refseq transcripts plus the de novo assembled ones with the default parameters.
Quantification was done using Cuffdiff, another tool from the same suite, which allowed
quantification of transcripts even without replicates, using options -no-effective-length-correction, –
multi-read-correct and supplying once more the rRNA and tRNA mask file.
Genes were considered expressed if their Fragments per kilo base per million mapped reads (FPKM)
in any of the three samples was at least 2.0 and misregulated if |log2FC| >= 1 in Med12hypo or Med12null
compared to WT. In order to be able to calculate lof2FC in samples with FPKM = 0 in one of the samples,
the log2FC was calculate after adding 1.0 to both FPKM values in comparison. To generate files for
visualization of data on IGB genome browser, reads mapped to the positive or negative strand were
saved in separate .bam files and .wig files generated for mm10 mouse genome using
genomeCoverageBed with options –bga –trackline and converted to .bigwig with the tool wigToBigWig
with default parameters.
For analysing the generated RNA-seq data in section 3.5, read quality was analysed with FastQC which
allowed detecting an error during sequencing of base 40 of the second mate reducing the quality of the
remaining sequence. As such the last 36 nucleotides of mate 2 were trimmed with Seqtk. While for mate
Chapter 2
58
1 the whole read sequence was used, for mate 2 only the first 39 nucleotides were mapped against
mouse genome (mm10).
In order to compare the three aligners, Tophat2 (Kim et al. 2013), Hisat2 (Kim et al. 2015) and STAR
(Dobin et al. 2013) were used with default settings with the first replicate of WT sample. After mapping,
reads not a proper pair and or with a mapping score below 10 were excluded using bamtool filter option
with parameters “mapQuality": >= 10 "isProperPair" : "true" and remaining reads quantified with
samtools. Based on the final amount of reads, Star aligner was the chosen tool.
Star was used with default parameters, GenCODE annotation file M20 as the transcriptome database
and mapped reads were filtered as mentioned above. De novo transcripts were assembled using
Cufflinks and resulting files were merged in a single non-redundant list using Cuffmerge. Newly
assembled genes not described in the M20 annotation were filtered and only transcripts with more than
one exon and longer than 200 bp were kept for further analysis. For genes with multiple transcripts, if at
least one of the isoforms fulfilled the mentioned requirements then all transcripts for that gene were
kept for differential analysis. Filtered transcripts were added to the M20 annotation as well as the final
LN-BP18 structure (Figure 14a). Reads overlapping the described exons in the complemented annotation
were counted for each sample using Htseq (Anders et al. 2015) with options –count --mode=intersection-
nonempty --stranded=yes --minaqual=10 --type='exon' --idattr='gene_id'.
In order to perform differential gene analysis between samples, count tables generated by Htseq
were supplied to Deseq2 (Love et al. 2014), using a Galaxy instance maintained by the Freiburg
University (http://galaxy.uni-freiburg.de/), with default parameters, using all samples as different factor
levels for one single factor. Using R (https://www.r-project.org/), files generated for each pairwise
comparison were combined.
Genes with a p.adj < 0.05 and |log2FC| >= log2 (1.5) in Med12hypo or Med12null compared with
Med12flox were considered misregulated. Density plots were generated using R. IGB (Freese et al. 2016)
was used to visualize and export browser views.
Functional enrichment analysis of misregulated genes, gene ontology (GO) term enrichment analysis
was performed using DAVID (Huang da et al. 2009, Huang da et al. 2009) was used, supplying a list of
misregulated genes for functional analysis and either a list of expressed genes (section 3.1) or a list of all
genes with valid p.adj in at least one of the log2FC comparisons (section 3.5) as the background.
For heatmap generation, a file with gene names in the first column and expression values for each
sample in the remaining three columns was generated. This file was supplied to Gene Cluster
(http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm). Using this tool, expression values
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were log transformed and centered by mean. Genes were clustered using centered correlation as
similarity metric and centroid linkage as clustering method. Generated heatmaps were visualized using
Tree View (Saldanha 2004).
2.12.3. Embryonic tissues RNA-seq data analysis
In order to assess gene expression during embryonic development, a set of 67 transcriptome datasets
were obtained from Encode database (Supplementary Table 10). Read count tables for each sample
were generated with HtSeq as described in section 0. Expression values for each gene were calculated in
FPKM using Ballgown (Frazee et al. 2015) with default settings. Bar plots were generated with R.
2.12.4. Med12 Chromatin Immunoprecipitation analysis
In order to assess if any of the misregulated transcripts identified on section 3.5.1 could be a direct
target of Med12, Med12 ChIP-seq data was obtained from a previous study (Kagey et al. 2010). Fastq
files for two Med12 ChIP-seq replicates and one control with the run identifiers SRR058985, SRR058986
and SRR058997, respectively, were downloaded from the Gene Expression Omnibus (GEO) database and
mapped to mm10 genome using Star with default parameters. Obtained .bam files for both Med12
replicates were merged with samtools. MACS2 (Zhang et al. 2008) was used with option callpeak to call
peaks on the merged Med12 ChIP sample enriched again control, which resulted in 2269 peaks.
In order to check what genomic features overlapped with the peaks, annotation files containing the
promotor region (-2kb to +1kb of TSS) and gene body (+1kb of TSS to end of gene) were created by
manipulating genomic coordinates of annotation file using R.
With the Galaxy tool bedtools Intersect intervals (Quinlan et al. 2010) with option –wb, overlaps
between Med12 peaks and promotor regions were found as long as at least 1bp was overlapping on
either strand. Peaks found on promotors were removed from the peak list with Galaxy tool bedtools
SubtractBed. Remaining peaks were used to find overlaps with the gene body region using the same
strategy as for the promotor and again the overlapping peaks were removed from the peak list. Finally
for the peaks not overlapping either promotors or gene bodies, the nearest non overlapping gene either
upstream or downstream of the peak was found using Galaxy tool Fetch closest non-overlapping feature.





3.1. Transcriptome analysis and de novo transcript assembly using Med12 mutant embryonic
stem cells data
As it was shown in previous studies by the Schrewe laboratory (Rocha et al. 2010, Rocha et al. 2010),
Med12 is essential for canonical Wnt and Wnt/PCP pathways and its depletion resulted in striking
phenotypes during mouse development. Disruption of canonical Wnt pathway was confirmed by
observed downregulation of β-catenin target genes and by defects in processes where these genes are
involved, such as axis truncation and malformation of the branchial arcs. Other observed phenotypes are
associated with Wnt/PCR pathway such as defects in neural tube closure, closure of the ventricular
septum and open palate. MED12 mutations also affect the normal development in humans, with
patients suffering from different Med12 associated X-linked intellectual disabilities (XLID) syndromes
revealing multiple defects, such hypoplastic heart, agenesis of the corpus callosum and maxillary
hypoplasia (Graham et al. 2013). Mutations on Med12 have also been found in a number of different
cancer types, such as prostate cancer and chronic lymphocytic leukemia, but also in the majority of
analysed benign uterine leiomyomas and benign breast fibroadenoma, making the study of Med12
important also in a clinical setting.
In order to evaluate the impact of Med12 deficiency in a more homogeneous population, Med12
mutant embryonic stem cells (ESCs) that were previously generated in order to study the function of
Med12 in embryonic development were used. These clones were Med12hypo, in which Med12 expression
was reduced by 95% and Med12null, which were completely devoid of Med12 (Figure 6a) (Rocha et al.
2010).
The analysis of gene expression in embryos generated from these mutant cells was done mostly by
whole mount in situ hybridization (WISH), which despite allowing the detection of the spatial and
temporal expression of target genes in a whole embryo, it is a method that lack sensitivity and that does
not allow precise quantification of gene expression. To overcome these limitations, all the transcripts
expressed in the Med12 mutant ESC were quantified using RNA-seq data, which allows not only
quantifying gene expression more precisely and measuring small variations in expression between
samples, but also detecting lowly expressed genes. In order to verify genes misregulated in these ESC
mutants, a WT ESC control was also included in the analysis. This dataset included data generate for one
sample of each genotype. With the analysis of these RNA-seq dataset, disturbed gees with a role in
pathways and biological processes that would explain the observed defects in the embryos generated
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from these mutant ESCs were expected to be found. Furthermore, previous studies have shown the
existence of lncRNAs whose expression was dependent of Med12 in human cells (Lai et al. 2013). In
order to identify additional lncRNAs regulated by Med12 in ESC, non-coding annotations were also
included in the pipeline analysis.
One important factor in RNA-seq is variability, resulting from technical and biological variation. For
this reason, replicates are necessary to perform statistical tests on gene expression from which to
measure variation. As such, although analysis of these data could provide insights into Med12 influence
on overall gene expression, for certain genes, the differences observed between samples might be not
statistically significant.
Cufflinks is an algorithm that can perform de novo assembly of transcripts that are not present in the
annotation database. Before expression quantification, Cufflinks was used in order to find possible new
transcripts not described in the used RefSeq transcriptome data (Pruitt et al. 2007). This algorithm
predicted thousands of new transcripts. For several of them, the predicted structure was assembled with
either only a few reads supporting the structure, or the whole locus was transcribed but only a part of it
was predicted by Cufflinks. In order to minimize this kind of artefacts, only transcripts longer than 200 nt
were selected. This allowed discarding all the very small transcripts, which accounted for hundreds of
new transcripts. Additionally, transcripts with only one exon were discarded. This allowed keeping only
transcripts for which Cufflinks identified a spliced read, which should only occur on true transcribed
genes. Such filtering allowed to keep only the transcripts with higher probability to reflect true genes.
After gene expression quantification, the thousands of newly assembled transcripts by Cufflinks were
filtered (Figure 6b), reducing the number to almost 400 new genes. Out of over 23.000 genes analysed,
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Figure 6 – Med12 mutant ESC transcriptome analysis
a) Schematic representation of Med12 mutant alleles of the ESCs used and generated in a previous study
(Rocha et al. 2010). LoxP sites, yellow triangles; frt sites, red triangles; exons, blue boxes; exons removed
upon Cre expression, red boxes; neomycin resistance cassette, purple box; b) Flowchart of tools used
and their function for RNA-seq analysis.
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less than half were expressed above 2.0 FPKM (fragments per kilobase million) in one of the three
samples. Genes that did not meet this criterion were considered as not expressed, resulting in 11,000
expressed genes of which almost 1,700 were misregulated over 2-fold in the Med12hypo and/or the
Med12null mutant. The vast majority of these were coding genes, with 14% either annotated as non-
coding or new Cufflinks genes.
3.1.1. Analysis of misregulated protein coding genes
Analysis of misregulated genes in Med12 deficient ESC was first focused on the annotated protein
coding genes, in order to correlated with results obtained from a previous study which made use of
these cells (Rocha et al. 2010). Misregulated coding genes were clustered based on their expression in
the three samples; WT, Med12hypo and Med12null (Figure 7), which revealed groups of misregulated genes
with a similar expression dynamic in all the samples. Heatmaps of these clustered genes were generated
and gene expression colour coded according to their Z-score, a normalized expression value that allows
more easily to compare genes with different orders of expression values. Despite the formation of five
clusters, genes were observed to be either upregulated (clusters 1, 3 and 5) or downregulated (clusters 2
and 4) in both mutants, but with different degrees of misregulation between samples.
Using functional enrichment analysis, genes that share a biological function and that are over-
represented in a specific dataset can be identified. The Database for Annotation, Visualization
and Integrated Discovery (DAVID) tools allow to identify enriched Gene ontology (GO) terms in a given
dataset. These GO terms describe gene function, identifying, among other aspects, the biological process
in which a gene is involved, such as “neural tube closure”. To understand the biological significance of
the generated clusters for the misregulated coding genes, GO term enrichment analysis was performed
for each of the five identified clusters using DAVID. For this analysis, misregulated genes on each cluster
were supplied as individual lists and the full list of expressed genes in any of the three samples was used
as background (Table 1). Over 30 genes encoding for ribosomal proteins (such as Ribosomal protein S7
(RPS17) or RPL22) were upregulated in the mutant cells and assigned to cluster 1. As such, terms linked
to translation were among the most enriched hits in this cluster. When looking at downregulated genes
in both mutants (cluster 2 and 4) several are involved in diverse organs development processes such as
heart development (e.g. Spalt like transcription factor 1 (Sall1), Gli family zinc finger 2 (Gli2) and TEA






















Figure 7 - Clustering of misregulated protein coding genes
Clustering was based on genes expression in the different samples analysed and revealed genes similarly
misregulated in both Med12 mutants. The expression of each gene was expressed using Z-score, a
normalized expression value, in order to compare genes with different expression levels. Genes with
lower expression values are coloured in green and with higher expression coloured in red.
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Table 1 - Gene ontology enrichment analysis on 5 clusters identified for misregulated genes in Med12
mutant ESCs.
Selected hits are presented in this table. A more complete list of terms is shown on Supplementary Table
12.
Cluster Go term p-value
1
translation 1.30E-07
ribosomal small subunit assembly 1.30E-05
cardiac muscle contraction 4.20E-02
2





outer dynein arm assembly 9.50E-04
outflow tract septum morphogenesis 5.20E-02
4
regulation of transcription from Pol II promoters 6.20E-06
axon guidance 6.30E-05






Genes such as Roundabout guidance receptor 1 (Robo1) and Gastrulation brain homeobox 2 (Gbx2)
are among the downregulated genes that function in axon guidance, a process critical for the proper
closure of the neural tube. In cluster 5, upregulated genes in the mutants are involved in different
processes important for brain development (e.g. Secretin (SCT), Collagen type IV alpha 1 chain (Col4a1)
and Cbp/P300-interacting transactivator 1 (Cited1)), such as angiogenesis, an important process for
normal development of most organs with upregulated genes important for this process such as Wnt7b
(Wnt family member 7Bb) and Heart and neural crest derivatives expressed 1 (Hand1). Genes important
for proper neuron differentiation were also assigned to cluster 5, including Inhibitor of differentiation 1
(Id1) and DNA damage inducible transcript 4 (DDIT4). While both Med12 mutant cells show a similar
variation on gene expression, as observed by cluster 1, 2, 4 and 5, in cluster 3 are genes for which the
remaining 5% of Med12 in the Med12hypo mutant (Rocha et al. 2010) was enough to keep them partially
repressed. Genes in this cluster were slightly upregulated in the Med12hypo mutant and even more
upregulated in the Med12null. Multiple genes in this cluster were involved in cell movement (outer dynein
arm plays a role in the beating movement of cilia or flagella). Interestingly, enrichment of genes involved
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in heart development and axon guidance reflected two phenotypes observed on reported embryos:
heart defects and neural tube closure defects. The fact that the identified misregulated genes in Med12
mutant cells and their known functions validate the defects observed in the reported embryos generated
from the same cells, confirms the observations of this analysis.
A previous study has concluded that Med12 was important for proper maintenance of Nanog target
genes expression, since knockdown of Med12 in mESC by small interfering RNAs resulted in
downregulation of Nanog and consequent misregulation of its target genes, such as Sox2, Oct4 and Dkk1
(Tutter et al. 2009). However a more recent paper, where Med12 was depleted in mESC by direct
genomic editing, no effect on Nanog target genes was observed (Rocha et al. 2010). The role of Med12 in
pluripotency was also not supported by the analysed RNA-seq data from Med12 mutant ESCs, since no
effect on the mentioned Nanog target genes or on Nanog was observed (data not shown)
3.1.2. Analysis of the non-coding transcriptome
Previous studies have linked MED12 to the regulation of a multitude of coding genes, however few
have analysed the effect of Med12 on the expression of non-coding genes. One such study observed a
downregulation of a subset of lncRNAs upon depletion of MED12 in HeLa cells. During analysis the
transcriptome data of Med12hypo and Med12null mutant ESCs, in order to further verify the effect of
Med12 depletion on ncRNA expression, genes annotated as non-coding were analysed. Furthermore,
new transcripts were assembled based of the mapped reads with Cufflinks, allowing identification of
putative new genes.
Over 200 ncRNAs were identified as misregulated in one of the mutant cells analysed, including 38
putative new genes. Clustering of misregulated non-coding genes revealed that several were differently
affected in the two mutants (Figure 8a), contrary to what was observed for the coding genes (Figure 7).
Distribution of log2FC for misregulated coding genes (Figure 8b, left) confirmed the similar pattern on
both mutants, with a slightly stronger upregulation of genes on Med12null. However, when only the non-
coding genes were analysed, the difference between the two mutants became more evident (Figure 8b,
right). Although GO term enrichment analysis is a useful method to detect enrichment of coding genes in
a dataset that function on the same process, for studying ncRNAs, this method usually does not provide
any significant results. This is due to the fact that although thousands of ncRNAs have been described,
only for a small subset of these has their function been characterized. As such, the GO terms associated
with non-coding genes are far less than with coding genes. However, when this method was applied to
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the misregulated ncRNAS identified on Med12 deficient ESCs, enrichment of genes associated with the
process of X chromosome inactivation (XCI) was observed (Figure 8c).
While males have only one copy of the X chromosome, females have two. In order to prevent a double
dosage of genes of this chromosome, one of the X chromosomes in females is randomly inactivated
through XCI. This is one of the few processes where multiple lncRNAs are involved that has been deeply
Figure 8 - Analysis of ncRNAs in Med12 mutant cells transcriptome data
a) Clustered heatmap of misregulated lncRNAs expression in Med12 mutants and WT samples. Z-scores
represent normalized expression values, in order to compare genes with different expression levels.
Genes with lower expression values are coloured in green and with higher expression coloured in red; b)
density plots of log2FC distribution on both Med12 mutants compared to the WT sample for
misregulated protein coding genes (left) and ncRNAs (right) showing that the difference between
mutants was more accentuated for ncRNAs; c) GO term enrichment analysis terms for misregulated
ncRNAs; d) log2FC for Xist and other genes with a role on XCI calculated from the RNA-seq data.
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studied and characterized, explaining the association of the GO terms with genes in this process (Penny
et al. 1996, Lee et al. 1999, Sun et al. 2013). To verify the effect of Med12 depletion on XCI, log2FC for
Xist the main factor in XCI and its known regulators was calculated from the RNAseq data (Figure 8d).
Xist and multiple of its regulators were misregulated in at least one of the mutants, suggesting a
potential role for Med12 in this process. However, the ESCs used in this study were derived from male
blastocysts, as such XCI it should not be an active process in these cells. To confirm the role of Med12 in
XCI, a different system where XCI is active should be used, such as female Med12 deficient ESC.
Analysis of the Med12 depleted ESC transcriptome data revealed hundreds on misregulated ncRNAs,
including potential novel genes. These results confirm Med12 role as an important regulator of multiple
lncRNAs expression in ESCs.
3.1.3. Identification and validation of putative novel non-coding genes
Of the almost 400 Cufflinks putative new lncRNAs, 38 were found misregulated in Med12hypo and/or
Med12null. For these, the structure predicted by Cufflinks was visually inspected and compared to the
mapped reads in all samples. This allowed excluding loci where the mapped reads were not sufficient to
sustain the Cufflinks predictions. These included repetitive elements, which explained why an
accumulation of reads was observed, regions where reads were mapped at very low level, or long
genomics regions with reads mapped throughout the whole region, without the accumulation of reads
that usually occur at exons of mature RNAs. Of the 38 Cufflinks predictions, 11 displayed a promising
predicted structure that resembled a spliced gene (Figure 9, black track). For these, primers were
designed along the predicted exons and in nearby regions that, by assessing mapped reads distribution
on the locus, could be part of the predicted genes but were not be identified by Cufflinks. The primers
were used in all possible combinations for every predicted transcript.
Since there was no data confirming the presence of a poly-A tail in any of the transcripts, random
hexamers were used to reverse transcribe RNA extracted from WT G4 ESCs. The use of random
hexamers allows to generate cDNA from all the RNA molecules present in a sample, contrary to oligo dT
that only allows to reverse transcribe RNA molecules with a poly-A tail. PCR amplified fragments were
separated by size using gel electrophoresis and the individual bands for each gene purified from the
agarose gel, cloned into pCR2.1-TOPO vector and the sequence of inserted fragments determined by
Sanger sequencing. With this approach all of the 11 predicted genes were confirmed to be expressed in
ESCs and, for a subset of them, multiple isoforms could be isolated (Figure 9, blue track). Most of the
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identified exons matched the mapped reads in at least one of the samples (Figure 9, red tracks),
confirming the obtained data from RNA-seq. Additionally, gene structures obtained by this experimental
procedure (Figure 9, blue track) were very similar to the predicted structures by Cufflinks (Figure 9, black
track), demonstrating the reliability of this tool in predicting potential new genes.
As it was shown for other putative lncRNAs, small peptides might arise from genes previously
characterized as a non-coding gene (Nelson et al. 2016). To evaluate the possibility of such small
peptides being encoded by the isolated novel transcripts, their coding potential was assessed using CPAT.
This tool calculates the coding probability of transcripts based on their sequence, with a cut-off
determined using a training set supplied (Wang et al. 2013). For mouse transcripts, the optimal threshold
used for defining non-coding transcripts was determined by the developers of CPAT to be 0.44, meaning
that transcripts with a lower score are not likely to code for proteins. For all the transcripts analysed,
their coding probability was below the threshold, supporting their non-coding character (Table 2).
Overall, the analyses allowed to identify 11 putative novel lncRNAs expressed in ESCs, in whose
































Figure 9 - Misregulated putative novel lncRNAs
Browser view of experimentally obtained gene structures for two of the identified misregulated putative
lncRNAs predicted by Cufflinks. Mapped reads from the 3 samples, red track; structure obtained for the genes
after PCR amplification, blue track; gene structure predicted by Cufflinks based on mapped reads, black track.
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Table 2 - coding potential of misregulated putative novel lncRNas
For each gene, only the isoform with the highest coding probability is shown; “mRNA size” represents
the total length of the transcripts after maturation, “ORF size” the size of the longest open reading frame
(ORF) found in any of the 3 reading frames on the same strand as the gene. Transcripts with a coding
probability below 0.44 do not code for any protein according to the CPAT algorithm.
Transcript mRNA size ORF size Coding probability
LN-BP02_1 676 162 0.06
LN-BP06_1 873 147 0.02
LN-BP07_1 410 159 0.06
LN-BP11_1 616 240 0.07
LN-BP13_1 932 282 0.12
LN-BP13_6 311 132 0.03
LN-BP17_1 704 156 0.03
LN-BP18_1 289 78 0.04
LN-BP23_1 704 174 0.16
LN-BP26_1 828 99 0.03
LN-BP31_1 911 114 0.03
3.1.4. Characterization of expression of novel non-coding genes in embryos
As shown, all of the 11 Cufflinks predicted novel genes were confirmed to be expressed in ESCs. In
order to study their potential expression pattern during mouse embryonic development, whole mount in
situ hybridization (WISH) was performed for all 11 lncRNAs, using E9.5, E10.5 and E11.5 WT embryos.
The isolated transcripts (Figure 9 and Supplementary Figure 1) were used to generate antisense RNA
probes. These probes were labelled with Digoxigenin11dUTP (DIG) and their location determined with
anti-DIG antibody. As showed in Figure 10a, no distinct specific pattern could be identified for the tested
genes. Although no specific staining was observed for these genes, there was some signal obtained that
very likely resulted from trapping of the probe or of the staining solution. The unspecific staining
resulted from trapping in the embryos brain, as observed to LN-BP13 or LN-BP31, from staining solution
deposited in the mouse surface, as is the case of the signal observed in the limbs and neural tube of
embryo used for LN-B06 detection or from trapping in the otic vesicles, a signal obtained for several of
the analysed embryos (Figure 10a). However, a specific signal could be observed for LN-BP18, with a
faint expression domain observed on both limbs and also on the caudal end of the embryos (Figure 10b,
bottom row).
Multiple lncRNAs have been shown to regulate the expression of their neighbouring coding genes
(Anderson et al. 2016, Paralkar et al. 2016). Furthermore, genes with similar expression patterns suggest
a shared function and/or regulation. Sall1 is a transcription factor (TF) critical for normal development of
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the kidney, a tissue where it modulates Wnt signalling (Sato et al. 2004, Kiefer et al. 2010). It is also
involved in neural tube closure and in ESC differentiation (Bohm et al. 2008, Karantzali et al. 2011).
Interestingly, LN-BP18 and Sall1 are two divergent genes 9 kb apart, located on chromosome 8. To verify
if these genes were co-expressed, probes against Sall1 were used for WISH. The data obtained showed
that these two neighbouring genes were expressed in similar tissues, specifically in forelimbs, hind limbs
and in the caudal end (Figure 10b). Publicly available transcriptome data generated by the Wold
laboratory for 12 tissues (forebrain, midbrain, hindbrain, neural tube, heart, kidney, liver, lung, intestine,
stomach, limb and thymus) across up to 8 developmental time points, from E10.5 to postnatal day 0,
were downloaded in order to evaluate the in vivo expression of these two genes. The observed
expression domains identified by WISH were confirmed by the transcriptome data, corresponding to
tissues with high expression of both genes (Figure 10c). Additionally, new expression domains were
identified, namely the kidney and neural tube and throughout the brain, albeit at lower levels.
Furthermore, in most of the analysed tissues, Sall1 expression was 6-fold higher than that of LN-BP18.
Despite being expressed in ESC, all except one of the 11 analysed transcripts revealed an expression
pattern in E10.5 mouse embryos. For LN-BP18, expression was detected in the limbs and in the caudal
end of embryos, similar to the detected expression pattern of its coding neighbour Sall1.
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Figure 10 - In vivo expression of a misregulated putative novel lncRNAs
a) Whole mount in situ hybridization (WISH) performed on E11.5 WT mouse embryos using probes
against the putative new ncRNAs identified and b) against Sall1 and LN-BP18 in E10.5 and 11.5 CD1
embryos revealing similar pattern for these two genes; c) Sall1 and LN-BP18 expression quantified in 12
different tissues across eight developmental stages of mouse embryos, downloaded from Encode
database, d) LN-BP18 and Sall1 expression from the RNA-seq data from the three different ESCs analysed.
Results
73
3.2. Characterization of the long non-coding gene LN-BP18
As mentioned before, LN-BP18 was referred to as a novel gene since it was not described in the
Refseq database used for the analysis of transcriptome data from Med12 mutant cells. A search on the
GenCODE database (https://www.gencodegenes.org/), one of the most complete databases for ncRNAs
with data generated from different cell types and tissues, did not reveal any information regarding LN-
BP18. However, a predicated transcript generated by automated computational analysis, termed
Gm3134 (Figure 11, black track) has been described in the NCBI database
(https://www.ncbi.nlm.nih.gov/refseq/) in the same genomic region, on mouse chromosome 8. This
gene, annotated as a ncRNA, was automatically assembled by analyses of the mouse ENCODE
transcriptome data (Yue et al. 2014), which was generated from 123 mouse cell types and primary
tissues. Analyses of this transcriptome data showed a very low expression for this ncRNA in all the
analyzed tissues. However a small enrichment was described in the central nervous system, kidney and
liver. Associated with this gene was a single study with a specific mention of this locus (Thiagarajan et al.
2011). In this study, the only observation was the expression of a Sall1 divergent transcript with similar
expression pattern to Sall1. Specifically, using RNA-seq and histological sections in situ hybridization,
both were found to be expressed in early nephrons of E15.5 mice embryos. No further characterization
was performed on this divergent transcript. Thus, the only information available supporting expression
of a Sall1 divergent transcript was the prediction for Gm3134 and the observation that there was
transcription originating from this locus in mouse embryonic kidneys.
Comparing the experimentally obtained structure of LN-BP18 with the predicted for Gm3134
revealed big discrepancies (Figure 11). According to the automatically generated data, Gm3134 had 9
exons which could be spliced into 12 different isoforms, ranging from 370 bp to over 3.7 kb. The whole
gene spanned a genomic region of 31 kb on chromosome 8, including 5 kb which overlapped with the
coding region of Sall1 (Figure 11, black track). On the other hand, experimental data revealed 4 exons for
LN-BP18, including one not predicted for Gm3134. For LN-BP18, two small isoforms were identified with
sizes below 300 bp, spanning 16 kb and starting 9 kb downstream of Sall1 (Figure 11, blue track).
In order to validate LN-BP18 gene structure and compare it with Gm3134 predictions, chromatin
immunoprecipitation sequencing (ChIP-seq) datasets for different histone modifications in ESC were
obtained from previously published studies (Mikkelsen et al. 2007, Marson et al. 2008, Creyghton et al.
2010). H3K27ac and H3K4me3 are two histone marks associated with active promoters. Since an active
transcription start site (TSS) is free of nucleosomes so that the pre-initiation complex (PIC) can assemble,
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usually these “active marks” accumulate in the nucleosomes flanking this region. This sort of “double
peak” enrichment was detected near the first exon of LN-BP18, supporting the Cufflinks prediction
(Figure 9). Additionally, in Med12hypo and Med12null, an upregulation was observed for this locus.
Analysing the reads mapped to the positive strand (Figure 11, top two red tracks), it could be observed
that the regions where more reads were mapped in the Med12null mutant, comparing to the WT sample,
corresponded to the identified LN-BP18 exons. The TSS of several predicted isoforms for Gm3134 resided
within the first intron of Sall1, in a region where “active marks” H3K4me3 and H3K27ac were present,
supporting this region as a potential active TSS. However Sall1 TSS was also near this region, making the
distinction between Sall1 and Gm3134 TSS associated histone marks difficult. The analysed data
generated from ESC did not support the NCBI prediction since no transcription was observed for most of
the predicted exons. This can be due to the prediction being based on mouse ENCODE transcriptome
data, a dataset generated from 123 cell types and tissues. As such, it was possible that some, if not most,















Figure 11 - Gm3134 locus and predicted structure
Histone modifications associated with active genes (H3K27ac and H3K4me3) are found at the
transcription start site (TSS) for LN-BP18 experimentally verified structure (Figure 9) (first exon, blue
track) and also the TSS of several of the Gm3134 predicted isoforms (first exons, black track). Histone
modification H3K36me3 is found along the gene body of expressed genes and is associated with Sall1
gene body and to a lower degree to LN-BP18 gene. LN-BP18 exons (blue boxes) correspond to the
genomic locations where an increased number of reads were mapped to in the Med12null mutant
compared to the WT sample (red tracks). Most of Gm3134 exons (black boxes) show no signs of




3.2.1. Characterization of LN-BP18 gene structure
The transcriptome data obtained for Med12 mutants ESCs supported the gene structure of LN-BP18
predicted by Cufflinks. However, it did not support the NCBI prediction for Gm3134, since no
transcription could be attributed to the predicted exons that did not overlap the LN-BP18 exons.
Additionally, the identified LN-BP18 gene structure did not match the predicted structure from NCBI,
including an exon not present in Gm3134. Furthermore, before functional analysis of a lncRNA can be
done, it is necessary to understand its transcript characteristics, such as transcription start site (TSS),
transcription end site (TES), possible isoforms, presence or lack of polyadenylated tail (poly-A tail). As
such, a more in depth characterization of this gene was performed.
3.2.1.1. Identification of LN-BP18 transcription start site
The identification of the TSS of a gene can be achieved by using 5’ rapid amplification of cDNA ends
(5’ RACE) approach. With this method a gene specific primer (GSP) is used to generate cDNA only from
the gene of interest. Through terminal deoxynucleotidyl transferase, a poly C tail is added to the 3’ of the
newly synthesized single strand cDNA, which is used as a binding site for an adapter primer. This allows
PCR amplification of transcripts without the prior knowledge of the original RNA 5’ end. Three different
GSP on the last two exons common to both isoforms of LN-BP18 (Figure 11 blue track) were used on WT
ESC cDNA. The TSS could be identified as part of a new exon located in the first intron of Sall1, 10 kb
upstream of the original prediction and overlapping two of Gm3134 predicted TSS (Figure 12, TSS1). A
second round of 5’ RACE using GSP located on the newly identified exon confirmed the location of LN-
BP18 TSS, termed TSS1. However, as discriminated on the previous section, several lines of evidence
supported the existence of the Cufflinks predicted TSS. Furthermore, the RNA-seq data obtained from
Med12 mutant ESCs (Figure 11, top red tracks) did not support transcription originating from TSS1. To
verify if the Cufflinks prediction TSS could be a true TSS, as supported by the mentioned data, a 5’ RACE
was repeated using primers targeting the predicted first exon. The new data indicated the presence of an
additional TSS located on this exon, which started 170 bp earlier than previously identified and was
designated as TSS2. Both identified TSSs of LN-BP18 were supported by the presence of H3K4me3 and
H3K27ac (Figure 11). In order to further validate the presence of these two TSSs, publicly available data
was obtained for ESCs (Figure 12, green tracks) and differentiated tissues (Figure 12, blue tracks). ChIP-
seq data for different histone modifications in ESCs revealed H3K4me3 and H3K27ac peaks around both
LN-BP18 TSSs, as observed before.
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During transcription by Pol II, a cap structure is added to the 5’ end of the transcripts. This cap,
consisting of an inverted 7-methyl guanosine, is added to the first residue of the nascent RNA and
protects it from exonucleases degradation and is important for different processes, such as nuclear
export and RNA splicing (Lewis et al. 1997). Cap analysis gene expression (CAGE) is a method that
enables the sequencing of the 5’ end of RNAs and allows the identification of TSSs in a genome-wide
scale. CAGE peaks were found closely to both TSSs of LN-BP18 (Figure 12, red peaks), which together
with the mentioned histone marks strongly support the true existence of both TSSs. Additionally DNase I
hypersensitive sites sequencing (DNase), which is used to identify regions of open chromatin and RNA
polymerase II (Pol II) ChIP-seq data revealed that, in ESC, both TSS are accessible and that RNA Pol II
binds them. On the other hand, when analysing the data originating from differentiated tissues, a loss of
both H3K4me3 and H3K27ac was observed on the TSS2 together with loss of Pol II binding and closure of
chromatin. These data obtained from the mentioned diverse methods supported the existence of two
different LN-BP18 TSSs. There is now clear evidence of active transcription in TSS1 in differentiated and


















Figure 12 - LN-BP18 TSS2 is ESC specific
LN-BP18 locus with both TSS indicated, together with signal from histone marks found at active promoters
(H3K27ac and H3K4me3). H3K36me3 is found on gene body of active genes. Pol II ChIP-seq and I data was
also obtained for both ESC and differentiated tissues and indicate regions with active or poised transcription
and accessible chromatin, respectively. Data in green generated from ESC and in blue from differentiated
tissue, with E14.5 mouse embryo brain used as a representative tissue. CAGE data was stranded and
generated from different mouse tissues and cell lines. CAGE data, red track
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chromatin is accessible (DNase I), Pol II is found binding in this region and a CAGE peak is found is close
proximity. However, for TSS2, clear evidence was found only in ESCs
3.2.1.2. Identification of LN-BP18 transcription end site
Having identified the different TSSs for LN-BP18, the next step was to determine the transcriptional
end site (TES) of LN-BP18 using a 3’ RACE protocol. This protocol can only be applied to transcripts with a
poly-A tail since it relies on the use of an oligo dT primer binding to this tail. As mentioned before, the
majority of lncRNAs possess a poly-A tail, however multiple functional lncRNAs, such as ecCEBPA which
interacts with DNA methyl transferase 1 (DNMT1) and keeps its own promoter free of methylation, do
not (Lai et al. 2014). To verify if LN-BP18 was modified with a poly-A tail, cDNA was generated using an
oligo dT primer instead of random hexamers. The use of oligo dT only generates cDNA from genes that
are modified with a poly-A tail. The cDNA generated from polyadenylated RNA was used as template for
PCR amplification of LN-BP18 transcripts, which resulted in their successful amplification, suggesting the
presence of a poly-A tail on LN-BP18.
With the assumption of the presence of a poly-A tail added to this gene, the 3’ RACE protocol could
be applied. However the obtained TES matched a stretch of 27 adenines present in the last exon (Figure
13a, black “A” in tandem). This led to the hypothesis that the oligo dT, used on the first step of the 3’
RACE protocol to generate cDNA, did not bind the poly-A tail added to processed RNAs, but bound
instead the stretch of adenines found. From a single RNA molecule, this would results in the generation
of two different cDNA fragments; one from the TSS up to the oligo dT that bound the adenines in
tandem in the last exon and the other comprising the sequence between both oligo dT (Figure 13a). To
confirm this hypothesis, cDNA generated with either oligo dT or random hexamers was used as template
for PCR using a primer on exon 1 and a reverse primer complementary to a downstream region of the
identified stretch of adenines (Figure 13a, red arrows). As shown in Figure 13b, when using oligo dT no
product was obtained, contrary to when random hexamers were used to generate the cDNA.
These data supported the hypothesis that the oligo dT used in the 3’ RACE bound prematurely to a
stretch of adenines on the last exon, which resulted in a truncated cDNA. Despite the premature binding
of the oligo dT on this secondary region, a different oligo dT should have still bound the LN-BP18 poly-A
tail and produced cDNA until the reverse transcriptase was released by the premature bound oligo. As
such, when using GSPs downstream of the premature binding region, they should allow identifying the
cDNA generated from the poly-A tail using 3’ RACE, which in turn would identify LN-BP18 TES. In fact,
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using these primers (Figure 13a, blue arrows), the majority of products obtained terminated shortly after
600bp of the beginning of the last exon, marking this as the LN-BP18 TES site.
Using 3’ RACE it was possible to determine LN-BP18 TES. This method can only be applied to
transcripts with a poly-A tail, suggesting that LN-BP18 transcripts are modified with such a tail. On the
identified TES a polyadenylation signal could be identified, further supporting the presence of a poly-A
tail on LN-BP18 transcripts.
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Figure 13 – LN-BP18 gene structure characterization and isoform identification
a) Schematic representation of LN-BP18 mature RNA. Known LN-BP18 exons, blue boxes; exons in
unknown configurations resulting from alternative splicing, red boxes; poly-A tail, red “A” in tandem,
stretch of adenines present at the last exons, black “A” in tandem; oligo dT used for cDNA generation
from tailed RNA, black arrows; GSP used for isoform identification, green arrows; GSP used to identify
LN-BP18 TES, blue arrows; GSP used on PCR from figure b), red arrows; b) PCR amplification of LN-BP18
transcripts using cDNA generated with either oligo dT (T) or random hexamers (R). GSP were located in
the first exon and downstream of the identified stretch of adenines found during the first round of 3’
RACE (red arrows, a)). Sizes of DNA marker used (M) are indicated in bp.
3.2.2. Identification of LN-BP18 isoforms
The first observations while studying this lncRNA was the presence of multiple isoforms. However,
since this first observation, its known gene structure became more complex, with new exons and
different TSSs identified. Additionally, according to the Gm3134 prediction based on data from different
tissues and cell lines, up to 12 isoforms originated from this gene. To experimentally confirm the
presence of different isoforms, cDNA was generated from WT and Med12null ESC RNA, in order to isolate
TSS2 transcripts and from forelimbs dissected from E11.5 WT embryos to amplify TSS1 transcripts. RNA
was reverse transcribed with SuperScript III using a primer at the TES, random hexamers or oligo dT. In
order to amplified the different LN-BP18 isoforms, primers near either TSS and at the TES were used and
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the amplified fragments sequenced by Sanger sequencing. This led to the identification of 7 exons,
revealing splice variants for three of the exons and nine different isoforms in total (Figure 14a). Fragment
LN-BP18_010 does not represent a complete isoform, since it was identified using primers on exons 1
and 3. As such, no information regarding the remaining transcript was obtained. However, it was still
included as it was the only instance where exon 2 and a long variant of exon 3 could be isolated.
Comparison of LN-BP identified isoforms with the Gm3134 predicted structure showed that although
similar, there were major differences between the two gene annotations. Exon 3, 4, 5 and 7 of LN-BP18
overlapped some of the Gm3134 exons with some differences in the full exon length, more notorious for
exons 5 and 7 of LN-BP18. The length of these two exons was of 170 and 600 bp for LN-BP18, while for
Gm3134 were 2300 and 1800 bp, respectively. Exon 1 of LN-BP18 also overlapped some of the predicted
exons. However the full length exon one was not part of the Gm3134 prediction. Finally, the identified
exons 2 and 6 have not been predicted for Gm3134. On the other hand, no evidence was found for three
of the Gm3134 exons.
The isoforms identified were more complex and diverse than the original two identified during the
first experiments detecting LN-BP18 expression in ESCs (Figure 9). As such, the isoforms were evaluated
for their coding potential, using again CPAT, in order to assess the probability of small peptides being
encoded by this lncRNAs, as previously observed for other lncRNAs (Nelson et al. 2016). None of the
identified isoforms possessed any coding potential, as evidence by the coding probability below the
threshold (0.44) (Figure 14b). PhyloCSF is another method to identify genomic regions that are likely to
represent protein coding sequences. This algorithm compares the alignment of 29 different mammal
datasets identifying evolutionary signatures, such as high frequency of synonymous codon substitution,
across all 6 reading frames. This algorithm has been successfully used to identify peptides originating
from presumably non-coding transcripts, such as Gm34302 gene and its small 34aa long encoded
peptide with roles in heart contractibility (Nelson et al. 2016). PhyloCSF data further confirmed the lack
of coding potential of LN-BP18, as no evolutionary signatures were detected throughout the whole LN-
BP18 locus in any of the reading frames. On the other hand, a clear signal from the coding sequence of
Sall1 was detectable (Figure 14c). Due to the complex splicing pattern observed for LN-BP18, which
included differently spliced variants for a subset of the exons, there was a chance that some of the
identified isoforms resulted from artefacts or anomalous splicing events. In order to further confirm the
observed splicing patterns, acceptor and donor splice sites of all exons were identified and for the vast



















Figure 14 - LN-BP18 isoforms and coding potential
a) LN-BP18 isoforms identified using primers on either TSS and on the TES. LN-BP18_010 resulted from
amplification with primers on the first and third exons and as such was not a full transcript. Gm3134
predicted structure in blue is also evidenced; b) evaluation of coding potential of all 10 isoforms
described using CPAT; c) PhyloCSF tracks from USCS browser for all 6 reading frames. In green, positive
strand; in red, negative strand; d) acceptor and donor splice sites from all LN-BP18 identified exons. In
red are the border nucleotides between exon and intron that correspond to the known mouse consensus
acceptor and donor sites. “Ex1sh” represents the exon 1 found on isoforms 003 and 004; “Ex1”
represents the second splice variant of exon 1 in isoform 005. While the 5’ sequence of this exon is
exclusive for this splice variant, the 3’ end is common to isoforms 001, 002 and 006. 3’ sequence of “Ex2”
matches the one found on fragment 010. For splice variants of exon 3 found on isoforms 007-009, no 3’
sequence analysis was performed since this corresponded to the second transcription start site. “Ex4sh”
is found on isoforms 002,004,005,006,008 and 009 and “Ex4ln” in isoforms 001,003,007.
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The only exceptions found were a short variant of exon 1, exon 2 and the long exon 3, found only on
either LN-BP18_010 or LN-BP18_005 (Figure 14d), revealing that these might be due to aberrant splicing
variants.
Additionally, BLAST searches were performed with the full mature transcript sequence, the DNA
sequence of the biggest open reading frame (ORF) found within each isoform or the amino acid encoded
by it, however no significantly similar sequences were identified. Despite no similar transcripts was
found on other species, an uncharacterized lncRNA divergent from Sall1 is also predicted in human. The
five transcripts predicted for this lncRNA, termed AC087564.1, were aligned against LN-BP18 isoforms
and identity between all transcripts calculated, with sequences for Fendrr and Hotair murine genes also
included as controls. The observed percentage of identity between LN-BP18 and AC087564.1 transcripts
was around 30%, lower than all alignments performed (Figure 15). Identity between these two lncRNAs
was similar to the identity with the used control genes. This revealed that there was no sequence
conservation between LN-BP18 and AC087564.1. LN-BP18 was slightly more similar to Hotair and Fendrr
transcripts, possible because all of these transcripts were found in mouse while AC087564.1 is a human
gene. A low conservation of transcripts between species is not exclusive of conserved function, as
observed for Gas5, a lncRNA that shows poor sequence conservation but its function as a regulator for
self-renewal and pluripotency is conserved (Tu et al. 2018). The fact that AC087564.1 is divergent of Sall1,
despite Sall1 location in a different chromosome (chromosome 8 in mouse and chromosome 16 in
human), strongly suggested a similar function as LN-BP18. As such, it would be interesting to verify if any
function discovered for LN-BP18 is conserved for AC087564.1.
Amplification by PCR of LN-BP18 using both ESC and tissue derived cDNA allowed to identify nine full
isoforms. Different splice variants were observed for three of the seven exons of LN-BP18, revealing a
complex splicing pattern for this lncRNA.
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Figure 15 – Sequence similarity between LN-BP18 and the human AC087564.1
Percentage of sequence identity between the different isoforms of LN-BP18 and AC087564.1. Green
denotes a high identity between transcripts and red a low identity.
3.2.3. Expression analysis of LN-BP18
Having identified this new lncRNA gene structure, the normal expression pattern was more finely
dissected, in order to complement the whole mount in situ hybridization (WISH) and tissue RNA-seq data
analysed in section 3.1.4. The cellular localization of a lncRNA can provide hints of its functions, e.g., a
lncRNA which recruits repressor complexes to target genes will be enriched in the nucleus, while
lncRNAs involved in mRNA stabilization and translation will be enriched in the cytosol. To determine LN-
BP18 cellular localization, nuclear and cytoplasmic fractions were obtained for WT ESCs. LN-BP18 levels
were then quantified by real-time quantitative PCR (qPCR), which allows performing a relative
quantification of gene expression. Using a dye that binds to double-stranded DNA, the fluorescent signal
reflects the amount of double-stranded PCR product that is generated during the reaction.
Analysing the isoforms identified for LN-BP18, exon 4 was always the second exon of the transcripts
with either exon 1 or 3 as the first exon, depending from which TSS the transcript originated from. As
such, the quantification of the splicing between exon 1 and exon 4 and between exon 3 and exon 4 was
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used to assess transcription from TSS1 and TSS2, respectively. Since in the majority of isoforms
originating from either TSS, exon 4 was proceeded by exon 7, quantification of this splicing was use as a
measure of the overall LN-BP18 expression. Since for exon 1 there were two different variants, two
different TSS1 quantifications could be used, matching what is found in LN-BP18_003 or in LN-BP18_001.
The same is observed for exon 4, which possessed two variants and as such, for assessment of LN-BP18
overall levels, two different splicings could be quantified, the one found on LN-BP18_001 and LN-
BP18_002. An average of the relative quantification for both splicing events from each TSS was
calculated.
Cellular localization was evaluated as a ratio between the nuclear and cytoplasmic level, as previously
applied to determine the nuclear location of the lncRNA Fendrr (Grote et al. 2013). Western blots using
antibodies against histone 3 (H3) and Gapdh, a nuclear and cytoplasmic marker, respectively, confirmed
the efficiency of fractionation, with the majority of H3 detected in the nuclear fraction while no Gapdh
was detectable in the cytoplasm (Figure 16a). Expression quantification by qPCR of LN-BP18 and
different controls was performed on these fractions. Xist is a key factor during XCI and as such is
enriched in the nucleus. Nanog and Sox2 are highly expressed in ESC and their mRNA needs to be
translated in order for the TFs to maintain the pluripotency network and so they are enriched in the
cytoplasm, where the translation machinery is. With this approach, no clear enrichment could be found
in any of the two fractions for LN-BP18 (Figure 16b).
WISH data revealed expression of LN-BP18 during embryonic development in forelimbs, hind limbs
and in the caudal end (Figure 10b), which was corroborated by tissues transcriptome data (Figure 10c). In
order to determine the in vivo expression of LN-BP18 while distinguishing both TSSs, E11.5 WT embryos
were dissected into 5 different tissues, according to the domains observed form the WISH data:
forelimbs, hind limbs, tail, head and then the remaining tissues as a single sample designated as “rest”.
Quantification by qPCR on these tissues confirmed an enrichment of LN-BP18 in limbs and tail, with
expression 4-fold higher in these tissues. No significant difference was observed between the expression
levels in the head and in the remaining tissues (rest). Additionally, isoforms originating from the TSS2
were not detectable in any of the tissues (Figure 16d). The RNA-seq data revealed a misregulation of LN-
BP18 when Med12 was depleted in ESCs. To verify if other Med12 mutants, which did not alter Med12
levels, could affect this lncRNA expression, a Med12-Opitz ESC mutant, previously generated by Dr.
Heinrich Schrewe using male cells, which expressed the Med12 R961W mutation associated with FG
syndrome, was used. Med12 levels were unaffected by the mutation and previous studies have shown
that it does not affect Med12 interaction with Mediator (Lai et al. 2013).
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Figure 16 - LN-BP18 in vivo expression
a) Western blot with proteins extracted from nuclear and cytoplasmic fraction of WT ESCs using anti-H3
and anti-Gapdh antibodies; b) quantification of LN-BP18 and both nuclear and cytoplasmic markers using
qPCR and expressed as a ratio between nuclear and cytoplasmic fractions normalized to Pmm2; c)
Relative quantification of overall (Ex4sh-7 and Ex4ln-7), TSS1 (Ex1sh-4 and Ex1ln-4) and TSS2 (Ex3-4) LN-
NP18 transcripts and possible related genes in WT, Med12-null and Med12-Opitz ESCs using qPCR.
Pmm2 was used as internal control and expression values normalized to WT sample; d) Relative
quantification of LN-BP18 in different tissues from E11.5 embryos. Expression was normalized to the
sample rest; n.d., expression not detectable (n=3, SD).
Analysis by qPCR was used to quantify expression of LN-BP18 and Sall1, together with other markers,
in Med12null and Med12-Opitz mutants.LN-BP18 TSS1 and Sall1 were downregulated in both mutants,
with expression 4-fold lower in the Med12null mutant (Figure 16c), with a more moderated effect
observed Med12-Opitz cells, with a 2 fold decrease in the expression of both genes. Despite the
observed effect on LN-BP18 TSS1 expression, TSS2 and overall levels remained unchanged. Analysis of
mutant ESCs where LN-BP18 was misregulated is useful since it might indicate possible contexts where
its function might be relevant. However, to determine its function, mutants with targeted perturbations
on LN-BP18 expression were necessary.
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3.3. Generation of LN-BP18 mutants mESC
Having characterized the locus and transcripts of this novel lncRNA, the next important step would be
a functional analysis of this gene. In contrast to protein coding genes, where disruption of the open
reading frame leads to its deficiency, non-coding genes need different strategies, such as inactivation of
the TSS, insertion transcription stop signals or insertion of the coding sequence of a reporter gene. All of
the three strategies mentioned were used to inactivate LN-BP18 expression in mouse embryonic stem
cells.
3.3.1. Beta-galactosidase reporter line generation
As it was observed by whole mount in situ hybridization (WISH), LN-BP18 was lowly expressed in vivo.
As such, a LN-BP18-β-galactosidase (LN-BP18-β-gal) reporter mutant was generated, since this reporter
presents a higher sensitivity than the previously used WISH. One strategy already mentioned to study
the function of lncRNAs is the replacement of the whole locus by a β-gal cassette, leaving the regulatory
region intact.
This method allowed a simultaneous perturbation of the gene and the generation of a reporter line
(Sauvageau et al. 2013). However, since LN-BP18 was expressed in an antisense overlapping orientation
of Sall1, deletion of this locus would also disrupt the Sall1 gene structure. As such, instead of replacing
the whole locus, a β-gal cassette which was codon optimized for mouse, followed by a triple pA signal
was inserted into exon 4 of LN-BP18. Exon 4 was targeted for insertion since it was present in all
identified isoforms (Figure 14a) originating from either TSS, allowing targeting transcripts regardless
from which TSS they were transcribed. Since the inserted cassette contained no promoter and the
regulatory region of LN-BP18 was left intact, the reporter expression should be driven by the same
regulators of LN-BP18 and expression observed in the same cells as the lncRNA. Additionally, due to the
triple pA signal inserted, transcription was expected to terminate after the reporter cassette. Insertion of
β-gal and triple pA signal was achieved through homologous recombination and in order to increase
recombination frequency, a double strand break (DSB) was induced on exon 4 through CRISPR-Cas9.
Homology arms of 120 bp matching the immediately upstream (5’ homology) and downstream (3’
homology) genomic sequence of the DSB were used (Figure 17a). Previous data by other groups have









Primer pair 1 - Cassette insertion Primer pair 2 - WT locus
Cas9
Ex1 Ex2 Ex3 Ex4 Ex5 Ex6 Ex7
Exon 4 β-gal
Clone A12
Figure 17 - CRISPR-Cas9 strategy used for β-gal knock-in
a) Schematic representation of strategy used to generate LN-BP18 β-gal reporter line. Homology arms of
120 bp, red boxes; primers used for WT clones screening by PCR, green arrows; primer used for
screening the cassette insertion, blue arrow; b) Screening of 96 clones using PCR. For primer pair 1, only
clones with insertion of β-gal cassette in the correct LN-BP18 locus should give a signal. With primer pair
2, clones with at least 1 WT locus should generate a signal. Example of heterozygous clones, red arrow;
example of WT clone, yellow arrows; c) chromatogram of 5’ border of β-gal insertion for clone A12
evidencing correct insertion; d) Sequencing of Cas9 target region for double strand break generation
during homologous recombination, with a polymorphism evident on the PAM sequence of the G4 hybrid
cell used (black arrow).
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Through PCR, the β-gal cassette and the triple pA signal were amplified from a vector kindly gifted by
Dr. Frederik Koch (Max Planck Institute for Molecular Genetics, Berlin) and from pCCALL vector,
respectively and homology arms amplified from G4 WT genomic DNA. These four elements were cloned
into pBluescript SK vector as a single cassette consisting of 5’ homology-β-gal-3xpA-3’ homology (Figure
17a). This whole cassette was flanked by the same genomic region and the protospacer adjacent motif
(PAM) sequence targeted by Cas9 which allowed the nuclease do excise the cassette from the
pBluescript upon ESC transformation.
Transformation of ESC was performed as described in section 2.4.2. Briefly, 3.0x105 G4 129S6/C57BL6
hybrid cells (George et al. 2007) were seeded on a monolayer of feeder cells and cultured for 24h. To
transform cells, Lipofectamin 2000 was used according to manufacturer’s instruction using 2 µg of
CRISPR-Cas9 vector and 6 µg of donor vector. Cells were cultured for seven days using puromycin
selection for the first three days. 96 colonies were picked into a 96 well plate and cultured to confluency.
Afterwards, 1/3 of cells were frozen as a “Master Plate” and the remaining 2/3 were cultured in two
96well plates until confluency and used to extract DNA according to the protocol described in
section2.4.5. The clones were screened by PCR using the strategy indicated in Figure 17a. For WT
screening, primers flanking exon 4 were used (Figure 17a, green arrows), while for successful cassette
insertion, the forward primer for WT screen and a reverse primer in the β-gal cassette were used (Figure
17a, left green arrow and blue arrow, respectively). With this screening strategy, WT clones should
generate signal only when using primer pair 2 (Figure 17b, yellow arrow), heterozygous clones, with
insertion in only one of the alleles, should generate signal with both pairs (Figure 17b, red arrow) and
homozygous clones, with insertion in both alleles should give signal only with pair 1.
Transformed clones were screened for insertion of reporter cassette using the mentioned PCR
strategy. Correct transformation of these clones was further confirmed by Sanger sequencing of
amplified PCR fragments (Figure 17c). Curiously, all the successfully transformed G4 clones were
heterozygous, with no homozygous insertion obtained despite the high efficiency of transformation
(>30% of screened clones). When designing guide RNAs for the Cas9 nuclease, the reference mouse
genome used was generated from a C57Bl6 strain. However the G4 cells used for the transformation
were derived from a F1 hybrid cross between C57Bl6 and 129S6, which meant that the maternal
inherited chromosomes were derived from 129S6 strain while paternal inherited chromosomes were
derived from C57Bl6 (George et al. 2007). Public genomic sequencing data revealed a mutation on the
PAM sequence used by the designed guide RNA on the 129S6 allele. The mutation, which rendered
targeting of this allele by Cas9 nuclease impossible, was confirmed by Sanger sequencing (Figure 17d).
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Figure 18 - Screening of JM8-LN-BP18-β-gal clones
a) Schematic representation of β-gal cassette insertion in LN-BP18 exon 4. Due to BamHI restriction sites
present in the cassette, a smaller fragment is detected by southern blot when using the indicated probe.
In the WT locus, a fragment of 7.5kb is detected, while on the transformed allele, a 3 kb fragment is
detected. Southern probe used to screen clones, green box; BamHI restriction sites in the LN-BP18 locus
and β-gal cassette, bold “B”; b) southern blot result from 96 screened clones. Example of homozygous
clone, green arrow; heterozygous clone, red arrow; WT clone, yellow arrow.
As such, only the paternal allele could be edited, which explained the generation of only heterozygous
clones in G4 cells.
Since the established protocol was successful in transforming the C57Bl6 allele, JM8 cells derived
from C57BL/6N background were transformed in order to generate not only heterozygous but also
homozygous reporter cells. The same protocol used to transform, select and screen transformed G4
mutants was repeated for the JM8 cells. However, the PCR screen was not very informative since
unspecific amplicons were obtained and results were not concordant between different screens
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performed (data not shown). As such, another screening method was used and successfully transformed
cells were screen by Southern blot, by digesting genomic DNA with BamHI and using an external probe of
the 3’ homology arm. Positive recombination led to the detection of a 3.0 KB fragment, while on WT
allele a 7.5 kb fragment was detected. 192 JM8 clones were picked and treated as described for G4
clones. Extracted DNA was digested with BamHI and resulting fragments size separated in an agarose gel
by electrophoresis. DNA was then transferred to a nylon membrane and a radioactively labelled probe
was used to detect the shift in size of the fragment, resulting from the cassette insertion (Figure 18a,
green box). With this method, multiple potential heterozygous and homozygous JM8 mutant cells were
identified (Figure 18b).
3.3.1.1. LN-BP18 expression analysis in β-gal reporter mutant cells
Having successfully edited the LN-BP18 locus in ESCs, the next step was to evaluate the activity of the
β-gal reporter. As described in section 2.4.4, for each plate of picked colonies, two distinct DNA plates
were prepared. While one plate was used for preparing DNA, which allowed screening clones with
southern blot, the other was used for X-gal staining, which allowed assessing activity of the β-gal
reporter. Briefly, G4 cells were washed with cell-culture grade D-PBS, fixed with 4% PFA/PBS for 5min
and incubated with staining solution at 37°C o/n. Cells were then washed again with cell-culture grade D-
PBS and re-fixed with 4% PFA/PBS before detecting the resulting signal. However, no reporter signal was
detectable on any of the G4 heterozygous clones (data not shown). Since LN-BP18 expression was very
low in ESCs it is possible that the low expression was the cause for the lack of reporter activity. As such, a
different condition was used to test the activity of the reporter cassette.
In a recent paper, fluorescence-activated cell sorting (FACS) was used to isolate neuro-mesodermal
progenitors cells (NMPs) that co-expressed Brachyury (T) and Sox2 reporters. Sorted cells were used to
generate transcriptome data and interestingly, LN-BP18 was found to be expressed in T+, Sox2+ and
double T+/Sox2+ cells (Figure 19a) (Koch et al. 2017). Based on this finding, a five days in vitro
differentiation protocol (Figure 19b) previously published was used to differentiate ESCs into NMPs
(Gouti et al. 2014). At day 3 of the differentiation protocol the differentiated cells were similar to the
T+/Sox2+ double positive cells found In vivo at the caudal end of E8.5 embryos and at day 5 they were
similar to the T+ cells (Gouti et al. 2014, Koch et al. 2017). Two different G4 derived clones (C5 and D1),
heterozygous for the β-gal cassette insertion, were differentiated following this protocol. Briefly, clones
were expanded, feeder depleted and seeded into a 12 well plate coated with synthemax.
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Figure 19 - Characterization of LN-BP18 β-gal reporter ESCs mutants
a) Genome browser track showing RNA-seq data of T+/Sox2+ double positive cells FACS cells from caudal
end E8.5 embryos showing LN-BP18 expression on these cells. Similar expression was also observed on
single T+ or Sox2+ positive cells (Koch et al. 2017); b) differentiation protocol scheme followed to
differentiate ESCs into mesodermal. Cells at day 3 of differentiation are similar to the T+/Sox2+ double
positive found at caudal end of E8.5 embryos (Gouti et al. 2014); c) LN-BP18 and β-gal cassette
expression quantified by qPCR through the differentiation course for two G4 LN-BP18-β-gal heterozygous
clones. Expression was normalized to ESCs cultured for 24h with ES+LIF medium; d) quantification of LN-
BP18 and β-gal expression on C57Bl6-LN-BP18-β-gal heterozygous and homozygous clones with qpCR.
Expression was normalized to WT control. Since no β-gal transcripts could be detected for the WT
control, the minimum detectable values was attributed in order to obtain a relative value for the




For each clone 12 wells were prepared and after every 24 h of culture, a well of each clone was used
for X-gal staining and another for RNA extraction for qPCR quantification. Cells cultured for 24h in the
same conditions but using ES+LIF medium were used as the control to which expression levels were
normalized. X-gal staining at each of the five time points analysed yielded no detectable signal (data not
shown).Despite the lack of signal from the X-gal staining, by qPCR it was possible to observe an
upregulation of the cassette expression by day 5 (Figure 19d). Additionally, the qPCR data revealed that,
upon differentiation the expression of LN-BP18 isoforms originating from TSS2 (Figure 19d, Ex3-4) were
decreased. Simultaneously, transcription of isoforms originating from TSS1 increased throughout the
course of differentiation (Figure 19d, Ex1-4).
Expression analysis by qPCR of LN-BP18 and β-gal cassette expression levels on C57Bl6 reporter ESCs
revealed that transcription of isoforms originating from TSS2 were not affected. In heterozygous clones
there was a 2-fold downregulation of transcripts containing exons downstream of the targeted exon 4,
consistent with premature termination of one of the alleles. In turn, in homozygous clones, this
downregulation was stronger, further demonstrating the efficiency of the stop cassette. The β-gal
cassette was transcribed as part of the LN-BP18 RNA, since transcripts containing either exon 1 or 3
followed by the β-gal (Ex1-beta-gal and Ex3-beta-gal, respectively) could be detected (Figure 19d). No
transcript was detected containing both the β-gal and exon 7 (beta-gal-ex7) in any of the mutants,
revealing an abortion of transcription after the triple pA signal inserted.
Analysis of Sall1 expression additionally confirmed that the insertion did not affect the normal Sall1
levels (Figure 19d), confirming that the inserted cassette affected the expression of only LN-BP18. As
such, any possible misregulated genes or phenotypes detected using these cells should be driven by LN-
BP18 deficiency. However, expression from TSS1 transcripts was upregulated in all mutant clones.
Despite their upregulation, TSS1 transcripts were on average 13-fold lower expressed than TSS2
transcripts (data not shown).
3.3.1.2. Analysis of LN-BP18-β-gal embryos
Despite no activity of the β-gal reporter could be detected in cultured mutant cells or in in vitro
differentiated G4 heterozygous clones, expression of the cassette could be detected in all successfully
transformed clones (Figure 19d). As such, different G4 heterozygous clones were used to generate
embryos by tetraploid complementation assay. Preliminary data from one E11.5 embryo generated from
the ESC clone C5 has revealed that the construct generated is functional, with the expression of β-gal
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driven by the intact LN-BP18 regulatory region. A strong signal was obtained in the mesenchyme of
forelimbs and hind limbs buds as well as in the caudal end (Figure 20), confirming the expression


























Figure 20 - X-Gal staining of E11.5 embryo generated from a G4 derived LN-BP18-β-Gal heterozygous
clone
a) Lateral view. Embryo was dissected using the cutting planes indicated with red dash to generate figure
c); b) dorsal view of the embryo; c) ventral view of the dissected embryo. A strong reporter activity was
obtained in the: caudal end (CE); late somites (LS); mesenchyme of forelimbs (FL) and hind limbs (HL) bud;
neural tube (NT); pronephros (PN); in the midbrain-hindbrain boundary (MHB) and midbrain-forebrain
boundary (MFB) and axial structures (AS) that could represent notochord, floor plate or both. A weaker
and more diffused signal was detected in the genital region (GR) and also at the heart (not shown).
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A strong signal was also observed in the recently formed somites, with a weaker signal detected in
older somites. A specific and strong was detectable in the isthmus, which separates hindbrain from
midbrain and also in the boundary between midbrain and forebrain, confirming the expression in these
three sections of the brain, as was indicated from the embryonic tissue RNA-seq data (Figure 10c). This
RNA-seq data also indicates that the higher expression of LN-BP18 is found in embryonic kidneys, an
indication supported by the β-gal reporter, where expression is found in the pronephros, which
correspond to the first stage of kidney development. A clear signal was also observed on the dorsal side
of the embryo, in the neural tube, which was identified from the RNA-seq as one of the tissues with
higher expression of LN-BP18 (Figure 10c).. A clear signal was also observed in axial structures, which
could be either notochord or floor plate or even both. A weaker expression was observed for other
regions such as the heart and genital region. The observed speckled pattern, especially in regions with
low signal, resulted from a nuclear localization signal on the β-gal cassette.
LN-BP18 and Sall1 have been found to be co-expressed, as observed with WISH, RNA-seq and now
with a reporter construct for LN-BP18, since Sall1 was previously reported to be expressed in the same
tissues as the observed signal from the LN-BP18-β-gal reporter embryo (Buck et al. 2001).
3.3.2. LN-BP18 gene inactivation by excision of its transcription start sites (TSS)
Although the β-gal reporter line generated for LN-BP18 affected the normal transcription of the
lncRNA, due to the stop cassette (3x pA) inserted downstream of the β-gal sequence, the first four exons
could still be expressed (Figure 19d). In the case of the isoform LN-BP18_001 (Figure 14a), this
corresponded to 40% of the total isoform. Therefore, to inactivate the LN-BP18 gene, a different
approach using CRISPR-Cas9 to completely excise either of the TSS, was used. To excise the desired
regions, two different guides were designed for each excision, flanking the targeted region. Cas9
generated DSB at this two sites and repair of these breaks by non-homologous end joining resulted, in
some cells, in the excision of the whole region within the two breaks. Due to positioning of TSS1 within
Sall1 intron, this TSS was excised using guides that kept the Sall1 donor and acceptor splicing sites intact.
For TSS2, a 2.3kb region was deleted, including the full exon 3 (Figure 21a). A double deletion could also
be performed in order to completely abolish LN-BP18 expression, however, individual deletion of each
allowed assessing the impact of TSS on LN-BP18 expression but also of potential interactors, such as Sall1.
As for the generation of the LN-BP18 reporter mutants, G4 cells were cultured, transformed, selected,
frozen and DNA extracted using the same protocol (section 0). In the generation of TSS-KO mutants, 4 µg
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of each CRISPR-Cas9 vector was used to transform G4 cells and for each transformation, 96 clones were
picked and screened by PCR using primers flanking the deleted region and flanking the 5’ induced DSB
(Figure 21c and d, red arrows). With the used PCR conditions (Supplementary Table 4), primers flanking
the excised regions should not generate any signal due to the large size of the flanked region. However,
upon excision of the TSS region, the fragment that these primers amplified was smaller, allowing its
amplification and detection by PCR (Figure 21b, “KO signal”). The use of primers flanking one of the
excision borders generated signal only on the WT allele, since upon excision of TSS, the binding site for
the primer within this regions was lost (Figure 21b,”WT signal”).
The PCR used to screen TSS1-KO mutants generated unspecific amplicons and included in some cases
contamination by feeders DNA that complicated discrimination of heterozygous and homozygous clones.
As such, for promising candidates, clones were expanded, feeder depleted as described in section 2.4.7
and DNA extracted. This DNA free of feeder contamination was used to screen TSS1-KO clones (Figure
21b, left pictures). For TSS2-KO screening results, clean results were observed without any feeder
contamination (Figure 21b, right pictures). Successful excision of the desired genomic region was
confirmed by Sanger sequencing in screened clones (Figure 21c, d). Although for some clones,
sequencing results demonstrated break points precisely at the induced DSB (e.g. TSS1 clone 4E, Figure
21c), in others, slightly different break points were observed, such as for clone TSS2 3C (Figure 21d). For




Figure 21 - Excision of LN-BP18 TSS in mouse embryonic stem cells
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a) Schematic representation of LN-BP18 and Sall1 locus, evidencing the excisions performed to remove
either of LN-BP18 TSS; b) PCR screen of TSS mutant clones. PCR used to detect excision of TSS1 (KO signal)
generated several fainter unspecific bands. A clear and strong signal was obtained for clone 11C, 12C and
2G, c) and d) schematic representation of double strand breaks (DSB) performed by Cas9 in order to
excise TSS1 or TSS2. The chromatogram confirms that the clones had their respective TSS removed,
demonstrating either c) the predicted KO locus, with the break points precisely at the induced DSB or d)
different break points from the predicted ones but still very close to the induced DSB. Primers used for
screening potential mutant clones, red arrows.
3.3.2.1. Characterization of LN-BP18 expression in TSS-KO mutant ES cells
For successfully transformed clones, quantification of LN-BP18 expression by qPCR was performed.
For this, clones were expanded, feeder depleted and their RNA extracted as described before. 5 µg of
RNA were reversed transcribed into cDNA and used for qPCR quantification using splice forms specific
primer sets. To normalize the amount of input material on each sample, the housekeeping gene Pmm2
was used and all samples were quantified in three technical replicates. Results from qPCR revealed that
for five of the eight LN-BP18-TSS1-KO homozygous mutant clones, no LN-BP18 transcripts originating
from TSS1 could be detected (Figure 22a). In the two of the remaining homozygous clones and in
heterozygous clones transcripts containing the longer exon 1 (Ex1ln-4), such as LN-BP18_001, could not
be detected. On the other hand, transcripts, such as LN-BP18_003, that contained a shorter exon 1
(Ex1sh-4) were downregulated but still detectable. Clone 1H was the only analysed clone where an
upregulation was observed for TSS1. This discrepancy with the results of the remaining clones revealed
this was an abnormal clone, or that some contamination with uncharacterized ESC occurred. As such this
clone was not further studied. Transcription from TSS2 was not affect in most homozygous and
heterozygous clones, with a downregulation observed in a homozygous mutant ESC (Clone 11E). For this
homozygous clone and for one of the heterozygous clones the overall LN-BP18 level was downregulated,
while for remaining clones it was either unaffected or slightly downregulated (Figure 22a).
In TSS2 mutants, there was a downregulation of transcripts originating from this TSS and
downregulation of the overall expression of LN-BP18 was also detected, contrary to the effects of TSS1
deletion (Figure 22c). Importantly, Sall1 expression was not affected in TSS2 clones (Figure 22c) neither
in TSS1 clones, even on homozygous TSS1-KO where most of its intron was deleted. This revealed that its
regulatory region was left intact and that splicing was not affected (Figure 22b). The TSS1 homozygous
KO clone 11E was the only homozygous clone with a downregulation of TSS2 and overall LN-BP18
expression, and was additionally the clone with the lowest expression of Sall1. These data revealed
possible genomic alterations not intendent that could not be detected through the screening methods
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applied. As such and as concluded for clone 1H, clone 11E was discarded from further analysis. To test
the effect of LN-BP18 TSS inactivation on other two important pluripotency genes, Nanog and Oct4, were
selected for expression analysis. Unlike Sall1, expression of these genes was upregulated approximately
2-fold in TSS1 mutant clones (Figure 22b). However, when TSS2 was inactivated, this effect was not
observed (Figure 22c). For TSS1 KO cells, plotting LN-BP18 overall levels against Nanog and Oct4, a
positive correlation was observed, with an R squared of 0.410 and 0.387, respectively (Figure 22e).
Figure 22 - Excision of LN-BP18 TSS through CRSIPR-Cas9
Quantification by qPCR normalized to Pmm2 expression and compared to WT sample of a) of LN-BP18
overall, TSS1 and TSS2 transcripts and b) Sall1, pluripotency and differentiation markers in LN-BP18-TSS1
mutants.; c) relative quantification in TSS2 mutant cells of the indicated genes; d) correlation between
ΔΔCT for Nanog and Oct4 against Sall1, e) LN-BP18 overall or f) TSS2 transcripts in LN-BP18-TSS1 mutant
ESCs. Pmm2 was used as an internal control and expression normalized to WT sample (n=3, SD); n.d.,
expression not detectable in sample.
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Additionally, when correlating expression of the two TFs to the expression of isoforms originating from
the TSS2, the coefficient was even higher, with a value of 0.660 and 0.867 for Nanog and Oct4,
respectively (Figure 22f). A similar correlation between the mentioned key pluripotency TFs and Sall1
was also observed (Figure 22d). This correlation between genes expression indicated a possible co-
regulation of these genes or that one of the genes activates the expression of the other.
To better understand the relation between LN-BP18 and Sall1 and untangle their possible role in
pluripotency regulators expression, Sall1 depleted mutants were generated.
3.4. Generation of Sall1 depleted mESC
As already demonstrated, LN-BP18 and Sall1 were expressed in similar tissues and both were affected
by a decrease of Med12 levels (Figure 10b-d). However, LN-BP18 is already lowly expressed in ESC and as
such, the generated LN-BP18 mutant ESCs, which result in a decrease the already low expression of the
lncRNA might not generate any observable effects in ESCs. However, Sall1 is highly expressed in ESC,
where it has been identified as an important factor in pluripotency maintenance (Karantzali et al. 2011).
As such, should Sall1 depletion increase LN-BP18 expression, this effect would be easier to quantify than
a decrease of the lncRNA expression. Additionally, Sall1 depletion could provide insight into these
antisense genes relation and their function in ESCs.
To generate Sall1-KO mutant ESCs, guide RNAs flanking most of its coding sequence were designed in
order to excise the majority of the protein sequence (Figure 23a). As before, G4 cells were transformed
with CRISPR-Cas9 vectors and individual clones were screened for the excision of the coding sequence of
the Sall1 gene. Contrary to LN-BP18 generated mutant cells, where the levels of the mutated gene could
only be quantified on the RNA level, with Sall1 mutant cells the protein level can also be quantified using
a western blot. For this, cells were expanded and protein extracted as described in section 0. The protein
levels of the housekeeping gene β-actin were used to normalize the amount of input used.
Quantification of Sall1 protein levels in mutant clones allowed the identification of heterozygous and
homozygous deletions. While on heterozygous clones Sall1 protein levels were 4-fold lower when
compared to the WT samples (clone 8E and 12E), in homozygous clones (clones 9G and 12D) no Sall1
protein could be detected (Figure 23b). Sanger sequencing of the homozygous clones locus showed that,
in clone 12D both alleles had a deletion of the coding region, with a ~400bp shift downstream in one of
the alleles (Figure 23a and c, “Deletion 2”).
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Figure 23 - Generation of Sall1 depleted ESCs mutant cells
a) Schematic representation of Sall1 locus in WT genome (green background) and in two homozygous
clones, with indication of the induced double strand breaks (DSB) in order to excise the majority of Sall1
coding sequence. Top green track: RNA-seq data for Sall1 obtained for WT sample from section 3.1, b)
Western blot on protein extracts of Sall1 deficient ESC using anti-Sall1 and anti-β-actin antibodies. β-
actin was used as a house keeping gene in order to normalized the amount protein extract used; Sall1
homozygous mutant clones are highlighted in red; c) Chromatogram obtain with Sanger sequencing of
the mutant clones genome. “Deletion 1” represents the predicted deletion, with break point matching
precisely the induced DSB. “Deletion 2” was the deletion found on homozygous mutant clone 12D,
where the break points are located ~400bp downstream of both induced DSB. “Inversion 1” was the
genomic event observed for one of the alleles of clone 9G, where instead of excising the fragment within
the DSB, the whole fragment was inverted.
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Interestingly, in clone 9G while one of the alleles had the expected deletion (Figure 23a and c, “Deletion
1”)), on the other a complete inversion occurred (Figure 23and c, “Inversion”), which also resulted in a
potential null allele, as suggested by the lack of detectable Sall1 protein in this clone (Figure 23b).
3.4.1. Characterization of Sall1 depleted mutants
A previous study by the Kretsovali laboratory demonstrated that Sall1 synergizes with Nanog in the
activation of this key pluripotency TF target genes. It was also shown that Sall1 repressed mesodermal
and ectodermal differentiation markers in ESCs (Karantzali et al. 2011). The authors reduced Sall1
expression by 2-fold using siRNAs, resulting in a similar downregulation of Nanog, while other important
pluripotency factors, such as Oct4, where not affected. Through Sall1 overexpression during embryoid
body differentiation, the researchers also observed a repressor effect on several mesodermal and
ectodermal markers. This effect was further confirmed for Hand1 and T, two early mesoderm markers,
by their 2-fold increased expression in ESC upon Sall1 downregulation. To verify if these reported effects
were also detectable in the Sall1 mutants generated in this project, RNA was extracted from the Sall1
mutant ESC clones, reverse transcribed into cDNA and expression levels of T, Hand1, Nanog and Oct4
were evaluated by qPCR (Figure 24a, b). Contrary to what has been described on the report by the
Kretsovali group, no significant changes on normal Nanog levels were detected even in cells with devoid
Figure 24 - qPCR quantification in Sall1 depleted ESCs
a) Relative quantification of Sall1, Nanog, b) differentiation markers previously reported to be affected
by Sall1 depletion and c) LN-BP18. Pmm2 was used as an internal control and expression normalized to a
WT sample (n=3, SD); n.d., not detectable in sample.
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of Sall1, with T expression was also not effected in these mutant cells (Figure 24a). However a clear
change on Hand1 expression was detected, being upregulated in five of the seven mutant clones.
Interestingly, the reported effects of Sall1 depletion on Nanog and Hand1 expression levels could be
recapitulated on Med12 depleted ESCs. In the Med12null mutant, Sall1 and Nanog were 4-fold and 2-fold
downregulated, respectively, while Hand1 was 8-fold upregulated.
LN-BP18 was quantified in the Sall1 depleted cells. While TSS1 transcripts were downregulated over
2-fold, the overall and TSS2 levels were only mildly downregulated (Figure 24c), suggesting an activating
effect of Sall1 on LN-BP18, acting on transcription originating from TSS1.
3.5. Identification of lncRNAs targets of Med12
Analysis of transcriptome data previously generated by the Schrewe group for Med12null, Med12hypo
and WT ESCs revealed Med12 as an important regulator of ncRNAs expression in ESC (section 3.1). With
these data, over 200 non-coding genes were found misregulated, including several putative novel
lncRNAs, such as LN-BP18. However, as already mentioned, technical and biological variability is a critical
aspect of RNA-seq data analysis, since if not account for, the expression values obtained are not reliable.
This variability is even more important to take into account when analysing lowly expressed genes, as is
the case of most lncRNAs, or when identifying genes with only a slight variation in expression between
the different conditions. This might result a high percentage of false positives and false negatives when
classifying genes as misregulated, as observed for LN-BP18. Although analysis of the original RNA-seq
datasets identified LN-BP18 as upregulated in both Med12 mutant ESCs, with a 3-fold upregulation in its
expression (Figure 10d), qPCR quantification in Med12null cells showed that this lncRNA overall levels
were slightly downregulated and that transcription from TSS1 was 4-fold downregulated.
In order to identify lncRNAs that might be regulated by Med12 and considering the lack of statistical
confidence observed for the original data analysed, new RNA-seq data was generated, using the same
mutant ESCs. Additionally, the Med12flox mutant ESC was also included in the generated data. This
mutant has been previously showed to express Med12 at normal levels and mice generated with it
showed no distinct phenotype and were fertile (Rocha et al. 2010).
Two different biological replicates were used for each sample, which allowed accounting for the
technical and biological variability by performing statistical tests between replicates. All cells were
cultured in 6cm plates until confluent, feeder depleted and RNA extracted with RNeasy Micro kits. rRNA
was depleted from 500 ng total RNA using Ribo-Zero Magnetic Kit and strand specific cDNA was
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generated with ScriptSeq V2 RNA-Seq Library Preparation Kit. To each sample a different index was
added and all samples were pooled and analysed in a lane of a HiSeq 2500 system. Around 45 million
paired end reads with a length of 75 nt were obtained for each sample. Using a longer read size (75 nt in
the new data compared to 50 nt in the original data) increased the likelihood of mapping a spliced reads,
an important aspect when using tools as Cufflinks to identified putative novel genes.
In paired ended sequencing, each fragment is sequenced from both ends. This results in two
sequences for each fragment, called mates. While the first mate results in 5’ to 3’ sequencing of the top
strand of the fragment, the second mate results in the 5’ to 3’ sequencing of the bottom strand of the
same fragment. In order to assess the quality of the generate transcriptome data, FastQC was used on all
samples. This tool allowed detecting and error during the sequencing cycle 40 of the second mate,
rendering all the sequences obtained after position 39 unreliable (Figure 25b). As such only the first 39nt
of mate 2 were used.
Since the analysis of the original RNA-seq data, multiple aligners have been created and newer
versions released for older tools. Since one of the main goals of this dataset was to study lncRNAs, which
are usually lowly expressed, the more reads were mapped to the genome, the more reliable the
expression results for these genes would be. As such, in order to evaluate if a different aligner perform
better than the Hisat2 used to map the original RNA-seq data, Tophat2 (Kim et al. 2013) and Star (Dobin
et al. 2013), two of the most commonly used aligner were evaluated together with Hisat2. The Tophat2 it
is an aligner routinely used in-house and developed to be used together with Cufflinks in a pipeline while
STAR is one of the most commonly used aligners, with benchmark tests identifying this tool as one of the
aligners with higher sensitivity and precision (Baruzzo et al. 2017).Using one of the WT replicates, the
tools were evaluated regarding the number of mapped reads in a proper pair with a mapping score
above 10 (Figure 25a). Among the tested tools, STAR was the one which mapped more reads fulfilling the
filtering criteria with the added bonus of also being the fastest tool (Figure 25a).
The fact that more reads were kept, indicated a potentially higher sensitivity for STAR, which allows
mapping more reads and thus making it easier to detect genes with a low expression, such as lncRNAs.
For this reason, STAR was the chosen aligner for this analysis. De novo transcript assembly was once
again performed before differential gene analysis. Cufflinks de novo assembled transcripts longer than
200bp and with more than one exon were kept, discarding all others, resulting in the addition of almost
420 novel predicted genes. The novel transcripts were filtered before gene quantification since if
maintained in the annotation, these transcripts would be accounted for the read depth normalization
step and as such removing them before this step allowed for a more accurate normalization.
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Cuffdiff is a tool specialized in transcripts quantification, not being the most appropriate tool for gene
quantification. In some cases, this tool also combines multiple genes into a single entry. This merging
behaviour occurs when mapped reads allow assembly of a single transcript that spans genes in close
proximity. One such example is the case of the genes Cd68, Eif4a1, Senp3, Tnfsf12 and Tnfsf13, which
are in close proximity and as such were assigned to one entry with a single expression value, not allowing
quantification of each gene separately. As such, Deseq2 was used instead (Love et al. 2014). This is one
of the most commonly used tools for differential gene analysis, performing a series of statistical tests for
each gene in every pairwise comparison. Principal component analysis revealed that both replicates for
each sample clustered together and separately from the remaining samples, as expected (Figure 25c).








Figure 25- Med12 mutant cells transcriptome data quality control
a) Comparison of performance for the three tested aligners using WT_rep1 sample. Time necessary and
amount of reads in proper pair with a score above 10 after mapping were evaluated; b) Fasqc report for
WT_rep1, representative of all samples, revealing a sequencing error at cycle 40 of second mate; c)
principal component analysis on all samples revealed that all replicates clustered together and away
from other samples; d) sample to sample distances, evidencing the most similar samples.
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Med12hypo and Med12null more similar to one another than to any of the remaining samples (Figure 25d).
Due to the similarity between WT and the Med12flox the latter was used as the control sample (Figure 6a).
This allowed to normalize expression to possible effects resulting from the transformation protocol used
to generate these cells and from the presence of the LoxP sites on the Med12 locus, since it has been
show before that the Cre-Lox system might generate unintended effects throughout the genome (Harno
et al. 2013).
3.5.1. Analysis of misregulated genes in Med12 depleted mESC
Of the 55,000 genes included in the quantification, for 5,000 genes Deseq2 statistical test could be
successfully applied. These tests could not be applied to the remaining genes since they were either
lowly expressed or not expressed in all samples. Over 2,000 genes had their expression effected in one of
the mutants with changes above 50% in expression compared to the Med12flox control, with a false
discovery rate (FDR) < 0.05 (Figure 26a). Although the majority of misregulated genes were protein
coding, 200 were non-coding genes, 50 of which were new transcripts predicted by Cufflinks (Figure 26b).
Contrary to what as observed in the original RNA-seq analysis and as previously demonstrated by qPCR
data (Figure 16c), the overall LN-BP18 level were not significant affected by Med12 deficiency in this new
RNA-seq data.
Comparing the log2FC distribution revealed that genes were similarly misregulated in both mutants, with
upregulated genes showing a higher fold change on Med12null (Figure 26b). This suggested that the 5%
remaining Med12 in the Med12hypo mutant was sufficient to partially repress some of the affected genes.
However, restricting the distribution to misregulated ncRNAs, the differences were more subtle, with
genes more downregulated in the Med12null, contrary to the original data analysed (Figure 8b). GO term
enrichment analysis revealed cell differentiation as the most enriched hit on misregulated coding genes
(Figure 26e), due to misregulated genes such as Forkhead box N4 (Foxn4) and Homeobox protein NK-6
homolog B (Nkx6-2) and genes also misregulated in the original RNA-seq data such as GLI family zinc
finger 2 (Gli2) and Neurogenic locus notch homolog protein 3 (Notch3). This enriched term, together
with regulation of apoptotic process (e.g. Fibroblast growth factor receptor substrate 2 (Frs2) and Early
growth response 1 (Egr1)), cell adhesion (e.g. NUAK family kinase 1 (Nuak1) and Filamin binding LIM
protein 1 (Fblim1)) and cell proliferation (e.g. Cyclin dependent kinase inhibitor 1B (Cdkn1) and
Fibroblast growth factor 5 (Fgf5)) represent diverse processes that act in concert for the proper
development of different organs and tissues. Other enriched terms indicated more specific
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developmental process, such as lung (e.g. Gli3 and Paired like homeodomain 2 (Pitx2)) and limb
development (e.g. Wnt family member 3 (Wnt3) and SPARC related modular calcium binding 1 (Smoc1)),
with the last being one of the expression domains identified for LN-BP18 and Sall1.
Different pathways where Med12 plays clear roles were also identified, due to enrichment of genes
with function on canonical Wnt or BMP signalling pathways (Rocha et al. 2010, Huang et al. 2012),
further confirming the confidence of the identified hits. The broad terms enriched on Med12 depleted
mutants were expected since this gene has been identified as one of the few “hub” genes, on which
multiple processes converge. As such, depletion of this gene affected a variety of developmental
processes, as confirmed by the diverse phenotypes associated with Med12hypo mutants (Rocha et al.
2010).Several of the GO terms enriched in the misregulated coding genes were also enriched for the
misregulated coding genes of the original RNA-seq data (Table 1), such as angiogenesis and axon
guidance, further supporting to the results presented in section 3.1.1. Canonical Wnt signalling was one
of the enriched GO terms identified in the analysis of misregulated protein coding genes (Figure 26e).
However, several of the Wnt targets that had been found to be originally misregulated, such as T, Axin2
and Sall4, in the newer data their expression is not affect by Med12 depletion (data not shown). These
observations reveal that, for some individual genes, the results previously obtained are not supported by
the most recent data. However, the disturbance of important pathways and biological process were
supported.
Interestingly, GO terms were enriched in misregulated ncRNAs, including DNA methylation, with Ftx
as one of the genes identified (Figure 26f). Ftx is one of the Xist regulators in XCI, a process in which
several of its regulators were found misregulated in the previously mentioned RNA-seq data (section 3.1).
From the analysed Xist regulatory genes, only Ftx was found misregulated (Figure 26d), contrary to what
was observed on the previously analysed data (Figure 8d). Despite no clear effect of Med12 on XCI, with
only one of the main regulators of this process misregulated, the data suggested a role for Med12 in the
proper expression of regulators of this process.
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Figure 26 - Med12 mutants RNA-seq analysis
a) Scatter plot of Med12hypo and Med12Nul log2FC for the 5000 genes with a successful statistical test; in
red misregulated genes; b) gene type of misregulated genes; d) log2FC on Med12 mutants of genes
associated with XCI; c) density plots of log2FC distribution on both mutants for all misregulated genes
(left) or misregulated non-coding genes (right); e) GO term enrichment analysis non redundant top hits
for misregulated coding genes or f) non-coding genes.
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3.5.2. Med12 Chromatin Immunoprecipitation data analysis
Analysis of the Med12 mutant cells revealed 150 annotated non-coding genes as well as 50
misregulated putative new genes predicted by Cufflinks as misregulated in at least one of the mutant
samples. Due to the role of MED12 in a plethora of different processes and pathways, demonstrated by
the misregulation of almost 2000 protein coding genes in the analysed Med12 deficient cells, for most of
the misregulated lncRNAs there was a high chance that their expression was indirectly affected by
Med12 depletion and the observed effect was due to misregulation of one or several regulators of these
non-coding genes. If expression of a lncRNA is directly affected by reduced levels of Med12, then this
subunit should be found binding at its promoter or gene body. To identify putative direct targets of
Med12, ChIP-seq data for Med12 in ESC from a previous study was analysed (Kagey et al. 2010). Reads
were mapped with STAR and peaks enriched in the Med12 immunoprecipitated sample against the input
were determined using MACS2, identifying over 2,200 peaks, representing Med12 binding sites in the
genome. Identified peaks were assigned to either promoter, gene body or to intergenic regions (Figure
27a). While the majority of peaks were found associated with protein coding genes in any of the three
regions, significant differences were observed between this regions. In the other regions half of the
identified genes were protein coding, this number increases to 76% when looking at genes bodies (Figure
27b). One explanation for this increase could be the presence of more and larger introns on protein
coding genes, resulting in more peaks found on them. Interestingly, some of the Med12 peaks were
associated with Cufflinks assembled genes, supporting the hypothesis that these might be Med12 direct
targets. Log2FC for both mutants was plotted for all misregulated genes associated with Med12 peaks
(Figure 27c).Genes with peaks in promoter, gene body or in both could be found either up or
downregulated, with a small enrichment for downregulated genes By calculating the density of log2FC
distribution of misregulated genes with peaks in promoter or in gene body it could be observed if Med12
binding affected these genes differently upon the subunit depletion. When looking at all the
misregulated genes, there was a higher density of upregulated genes in the Med12 mutants (Figure 26b,
left). On the other hand, when restricting this analysis to genes with Med12 peaks in the gene body, no
significant difference could be observed in the density of up and downregulated genes (Figure 27e, top
left). Furthermore, the majority of genes where Med12 was found binding at their promoter were
downregulated (Figure 27e, top right). Focusing analysis on the misregulated ncRNAs, the vast majority




Figure 27 - Analysis of Med12 ChIP-seq public data
a) Peak association with different gene regions: promoter (-2kb/+1kb TSS); gene body (-1kb TSS to TES);
Intergenic peaks were associated with the closest gene; b) gene type of genes with peaks on promoter
(top left), gene body (top right) or closest to an intergenic peak (bottom); c) log2FC of misregulated
genes with Med12 binding at promoter and/or gene body; d) venn diagram showing overlap between
misregulated ncRNAs and misregulated genes with Med12 peaks at their promoter and/or gene body ; e)
log2FC distribution for misregulated genes with Med12 peaks in promoter (top left) or gene body (top
right) and for misregulated ncRNAs with Med12 peaks at promoter (bottom).
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However for the ones that were associated with Med12 binding at their promoter, they were mostly
downregulated, revealing these genes as good candidates for being direct targets of Med12 (Figure 27e,
bottom). For these ncRNAs, evidence suggested that Med12 was necessary for their activation,
consistent with the data reported previously on a subset of lncRNA (Lai et al. 2013).
3.5.3. Characterization of lncRNAs putative Med12 targets
Of the 50 misregulated ncRNAs that were predicted by Cufflinks, four had Med12 binding to their
promoter. None of these four genes showed any coding probability by CPAT analysis (data not shown).
Additionally, eight annotated lincRNAs were also misregulated in Med12 depleted ESCs and this subunit
bound their promoter or gene body. Among these was the already mentioned Malat1 and Platr26, a
lncRNA associated with pluripotency.
These genes represent a starting point for future experiments for identifying and characterizing
lncRNAs regulated by Med12. RNA-seq data for embryonic tissues obtained from public databases
indicated that the several of these candidate lncRNAs are expressed mainly on ESC. Additionally the
expression pattern in mouse embryos of these Med12 target candidates and the log2FC of genes within
100 kb of candidate genes was compiled in Figure 28. Misregulated genes within this window represent
putative targets for the candidate lncRNAs, since for multiple lncRNAs it has been shown that they affect







Figure 28 - Candidate direct Med12 target lncRNAs
Log2FC determined for Med12null and Med12hypo for all genes up to 100kb away from the identified
candidate lncRNA (top) and candidate lncRNA expression in 13 different tissues across 8 developmental
stages on mice embryos , downloaded from Encode database and in the analysed ESCs mutants (bottom)
for a) Malat1; b) Platr26; c) 1110002J07Rik; d) Gm26564; e) 2610037D02Rik; f) 4930461G14Rik; g)
Gm47599; h) Gm20703; i) XLOC_033523; j) XLOC_004997; k) XLOC_008906; l) XLOC_057857. For plots of
log2FC, genes are displayed in order they appear in the selected genomic window, from 5’ to 3’ of the
chromosome. Genes without any log2FC calculated for any of the samples were omitted. For genes with




4.1. Med12 depletion in mESCs reflects the phenotypes observed in mutant embryos
Mediator, a conserved multi protein complex involved in the transcription of RNA polymerase II (Pol II)
target genes, acts as a molecular bridge that transduces information from enhancers to the general
transcription machinery at target gene promoters (Krishnamurthy et al. 2009). Among the 30 subunits
that compose this complex, the kinase module subunit Med12has been described as a genetic hub, due
to its function in multiple developmental pathways (Lehner et al. 2006). In humans, mutations of this
gene have been associated with a variety of human pathologies such as cancer (Assie et al. 2014, Lim et
al. 2014) and intellectual disabilities syndromes. Patients with these syndromes show characteristics
resulting from abnormal development of diverse tissues, such as syndactyly, hypoplastic heart defects,
agenesis of the corpus callosum, anal atresia and diverse craniofacial defects (Risheg et al. 2007,
Schwartz et al. 2007, Vulto-van Silfhout et al. 2013). In mouse, embryos generated from Med12null
(producing no Med12 protein) mutant embryonic stem cells (ESCs) died during early gastrulation, with
severe disruption of canonical Wnt pathway (Rocha et al. 2010). Embryos generated with Med12hypo
mutant ESC (with 5% of normal Med12 expression) developed further and displayed striking defects,
such as neural tube closure defects, axis truncation and cardiac malformations, with the latter indicated
as the probable cause of lethality. Whole mount in situ hybridization (WISH) revealed a perturbed
activation of multiple β-catenin target genes in these embryos, correlating with the observed defects and
demonstrating the essential role of Med12 in the activation of Wnt targets in the mouse (Rocha et al.
2010).
To confirm the observations from the mentioned study and to evaluate the impact of Med12
depletion in a more homogeneous sample, Med12hypo and Med12null mutant ESCs, from which embryos
were previously generated were analysed (Rocha et al. 2010). The effects of Med12 depletion in these
cells were evaluated with RNA-seq, a method that allowed to study all expressed genes and
simultaneously to quantify their expression even for lowly expressed genes. RNA-seq data for these
Med12 mutant ESCs and for WT ESCs were previously generated by the Schrewe laboratory. Analysis of
this transcriptome data revealed over 1,400 misregulated coding genes in Med12hypo and/or Med12null
mutants. Clustering of these genes showed that both Med12 mutant cells were very similar in their
expression data, with misregulated genes either up- (clusters 1, 3 and 5) or downregulated (clusters 2
and 4) in both samples (Figure 7). Within the identified clusters, gene ontology (GO) enrichment analysis
on the misregulated genes allowed to identify loci with similar functions within each cluster. This analysis
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revealed genes associated with positive and negative regulation from Pol II transcripts (Table 1),
consistent with the known functions of Mediator. Interestingly, it was observed an enrichment of
misregulated genes involved in heart development, such as motile sperm domain containing 3 (Mospd3)
and Roundabout guidance receptor 1 (Robo1), with the latter also involved in axon guidance (Pall et al.
2004, Blockus et al. 2016). The two GO terms mentioned are linked to of the defects observed in
Med12hypo embryos: abnormal heart development and neural tube closure defects (Rocha et al. 2010).
This observation revealed that strong effects of Med12 depletion could be detected in the analysed data.
The study of the Schrewe group concluded that Med12 was important for the proper activation of
Wnt target genes. This was demonstrated by downregulation of multiple Wnt targets in Med12null
embryos and by the compromised response to canonical Wnt signalling in Med12hypo ESC (Rocha et al.
2010). Analysis of the transcriptome data allowed to confirm misregulation of several Wnt targets, such
as T, Axin2, Ccnd1 and Myc, that had been found downregulated in the reported embryos. Sall4 and Sall1
are two genes important for proper neural tube closure which were found misregulated in the mutant
cells, suggesting these genes as potentially involved in the neural tube defects observed on the reported
mutant embryos (Bohm et al. 2008). As could be shown by the misregulation of the mentioned genes,
the transcriptome data confirmed disruption of β-catenin activation of Wnt target genes upon Med12
depletion.
Even though the RNA-seq data analysed was generated from ESC, several genes with roles in
development were found downregulated (Figure 7, clusters 2 and 4). Downregulation of genes that in
principle should not be expressed in ESC can have two explanations. On one hand, these genes can have
a basal expression level in ESC but, due to Med12 depletion, the Mediator role in basal expression can be
disturbed and so further reduce expression (Lacombe et al. 2013). On the other hand, these genes can
be required for normal development and have additional functions in ESC. Indeed, Sall1 is an important
gene for proper neural tube closure and kidney development and is additionally associated with
pluripotency maintenance (Bohm et al. 2008, Kiefer et al. 2010, Karantzali et al. 2011).
Protein coding genes and ncRNAs were differently affect by the remaining 5% Med12 expressed in
the Med12hypo mutant. This could be observed in the performed clustering, with protein coding genes
similarly misregulated in both mutant cells (Figure 7). By contrast, clustering of the non-coding genes,
revealed clusters with genes differently misregulated in the two mutants (Figure 8a). This was evident,
for example for the first two clusters, where genes were upregulated in only one of the mutant cells. By
plotting the distribution of log2FC for misregulated genes, it was further confirmed the similar effect of
both Med12 mutations in the expression of coding genes and the difference in the ncRNAs expression
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(Figure 8b). Furthermore, through this plot it was possible to observe that the majority of misregulated
non-coding genes were upregulated in both Med12 mutant cells and that more genes were upregulated
in the Med12null compared to Med12hypo. Additionally, a number of misregulated non-coding genes in the
Med12null mutant were not affected by the decrease of Med12 expression in the Med12hypo mutant, as
observed by the higher density of genes in this mutant with a log2FC between -1 and +1 (Figure 8b, plot
on the right). The difference observed between coding and non-coding genes in both mutants revealed
that ncRNAs are more sensible to the remaining 5% Med12 in the Med12hypo mutants.
While the reported embryos generated from Med12null ESCs died at E7.5, the Med12hypo embryos
survived up to E10.5 (Rocha et al. 2010). This difference in embryonic phenotype was due to the 5% of
Med12 still expressed by the Med12Hypo, and this level was suggested to be enough to activate early
processes controlled by Wnt signalling but not for the later processes. In contrast to this hypothesis,
multiple Wnt targets were similarly misregulated in both Med12 mutant ESCs. Several reasons might
explain the observed difference in the generated embryos and the transcriptome data from ESCs. It is
possible that, while the mentioned Wnt targets had a similar expression in both ESCs mutants, the
factors activated by β-catenin at later developmental stages would be differently affected by the residual
Med12. It is also possible that due to the different expression profiles between ESCs and the
differentiated tissues in the embryos, the same Wnt targets would be differently regulated in both cases.
Finally, one of the observations that resulted from the transcriptome data analysis of mutant ESc was the
similar expression of protein coding genes in both Med12 mutants, while non-coding genes were more
sensible to the different Med12 levels. This suggests non-coding genes as a potential source for the
difference in phenotypes observed on the reported embryos.
Despite the known role of Med12 in multiple developmental pathways, one controversial role was in
the maintenance of pluripotency in ESCs. In a study where Med12 was knocked down in ESCs using small
interfering RNAs (siRNAs), Nanog was similarly downregulated which resulted in the downregulation of
pluripotency genes and upregulation of differentiation markers (Tutter et al. 2009). By contrast, previous
analysis of Med12hypo mutant ESC revealed that the reported genes were not misregulated in this mutant
(Rocha et al. 2010). This observation was supported by the RNA-seq analysis of Med12 mutant ESC
performed in this section, since no variation in Nanog or its target genes was detected (data not shown).
The discrepancies observed between the two studies very probably arise from the difference in the
method used to knock down Med12 expression. In the study from the Schrewe laboratory, the Med12
genomic locus was directly manipulated with precise editing (Rocha et al. 2010). However, in the study
from the Kadam group siRNAs were used, that are known to potentially have severe off targets effects,
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which could result in the downregulation on unspecific genes (Tutter et al. 2009). One way to confirm
this hypothesis would be to perform a rescue experiment. For this, the same siRNA would be used in ESC
expressing a mutated Med12 mRNA that is resistant to siRNAs inactivation, an approach successfully
used in previous studies (Jiang et al. 2004). If the expression of Nanog and its target genes was still
perturbed in this experiment, then it could be concluded that the defects were due to unspecific
targeting by the siRNAs.
4.2.Med12 regulates expression of putative novel long non-coding genes
As mentioned before, the Mediator complex is required for the proper expression of almost all Pol II
transcripts (Petrenko et al. 2017). Accordingly, depletion of its subunit Med12 affected expression of
over 1,400 protein coding genes in ESCs. Pol II mediates transcription of all mRNAs but also of most
ncRNAs (Bunch 2018). As such, analysis of the transcriptome of Med12 depleted ESCs also revealed
misregulation of over 200 non-coding genes. The majority of these were already annotated, such as
Platr3, a lncRNA that has been associated with pluripotency maintenance and that is upregulated 2-fold
in both mutants. Tsix and Xist are two extensively studied lncRNAs that were found misregulated in both
mutants, with the latter being the main factor in X chromosome inactivation (XCI). XCI is the process
through which double dosage from genes in the X chromosome is prevented by random inactivation one
of the copies in female cells. Tsix is a repressor of Xist that acts in cis, ensuring that only one of the X
chromosome copies is silenced (Penny et al. 1996, Lee et al. 1999). Other genes involved in this process,
such as Slc1a2 and Tsx, were also misregulated, supporting the identification of XCI as the most enriched
GO term in misregulated non-coding genes (Figure 8c). Misregulation of several genes with a role in XCI
in ESC mutants with decreased expression of Med12, suggests a potential role for this subunit in the
regulation of XCI (Figure 8d). XCI prevents X chromosome double dosage, a problem arising in female
cells which contain two copies of the X chromosome. In male cells that contain only one copy of the X
chromosome, as is the case of the G4 hybrid cells used in this study, this process should not be active. In
order to follow up this potential role for Med12 in XCI a more adequate system should be used, such as
Med12 depletion in female ESC, where XCI is induced upon differentiation.
The fact that only two GO terms were found enriched in the misregulated non-coding genes, while for
protein coding genes an extensive list was obtain can be explained by the reduced number of ncRNAs
that are associated with GO terms. Although thousands of non-coding genes have been described over
the years, only for a small subset was their function determined. As such no Go term is associated to the
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vast majority of identified ncRNAs, explaining not only the reduced GO term list obtained but also the
high p-value associated with them (Table 1).
Multiple other non-coding genes without a known function were also misregulated in at least one of
the Med12 mutant cells (Figure 8a), including putative new genes assembled during this study. Assembly
of novel genes was performed by Cuffllinks which identified thousands of new transcript (Trapnell et al.
2012). The assembled transcripts were filtered in order to select only those with a higher probability of
representing true expressed transcripts. For that reason, only predictions longer than 200 nt and with
multiple exons were kept in the analysis. Of the 400 predictions kept after filtering, 38 were found
misregulated in at least one of the Med12 mutant ESC. A visual inspection of Cufflinks predictions and
mapped reads distribution in the analysed clones for these 38 genes was performed. For 11 of the novel
genes, mapped reads supported the Cufflinks predictions and as such their expression was tested in vivo
using cDNA from WT ESCs. Using primers along the predicted exons, transcripts were amplified for all
genes and sequenced (Figure 9 and Supplementary Figure 1). The isolation of these transcripts
demonstrated that they represented real genes expressed in ESCs and confirmed the predictions made
by Cufflinks, including the multiple isoforms for some of the predictions (Figure 9 and Supplementary
Figure 1). The fact that all selected novel genes where expressed in vivo confirmed that the filtering
criteria applied to the transcripts predicted by Cufflinks, followed by the visual inspection comparing
them to the mapped reads was sufficient to select predictions that reflected real genes and not artefacts.
The identified gene structure for the 11 novel genes was in most cases similar to the Cufflinks predicted
one. As such, although the vast majority of predicted assemble transcripts failed the filtering criteria, for
the selected ones Cufflinks reliably predicted their structure.
Recent reports have shown that small functional peptides can originate from genes previously
characterized as lncRNAS (Nelson et al. 2016). In order to verify if any of the 11 novel genes could
represent a protein coding gene, the coding probability of the isolated isoforms was verified. Using the
tool CPAT, which calculates coding probability from the transcripts sequence, transcripts with a coding
probability below 0.44 are very unlikely to code for any peptide (Wang et al. 2013). This was the case
case for all analysed transcripts, supporting the hypothesis that these represented novel lncRNAs (Table
2).
Having confirmed the expression of these 11 novel lncRNAs in ESCs (Figure 9 and Supplementary
Figure 1) their possible expression pattern during embryonic development was assessed using whole
mount in situ hybridization (WISH). For this method, WT mouse embryos at E9.5, E10.5 and E11.5 were
analysed, using the isolated transcripts (Figure 9 and Supplementary Figure 1) as template for generating
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antisense RNA probes. For the majority of analysed genes, no specific expression pattern was observed
in the tested embryos (Figure 10a). The lack of a detectable specific pattern could be explained in
numerous ways. On one hand, the expression could be very low, which is usually observed for lncRNAS,
and resulting signal too weak to be detected (Cabili et al. 2011). On the other hand, the transcripts could
be expressed at different developmental stages other than the ones analysed. Furthermore, their
expression domain could be restricted to a small subset of cells and as such the signal generated was too
low. These genes could also be expressed in an internal tissue which is not easily observed when using
whole embryos. Finally, the identified transcripts could be ESC specific and not expressed in any
differentiated tissues of the embryo. Despite the lack of a specific signal, some signal was observed in
the analysed embryos (Figure 10a). However, it was not specific and resulted from either trapping of the
reagents in diverse mouse structures, such as observed in the brain vesicles or in the otic vesicles, or
from deposition of the staining subtract on the embryos surface. Nevertheless, for one of the novel
genes designated as LN-BP18, a specific expression in limbs and caudal end of E10.5 and E11.5 embryos
was detected (Figure 10b, bottom row). This new gene was located on chromosome 8, 9 kb downstream
of Sall1 which was closest gene. Since multiple lncRNAs were reported to have an effect in the
expression of their closest neighbour, Sall1 expression was also analysed (Anderson et al. 2016, Ritter et
al. 2019). In the analysed Med12 mutant cells LN-BP18 was upregulated 3-fold and Sall1 was 4-fold
downregulated and WISH performed for Sall1 transcripts revealed a similar expression pattern as LN-
BP18 (Figure 10b and d). Using publicly available RNA-seq data for diverse embryonic tissues at multiple
developmental stages, the spatial and temporal expression of these two genes was further analysed.
These data revealed that they were co-expressed in the analysed tissues, with the highest expression
detected in embryonic kidneys. Both genes were also enriched in limbs and neural tube and to a lesser
extent in forebrain, midbrain and hindbrain. Genes that are co-expressed across developmental time
suggest a shared function and/or regulation (Figure 10c). In accordance with this possibility, both genes
were misregulated in Med12 deplete ESCs (Figure 10d), supporting a interaction between them.
Despite the fact that LN-BP18 has not been characterized before, a previous study revealed that its
locus was co-expressed with Sall1 in early nephrons of E15.5 mice embryos (Thiagarajan et al. 2011).
However no attempt was done in identifying the gene in this locus, or in testing its expression in
different tissues and/or developmental stages. Furthermore, the only mention of a gene in this locus is a
NCBI automatic gene prediction termed Gm3134, which was based on data from over 120 mouse cells
and tissues (Yue et al. 2014), without any form of experimental validation. As such, despite hints
suggesting the existence of LN-BP18 transcript, no clear proof had been previously produced. Chromatin
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immunoprecipitation sequencing (ChIP-seq) data allows identifying the genomic location of the desired
protein. By using antibodies specific for a certain histone modification, their presence can be determined
genome-wide. In active genes, their TSS is usually flanked by nucleosomes containing the histone marks
H3K4me3 and H327ac. Analysis of publicly available Chip-seq data for these histone modifications
supported the LN-BP18 structure that was experimentally obtained, since H3K27ac and H3K4me3 where
found flanking the predicted transcription start site (TSS) of LN-BP18 (Figure 11, blue track). These marks
were also found flanking the predicted TSS for Gm3134, also supporting this prediction. However, except
for the exons that overlapped the LN-BP18 exons, no transcription was detected for the Gm3134 exons
in the Med12 mutant and WT cells analysed (Figure 11, red tracks). As already mentioned, the Gm3134
prediction was based in data generated from of dozens of different cells and tissues, making it possible
that Gm3134 represented the true LN-BP18 structure in other cells. However, due to the discrepancies
between the predicted gene structure of Gm3134, and the verified gene structure of LN-BP18, these two
genes were considered as distinct throughout this thesis.
Interestingly, while mutations on MED12 have been associated with different syndromes, SALL1
mutations are associated with the autosomal dominant disorder Townes-Brocks syndrome (TBS)
(Kohlhase 1993). This syndrome is characterized by anorectal, ear and thumbs malformations and
frequently by heart and kidneys defects. Mental retardation is another recurrent defect, occurring in
about 10% of the patients. Most of enumerated TBS defects have also been associated with Med12
related XLID disorders, revealing a possible disruption of similar genes in both cases (Risheg et al. 2007,
Schwartz et al. 2007, Vulto-van Silfhout et al. 2013). The overlapping characteristics described for the
different syndromes, the effect of Med12 depletion on the expression of Sall1 and LN-BP18 in ESCs and
the observation that the expression profile of these two genes was very similar led to a more detailed
characterization of this novel lncRNA and of its possible interaction with Sall1.
4.3.LN-BP18 presents a complex gene structure
The gene structure of LN-BP18 predicted by Cufflinks (Figure 9, black track) was experimentally
validated using WT ESC cDNA (Figure 9, blue track), with the four exons identified spliced in two different
variants. However, RNA-seq data generated from Med12 mutant ESCs suggested that some of the exons
were actually longer then what was identified (Figure 9, red tracks). Additionally, one of the identified
exons was not supported by the analysed transcriptome data, since no reads were mapped to it. As such,
a more detailed characterization of this novel gene structure was performed.
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lncRNAs share multiple features with mRNA, such as addition of a cap to their 5’ end, that confers
stability to the RNA and protects it from exonucleases degradation. They can additionally be processed
and a poly adenylated tail (poly-A tail), which consists of hundreds of adenine bases in tandem, added to
their 3’ end. Most of the identified lncRNAs are also spliced, with an average of ~2.3 isoforms per gene
found for human lncRNAs (Guttman et al. 2009, Cabili et al. 2011). In order to identify the full length of
LN-BP18 transcript, the transcription start site (TSS) and transcription end site (TES) were determined. To
identify the TSS of LN-BP18, a 5’ RACE approach was applied to WT ESC cDNA. With this method the TSS
was identified in an additional exon 10 kb upstream of the previously identified first exon, in the first
intron of Sall1 (Figure 12, “TSS1”). Further 5’ RACE experiments using primers in the newly identified
exon confirmed the presence of this TSS. Additional 5’ RACE experiments identified an alternative TSS,
located slightly upstream of the first exon predicted by Cufflinks (Figure 12, “TSS2”). These data
suggested two alternative TSSs for LN-BP18. In order to validate the identified TSSs, additional data was
analysed. As mentioned before, the TSS of active genes is usually flanked by nucleosomes containing the
histone marks H3K4me3 and H3K27ac. Additionally, in order for the genes to be expressed the pre-
initiation complex (PIC) must be assembled near the TSS and chromatin in this region must be accessible
to allow binding of the different factors. This accessibility can be verified using DNaseI hypersensitivity
sites sequencing (DNase-seq) which identifies open chromatin regions based on their sensitivity to
DNaseI digestion. With cap analysis gene expression (CAGE), the 5’ end of RNAs is sequenced and
mapped genome-wide. With these data, the genomic location from where transcription started can be
identified. Data from the Fantom consortium combines CAGE data for multiple mouse cells and tissues
and the peaks present in these data represented potential TSS. Furthermore, since lncRNAs are
transcribed by Pol II, ChIP-seq data for this factor indicates where transcription is active or poised. Using
the mentioned data, obtained from public databases for ESC (Figure 12, green coloured data) and
different embryonic tissues from which E14.5 brain tissue data was representative (Figure 12, blue
coloured data), both identified TSS for LN-BP18 were characterized. The TSS1 of LN-BP18 was flanked by
an enrichment of H3K4me3 and H3K2ac histone modifications, with Pol II found binding in this TSS.
Additionally, this region consisted of open chromatin, as assessed by DNase sequencing and a CAGE peak
was present near the TSS1. All of these features were observed in ESC and also in differentiated tissues,
confirming TSS1 as a true TSS in all analysed cell types. In contrast, although the same features were
found confirming TSS2, this was only observed in in ESC. In differentiated tissues, no enrichment of
active histone marks was observed flanking this TSS, Pol II was not bound in this region and the
chromatin was condensed. These features suggest that while TSS1 is active in all cell types, TSS2 is active
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only in ESC, with transcription from TSS2repressed upon differentiation. These observations suggest that
the expression of LN-BP18 observed in different tissues by WISH or by RNA-seq data results from
transcription exclusively from the TSS1.
Having identified two distinct TSS for LN-BP18, its TES was identified with a 3’ RACE approach using
RNA extracted from WT ESC. The first step in this method is to reverse transcribe RNA using an oligo dT
primer. As such, only polyadenylated RNAs can be used with this approach. In order to confirm the
presence of a poly-A tail in LN-BP18 transcripts, RNA extracted from WT ESC was used to generate cDNA
with oligo dT primer. With this cDNA, gene specific primers (GSP) for LN-BP18 were used in order to
amplify fragments of LN-BP18. Amplification of LN-BP18 fragments from cDNA generated using oligo dt
primer, which should reverse transcribe only polyadenylated RNA, suggested the presence of a poly-A
tail in LN-BP18 transcripts (data not shown). Using the 3’ RACE approach with WT ESCs RNA, a stretch of
27 adenines in tandem was located in the last exon (Figure 13a). PCR amplification using primers flanking
this repetitive region on cDNA generated with random hexamers or with oligo dT primer revealed that
the oligo dT primer used during the first step of the 3’ RACE method bound to two distinct region: the
poly-A tail and the stretch of adenines present in the sequence of the last exon (Figure 13a, black arrows).
This caused the generation of two cDNA fragments from LN-BP18 transcripts: one from the poly-A tail up
to the stretch of adenines identified and another from this repetitive region to the 5’ end of the original
RNA. This hypothesis was supported by the lack of amplified fragments using cDNA generated with oligo
dT and primers flanking the stretch of 27 adenines (Figure 13a, red arrows and Figure 13b). Repeating
the 3’ RACE experiment using primers downstream of the repetitive region (Figure 13a, blue arrows)
allowed to identify the true TES of LN-BP18 (Figure 12). A consensus polyadenylation signal (AATAAA)
was identify in this genomic location, further supporting the identified TES and the presence of a poly-A
tail in LN-BP18 transcripts (Proudfoot et al. 1976).
The initial isolation of LN-BP18 transcripts from ESC revealed the presence of two distinct isoforms
(Figure 9). However, after this initial analysis additional exons and two distinct TSSs have been identified.
Analysis of active transcription marks indicated that TSS2 was only active in ESCs (Figure 12), suggesting
that all expression of LN-BP18 observed in embryonic tissues, such as in forelimbs, originated exclusively
from TSS1. Thus, to identify additional isoforms, cDNA was generated from RNA extracted from ESCs and
from forelimbs. Using these cDNAs, LN-BP18 transcripts were amplified by PCR using primers in either
TSS and in the TES (Figure 13a, green arrows). Since the initial PCR run resulted in low signals and in the
amplification of unspecific fragments, a nested PCR was performed using the original PCR as template
and primers adjacent to the first set of primers. Amplified fragments were sequence and their different
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splice variants identified. With this methodology, two additional exons and nine full isoforms were
identified (Figure 14a). For three of the seven exons (Exon 1, 3 and 4) different splice variants were also
identified, with shorter and longer versions of the same exons identified in different isoforms. Fragment
LN-BP_010 was obtained using primers in exons 1 and 3 and does not represent a full isoform since there
was no information regarding the reaming exons present after exon3. However this fragment was the
only instance were exon 2 was identified, and as such as still included.
Analysis of all isoforms by CAPT revealed a lack of coding potential for all isoforms (coding probability
< 0.44) (Figure 14b). In order to confirm this observation, PhyloCSF data was also analysed. These data
identify evolutionary signatures by aligning different mammal datasets and has been successfully used to
identify small peptides originating from genes characterized as lncRNAs (Nelson et al. 2016). A clear
signal was obtained in the coding regions of Sall1 (Figure 14c). In contrast, no signal was obtained in the
whole locus of LN-BP18, supporting the lack of coding potential for this gene. Since multiple isoforms
were identified for LN-BP and these were amplified using a nested PCR, which allows amplification of
very lowly expressed transcripts, it was possible that some of identified isoforms resulted from abnormal
splicing events that would usually be targeted for degradation (Wery et al. 2016). One way of verifying
this possibility is to analyse the splicing acceptor and donor sites in the identified exons (Senapathy et al.
1990). In exons without a consensus donor and/or acceptor sites, the hypothesis that they resulted from
aberrant splicing events is supported. Analysing the identified exons, majority of them contained the
mouse consensus acceptor and donor sites (Figure 14d). The exceptions were a smaller variant of exon 1
which was only found in isoform LN-BP18_005, exon 2 that is present only in the fragment LN-BP18_010
and the acceptor site for exon 3 only found in the same fragment. These exons were identified in a single
transcript, contrary to the remaining exons that were found in multiple isoforms. These data suggest that
isoform LN-BP18_005 and the fragment LN-BP18_010 are not true LN-BP18 isoforms but that in fact are
aberrant splice variants. The lack of an identified isoform containing both exon 1 and exon 3 reveals that
transcripts originating from TSS1 do not retain exon 3, where the TSS2 is located.
Comparing the predicted Gm3134 and LN-BP18 revealed a similar structure, with a predicted splice
pattern as complex as what was observed for LN-BP18 (Figure 14). The majority of exons were common
between LN-BP18 and Gm3134, although in some cases the described length was very different. These
discrepancies were observed for exon 5 of LN-BP18 which was 170 bp and in Gm3134 was predicted to
1800 bp long. Other exons were present in only one of the genes, such as exon 6 of LN-BP18. The
similarity between the predicted Gm3134 and the experimentally validated LN-BP18 revealed that the
automatic predictions can be very similar to the true gene structure, hence representing a good starting
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point for the study of the uncharacterized genes. Although some of Gm3134 features were not observed,
such as some exons, it is possible that they could be validated using tissues other than the ones used in
this study. As mentioned before, human lncRNAs show an average of ~2.3 isoforms (Cabili et al. 2011).
As such, the splicing pattern identified for LN-BP18 is far more complex that what is usual for lncRNAs.
Yet, previous reports have identified lncRNAs with an even more complex pattern, such as GNG12
antisense 1 (GNG12-AS1), a lncRNA with 10 exons that can be spliced into 38 different isoforms
(Niemczyk et al. 2013). This reveals that the complex splicing pattern of LN-BP18 was above average but
still within what has been found for other lncRNAs.
In order to identify possible conserved LN-BP18 transcripts in other species, BLAST searches using the
full sequence of the isoforms, together with identified open reading frames (ORFs) or putative proteins
coded by the ORFS found on each isoform revealed no homologous transcripts in other species. However,
an uncharacterized lncRNA termed AC087564.1 has been predicted in humans. Similarly to LN-BP18, this
predicted ncRNA is divergent of Sall1. Alignment of the isoforms of this predicted ncRNA and isoforms
identified for LN-BP18 confirmed the lack of conservation between the two genes. The calculated
identity between the isoforms of both genes was on the same levels as compared to completely
unrelated lncRNAs, such as Fendrr and Hotair (Figure 15). Multiple lncRNAS have demonstrated poor
sequence conservation but conserved function. Indeed, Gas5 is a lncRNA that acts as a regulator of self-
renewal and pluripotency in mouse ESC and in human induced pluripotent stem cells, despite poor
sequence conservation between the two species (Tu et al. 2018). The divergent position regarding Sall1
supports a relation between LN-BP18 and AC087564.1, which might translate in similar functions despite
the lack of sequence conservation. However, to confirm this hypothesis a more detailed characterization
of AC087564.1 is necessary.
4.4. LN-BP18 is dynamically expressed in vivo
The generated whole mount in situ hybridization (WISH) data allowed to detect LN-BP18 expression
in forelimbs, hind limbs and in the caudal end of E10.5 and E11.5 mice embryos. Publicly available
transcriptome data confirmed that LN-BP18 was enriched in these tissues and revealed additional
expression in kidney and in neural tube, with lower expression in brain. A silar expression pattern was
observed for Sall1, co-expression and/or similar functions (Figure 10b, c). Considering the identified TSSs
for LN-BP18 and the observation that TSS2 showed a ESCs specific activation, the lncRNA expression was
evaluated in different contexts. First it was quantified in nuclear and cytoplasmic fractions of ESCs, since
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the cellular localization of a lncRNA can provide hints for their function. For example, Xist plays a role in
transcription repression and so is found enriched in the nucleus (Penny et al. 1996). When LN-BP18
expression was quantified in these two fractions no clear enrichment could be observed for transcripts
originating from any of the TSSs (Figure 16b). Since the analysed RNA-seq data revealed a very low
expression of LN-BP18 in ESCs, with a PFKM of 2.6 (Figure 10d), it is possible that expression levels were
not sufficient to properly detect enrichment in any of the two analysed fractions. It was also possible the
LN-BP18 was located at similar levels in both fractions, with different function in each of them. To
properly identify the cellular location of LNBP18, a more robust and reliable approach would be to use
RNA fluorescence in situ hybridization (RNA-FISH) with labelled probes against LN-BP18 (Femino et al.
1998). With this method, it would be possible to determine LN-BP18 localization on ESCs despite its low
expression, as previously applied to other lowly expressed lncRNAs (Ritter et al. 2019).
By qPCR quantification LN-BP18 was found to be enriched 4 to 8-fold in forelimbs, hind limbs and the
caudal end of E11.5 embryos compared to the remaining analysed tissues (Figure 16d), confirming the
expression pattern detected with WISH (Figure 10b). Interestingly and in accordance with the hypothesis
that TSS2 represented a ESCs specific start site, no transcription initiating from TSS2 could be detected in
any of the embryonic tissues analysed (Figure 16d). This confirmed that in differentiated tissues, TSS1 is
the main start site used for LN-BP18 transcription. Quantification of LN-BP18 in Med12null ESCs, revealed
that LN-BP18 overall levels and transcription from TSS2 where not affected by Med12 deficiency. In
contrast, transcripts from TSS1 were 4-fold downregulated in these cells (Figure 16c). The strong
downregulation of LN-BP18 TSS1 while its overall levels and TSS2 transcription remained unchanged
revealed that the main TSS for LN-BP18 expression in ESC is the TSS2, contrary to what was observed in
differentiated tissues (Figure 16d). This observation was confirmed by the 40-fold lower abundancy of
TSS1 transcripts compared to TSS2 transcripts in G4 cells, as calculated by the qPCR data obtained (data
not shown). In mutant ESC expressing a mutated version of Med12 associated with Opitz-Kaveggia
syndrome (R961W), a similar but milder effect was observed. In this clone, LN-BP18 TSS1 transcripts
were 2-fold downregulated while no change in transcription from TSS2 was detected (Figure 16c). The
downregulation of TSS1 but not of TSS2 transcripts in the different Med12 mutant ESCs analysed
suggested different mechanisms regulating expression from each TSS. These data suggested that
activation of LN-BP18 transcription involved a mechanism mediated by Med12, while activation of TSS2
transcript was Med12-independent. Furthermore, Sall1 was also found downregulated in the Med12
mutant ESCs, with a stronger downregulation observed in the Med12null cells compared to Med12-Opitz
cells. While TSS2 transcripts were not affected, TSS1 and Sall1 were similarly downregulated in both
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mutants. This suggested a co-regulation between LN-BP18 TSS1 and Sall1, which might correlate with
shared function.
The downregulation of Sall1 observed in Med12-Opitz mutant ESCs (Figure 16c) suggested a role for
Sall1 in at least some of the defects observed in patients with Med12 associated pathologies, as is the
case of the Opitz-Kaveggia syndrome. Sall1 functions on heart development, limb morphogenesis and is
critical for proper kidney formation (Nishinakamura et al. 2005, Kawakami et al. 2009, Morita et al. 2016).
In Med12 associated intellectual disabilities, defects in all of these tissues have been described, further
supporting a disrupted function of Sall1 in these patients. Several mutant ESC and mouse expressing
mutated Med12 versions associated with Opitz-Kaveggia, Lujan-Fryns and Ohdo intellectual disabilities
syndromes have been generated by the Schrewe group and represent an extremely useful tool to further
study the mechanism behind the observed phenotypes in human patients. In Med12-Opitz mutant cells,
LN-BP18 transcription from TSS1 was also found misregulated. The effects caused by the Med12
mutated protein on LN-BP18 expression suggest a possible functional role for this lncRNA in pathologies.
The confirmation of LN-BP18 misregulation in the other mentioned Med12 mutant ESCs and especially in
mouse lines expressing these mutated Med12 would strengthen the claim of such functional role.
The methods used to evaluate LN-BP18 expression, present their own limitations. Although WISH
allows determining the spatial and temporal expression of a gene, it lacks sensitivity which makes it less
useful for studying genes lowly expressed, as is the case of LN-BP18 and lncRNAs in general. In contrast,
qPCR has a great sensitivity and allows to quantify even lowly expressed transcripts, however its capacity
to detect specific expression domains during embryo development is dependent on how finely dissected
the analysed sample is. The drawbacks for qPCR are also true for data generated by RNA-seq. The
generation of a reporter line, in which a gene that generates a signal quantifiable even at low levels and
under the control of the same regulatory elements as LN-BP18, allows to overcome the mentioned
limitations. Furthermore, by generating embryos with these reporter cells it is possible to assess the
temporal and spatial expression pattern of a gene with high sensitivity by detecting the signal generated
by the reporter cassette. To generate a reporter line for LN-BP18, a beta-galactosidade (β-gal) reporter
cassette was knocked-in into exon 4 of LN-BP18. Additionally, a triple polyadenylation signal (3x pA) was
included downstream of the reporter cassette. The generated transgene should be expressed only when
LN-BP18 expression is induced, reflecting this lncRNA true expression pattern. Due to the insertion of the
3x pA, transcription of the remaining LN-BP18 transcripts should be prevented, resulting in the
expression of only truncated transcripts. This disturbance of the normal LN-BP18 might result in
phenotypes in embryos generated from these reporter cells. Using CRISPR-Caas9 to insert this reporter
Chapter 4
126
cassette into LN-BP18 exon 4 through homologous recombination (Figure 17a) in G4 hybrid cells allowed
the generation of heterozygous ESC clones, which showed successful transformation of one of the alleles
(Figure 17b and c).
X-gal staining of heterozygous reporter ESCs cultures revealed no evidence of active reporter (data
not shown), even though expression of the reporter cassette expression could be detected by qPCR
(Figure 19d). The absence of reporter activity could have resulted from lack of necessary elements for
proper assembly of translational machinery or from adoption of complex structures by transcript which
prevented proper ribosomal function. The reporter could also be active but at such small levels that
could not be properly detected. To test the activity of the reporter cassette, additional systems were
tested. A previous study has generated RNA-seq data for mesodermal progenitors cells (NMPs) that co-
expressed Brachyury (T) and Sox2, as well as for cells expressing either T or Sox2 (Koch et al. 2017).
These populations were sorted from the caudal end of E8.5 embryos and analysis of their transcriptome
allowed to detect expression of LN-BP18 (Figure 19b).
To verify if reporter activity could be detected in these cells, a previously published protocol was used
to differentiate ESCs (Figure 19b). By day 3 of the in vitro differentiation protocol cells were
transcriptionally similar to the NMP population and by day 5 were similar to cells expressing T but not
Sox2 in the caudal end of E8.5 embryos (Gouti et al. 2014, Koch et al. 2017). This protocol was applied to
two different β-gal heterozygous clones and expression quantified throughout the course of
differentiation. Despite the 2-fold upregulation of the reporter cassette after five days of differentiation
(Figure 19c), no reporter activity was observed after X-Gal staining in any time point (data not shown).
These data supported the hypothesis of an inefficient translation of the cassette, since the expression of
the cassette was verified to be upregulated. However it could still be that despite the observed 2-fold
increased expression, the expression was still too low to be detected. Despite the lack of reporter activity,
quantification of LN-BP18 expression throughout the differentiation protocol revealed that transcription
from TSS1 increased from day 4 up to 8-fold by day 5. On the other hand, TSS2 transcription decreased
up to 10-fold from day 3 to day 5 of differentiation. This dynamic confirmed that TSS2 is active mainly in
ESCs and that upon differentiation, transcription is repressed from this site while from TSS1 is activated.
In the G4 (129S6/C57BL6) hybrid cells used, a mutation in the PAM sequence was identified in the
129S6 allele (Figure 17d). This mutation prevented the Cas9 nuclease to generate the intended DSB in
the 129S6 allele and as such, using the G4 cells only heterozygous clones could be obtained. Since the
transformation protocol was successful in transforming the allele with C57BL6 background, JM8 ESC
were used and the same protocol applied. In these cells, that have a C57BL6 background, homozygous
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and heterozygous transformed clones were successfully generated (Figure 18b). Analysis by qPCR on
these clones revealed that transcription after the 3x pA was 6-fold decreased in homozygous clones,
while on heterozygous clones it was 2-fold decreased (Figure 19d). These data support the high
efficiency of the inserted 3x pA signal in stopping transcription. Since the stop cassette was inserted into
exon 4, and the primers used to quantify TSS1 and TSS2 isoforms as well as the overall LN-BP18 levels
were located before the inserted cassette, it was still possible to quantify expression of these transcripts.
In the reporter clones, no changes were observed on LN-BP18 TSS2 transcription and on Sall1 expression.
In contrast, a 6-fold upregulation of TSS1 transcripts was observed (Figure 19e). In ESCs, even with this
upregulation, the TSS1 transcripts accounted for less than 6% of the total LN-BP18 transcripts. However,
since TSS1 is active mainly in differentiated cells, it is possible that upon differentiation the levels of LN-
BP18 originating from TSS1 in the reporter line would be higher than normal due to this effect. As such a
proper WT control should be used to account this possible variation.
Analysis of cultured mutant ESC transformed with the β-gal reporter construct revealed no activity of
the reporter. Additionally, no reporter activity was detectable when selected G4 derived heterozygous
clones were in vitro differentiated into mesodermal progenitors cells (NMPs) or paraxial mesoderm, cell
types which express LN-BP18 (Figure 19a). However, qPCR data for clones successfully transformed with
the β-gal reporter cassette revealed that the inserted cassette was expressed as part of LN-BP18
transcript (Figure 19d). In order to verify if the expressed cassette was functional in vivo, embryos were
generated from G4 derived LN-BP18-β-gal heterozygous clones through tetraploid complementation
assay. Preliminary data obtained for one E11.5 embryo generated from clone C5 (Figure 17b) revealed
that the inserted cassette is functional, since a specific signal could be detected in this embryo (Figure
20). Confirming the data from the WISH analysis (Figure 10b), a strong expression was observed in the
mesenchyme of forelimb (FL) and hind limb (HL) buds and in the caudal end (CE), where a strong signal
was also observed in late somites (S) (Figure 20). The strong reporter activity was restricted to late
somites, since the signal in early somites was significantly weaker suggesting a potential role in axis
elongation. Expression in the caudal end confirms the observation that LN-BP18 was expressed in cells
isolated from the caudal end of E8.5 embryos expressing T, Sox2 or both (Figure 19a) (Koch et al. 2017).
Expression of LN-BP18 in NMPs further revealed that LN-BP18 is expressed as early as E8.5 at the caudal
end and possibly in the other tissues where expression was detected. In agreement with the RNA-seq
data for different embryonic tissues (Figure 10c), expression was identified at the forebrain, midbrain
and hindbrain, specifically at the boundaries that separate these structures (Figure 19 , MHB and MFB).
Sall1 is an essential regulator of kidney development and since the data described before indicated that
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Sall1 and LN-BP18 are co-expressed (Figure 10b and c), LN-BP18 was also expected to be expressed in
these organs, a hypothesis supported by the RNA-seq data (Figure 10c). Although at E11.5 embryos the
kidneys have not started to form, a staining occurred at the intermediate mesoderm, more specifically at
pronephros. These structures correspond to the first of three stages of kidney development in mammals,
confirming the co-expression of Sall1 and LN-BP18 in these organs. As kidneys, the known role of Sall1 in
neural tube closure (Bohm et al. 2008) and the observed co-expression of this gene and LN-BP18
suggested expression of the lncRNA in this tissue, supported by RNA-seq data, in which a higher
expression of LN-BP18 observed in this tissue (Figure 10c). Expression of LN-BP18 in the neural tube was
confirmed with the reporter embryo, with a clear signal observed along neural tube (Figure 19, NT). A
clear signal was also obtained in axial structures, which can originated from notochord, floor plate or
both (Figure 19 , AS). However, due to their similar position and shape in the embryo, it is not possible to
distinguish in which of these structures the signal is generated. For this distinction, a more detailed
analysis is necessary, such as embedding the embryo and performing transversal sections of the spinal
cord. Imaging these sections should present clear evidence of which of these two structures revealed
reporter activity. Other expression domains with a lower signal have been additionally identified. These
included the genital region (Figure 19, GR) and the heart (not shown), with the latter being supported by
the RNA-seq data analysed (Figure 10c). Although no expression data are presented in this study to
support expression in the genital region, Sall1 has been shown to be expressed in the genital tubercle in
E11.5 mice embryos (Buck et al. 2001). Additionally, anorectal malformation are a common defect
observed in patients with Townes-Brocks syndrome (TBS) (Townes et al. 1972). Together with the
observed co-expression of Sall1 and Pn-BP18, These data support LN-BP18 expression in the genital
region of embryos. No clear phenotype was observed in this mutant, despite the disruption of LN-BP18
expression due to the presence of a stop cassette downstream of the β-gal cassette. It is possible that
since this was an heterozygous clone, LN-BP18 expression of the WT allele was enough to mitigate any
possible defects arising from the disruption of the transformed allele. In order to verify this hypothesis or
if no defects would be observed even if both alleles were disrupted, embryos should be generated from
the JM8 derived LN-BP18-β-gal homozygous reporter cells.
Disruption of LN-BP18 expression from TSS1 in Med12 mutant cells (Figure 16c) and the observed
expression in multiple tissues where defects were detected in previously reported Med12 deficient
embryos (Figure 20) (Rocha et al. 2010) suggest a potential role for LN-BP18 in these defects. Analysis of
LN-BP18 expression in the Med12 deficient embryos would allow verifying if this lncRNA is misregulated
in these embryos, supporting a functional role for LN-BP18 and mediation of its expression by Med12.
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4.5. LN-BP18 correlation with coding genes suggest a possible role in pluripotency
While the β-gal reporter line generated for LN-BP18 disrupted its expression, up to 40% of the lncRNA
was still expressed since the stop cassette was inserted in exon 4. In order to generate cells that do not
express LN-BP18, different mutants were created by complete excision of one of the two TSSs using
CRISPR-Cas9 (Figure 21a). Analysis of LN-BP18 expression in TSS1-KO clones revealed one of the clones as
abnormal (1H), since it was the only clone with an increased expression of TSS1 transcripts. This might
have results from some contamination with other cells, or from unpredicted genomic rearrangements in
the LN-BP18 locus that were not detected. As such, this clone was excluded from further analysis. Clone
11E was also excluded from the analysis since it was the only clone with a notorious downregulation of
LN-BP18 TSS2 transcripts and Sall1 expression (Figure 22a and b). For the remaining homozygous KO
clones, no transcripts originating from TSS1 could be detected. In heterozygous deletions, some of the
isoforms (e.g. LN-BP18_001) were downregulated 2-fold and others (e.g. LN-BP18_003) were not
detectable (Figure 22a). As observed before, in ESCs the TSS2 was the main active transcription site and
transcripts from TSS1 were near the detection limit. As such it is possible that a small decrease of these
transcripts would result in levels below the detection limit. This would lead to a lack of quantifiable
signal even in the heterozygous clones. The deletion in these clones specifically affected TSS1 transcripts
since there was no significant effect on the TSS2 transcripts in ESCs (Figure 22a). As TSS2 is the main
transcription site for LN-BP18 in ESCs, no effect on overall levels of LN-BP18 was observed in TSS1
mutant ESC. For TSS2 deletion, due to the small efficiency of transformation, only heterozygous clones
were obtained. On these, the opposite effect was observed. No changes were detected in TSS1
transcripts, while TSS2 and overall levels were 2-fold decreased. For both TSS1 and TSS2 mutants, no
changes were observed on Sall1 expression (Figure 22c). This suggested that LN-BP18 does not affect
Sall1 expression, since halving LN-BP18 levels by deleting one copy of TSS2 had no effect on Sall1
expression (Figure 22b).
Curiously, upon TSS1 deletion, expression of Nanog and Oct4, two important pluripotency genes, was
2-fold increased in these clones (Figure 22b). In TSS1-KO mutant cells, a positive correlation was
observed between LN-BP18 overall expression and Nanog and Oct4 gene expression (Figure 22e). The
correlation between the genes suggested that they were either co-regulated or that one of the genes
regulated the others. An even stronger correlation was observed between these two pluripotency genes
and TSS2 transcripts (Figure 22f). Since these transcripts are ESC specific, their correlation with two
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important pluripotency regulators suggested a function in the pluripotency network for LN-BP18
transcripts originating from TSS2. This hypothesis would explain why these isoforms are repressed upon
differentiation, since during this process the pluripotency network is suppressed in favour of
differentiation programs. Sall1 has been associated with maintenance of pluripotency and its depletion
with siRNAs resulted in Nanog downregulation in ESCs (Karantzali et al. 2011). In TSS1-KO mutant ESCs,
Sall1 expression was also correlated Nanog and Oct4 levels (Figure 22d). Since both LN-BP18 and Sall1
were correlated with pluripotency regulators, this suggested a shared function for these antisense
neighbours in the maintenance of pluripotency network in Esc. In contrast, it is also possible that only
one acts on the pluripotency network while simultaneously activating the expression of its neighbour.
4.6.Sall1 depletion in ESC suggests an activation function on LN-BP18 expression and supports a
role for the lncRNA in pluripotency
Sall1 has been linked to pluripotency in a previous study by the Kretsovali laboratory (Karantzali et al.
2011). In this study, depletion of Sall1 by siRNAs in ESCs resulted in a 2-fold downregulation of Nanog, a
key regulator of pluripotency. A 2-fold upregulation of Hand1 and T, two important differentiation
markers was also observed upon Sall1 depletion. This study suggested a double role for Sall1 in the ESC.
It induced Nanog expression and by consequence expression of Nanog target genes in ESCs, while also
repressing differentiation markers. In order to untangle the effect of Sall1 and LN-BP18 in pluripotency
maintenance and to better understand the relation between these two genes, Sall1 deficient EScs were
generated by excision of most of Sall1 coding region using the CRISPR-Cas9 method (Figure 23b). Despite
the very precise induction of double strand breaks (DSB) by the Cas9 nuclease, the repair mechanism can
repair these breaks in different ways, resulting in variations between clones, as observed by the
presence of bands of different sizes when screening LN-BP18-β-gal transformed colonies (Figure 17b).
Additionally, both alleles of Sall1 homozygous KO clone 12D had a deletion of similar size, but for one of
them a shit of the deleted region around 400bo was observed (Figure 23a and c). For the second Sall1
homozygous clone, it was observed a complete inversion of the whole region that should have been
excised, a phenomenon observed in previous studies and in some cases taken advantage of in order to
generate inversions or even duplications in the genome (Korablev et al. 2017). These observations
revealed that a proper screening strategy is necessary in order to detect the occurrence of such
anomalous events. Expression analysis in the generated Sall1-KO ESCs revealed a downregulation of Sall1
by 2 to 4-fold in heterozygous mutants (Figure 24a). In contrast to what was reported by the Kretsovali
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group, no effect was observed in Nanog expression (Figure 24a). Even on homozygous mutated clones,
where no Sall1 could be quantified, Nanog levels were unchanged (Figure 23b, Figure 24a). Additionally,
despite the report that Sall1 depletion did not affect Oct4 expression, a small downregulation of this
gene was observed in the generated mutants. Sall1 repressive effect on differentiation markers could be
confirmed for Hand1, with levels of this gene upregulated over 4-fold upon Sall1 depletion. However, for
T only a small increase, below 2-fold, was observed (Figure 24a, b). In the Kretsovali study,
downregulation of Sall1 was achieved by siRNAs, which are known to potentially have severe off-target
effects. However, the Sall1 depleted mutants here described were generated with a site specific deletion,
with a careful selection of guide sequence which showed the less probability of off-target effects. As
such, it is possible that the detected effects on T and Nanog expression levels observed in the Kretsovali
study resulted from off-target effects by the used siRNAs. The unspecific targeting by the used siRNA was
further supported by the observation that depleting Sall1 in ESCs did not affect Nanog and T expression.
Med12 mutant ESCs showed a downregulation of Sall1 and expression changes in Nanog and T similar to
the described in the Kretsovali study (Figure 16c). This observation suggested that the siRNA targeted
unspecifically possible regulators of Sall1 that could also regulate expression of Nanog. Additionally,
clones without Sall1 grew at similar rates as WT cells, without any notorious defects in morphology, and
without evidence of differentiation (data not shown), suggesting that Sall1 was not essential for the
maintenance of pluripotency.
LN-BP18 overall levels, as well as TSS1 and TSS2 transcription were quantified in Sall1 depleted clones,
with a slight downregulation observed for all three (Figure 24c). A stronger effect in the TSS1 transcripts
was observed, with these 2-fold downregulated. As observed before, deletion of LN-BP18 TSS1, together
with most of Sall1 first intron did not affect the expression of the coding gene (Figure 22b). Additionally,
when TSS2 was deleted from one allele, decreasing the levels of LN-BP18, Sall1 expression was also
unaffected (Figure 22c). However, the deletion performed for Sall1 depletion, which was 9 kb away from
LN-BP18 TSS1, resulted in a mild downregulation of this lncRNA, an effect observed for both TSSs and its
overall levels (Figure 24c). These data suggested Sall1 as an activator of LN-BP18. However, the LN-BP18
expression in WT ESCs was very low and as such, it is possible that only mild effects resulting from Sall1
deficiency could be detectable. The detected low expression of LN-BP18 in Sall1 deficient ESCs can be
due to the basal expression level of this gene without a regulator activating it, or due to a weak active
transcription induced by a different factor. Additionally, as quantified by qPCR in Med12null mutants,
upon depletion of Med12, Sall1 and LN-BP18 TSS1 were 6 and 4-fold downregulated, respectively, while
TSS2 and overall LN-BP18 levels unaffected (Figure 16c). This suggested that Sall1 activates LN-BP18
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expression in a mechanism that is dependent of Med12. Additionally it reveals that Sall1 acts mainly on
TSS1 transcripts. This activating function would explain the co-expression of Sall1 and LN-BP18 in all
observed tissues and the fact that only TSS1 was active in differentiated cells. It would also explain why
in all analysed tissues Sall1 expression was on average 6-fold higher than LN-BP18 (Figure 10c), while in
WT ESC it was almost 40-fold higher (Figure 10d). This suggests that different mechanisms act in
activating transcription for each TSS, with Sall1 potentially activating transcription from TSS1 in a Med12
dependent mechanism. In contrast, the lack of effect on TSS2 transcription in Med12 deficient cells
(Figure 16c) suggested a Med12-independent mechanism activating TSS2 transcription.
4.7. Identification of lncRNAs as candidates of Med12 target genes
Analysis of the initial RNA-seq data (section 3.1) for Med12hypo and Med12null mutant ESC confirmed
several observations of a previous study where embryos were generated from these cells (Rocha et al.
2010), such as downregulation of canonical Wnt targets and misregulation of genes with a role in heart
development and neural tube closure, two striking phenotypes observed in these embryos. From
analysis of this RNA-seq data, hundreds of non-coding genes were also found misregulated in these
clones, including a novel gene designated as LN-BP18. While from RNA-seq data a 2-fold upregulation of
LN-BP18 was observed in Med12null mutants, qPCR data from the same cells revealed that the overall
levels of this lncRNA were not affected (Figure 10d and Figure 16c). As mentioned in the beginning of this
study, a critical aspect of RNA-seq data is to account for biological and technical variation through the
use of replicates. However, in the original RNA-seq data analysed only a replicate per clone was
generated. Without replicates from with to assess variation of expression and perform statistical tests on
the obtained gene expression, no confidence could be assigned to the observed variations in gene
expression between different mutants. For highly expressed genes that showed a big variation in their
expression between samples, the chance that such variation would be due to biological or technical
variation was very low. However for genes with a less evident change in expression or that were lowly
expressed, the chance of wrongly classifying them as misregulated was higher. As such, in order to
confirm the results obtained from the analysis of the original RNA-seq data and to generate a list of
lncRNAs that are putative targets of Med12, new RNA-seq data was generated using two replicates for
each Med12 deficient ESC. Additionally, transcriptome data for the Med12flox clone (Figure 6a), a mutant
that showed normal Med12 expression and mice generated from it showed no evident phenotype, was
also generated (Rocha et al. 2010). With these new samples, misregulated genes could be identified
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considering the fold change between samples but also the false discovery rate (FDR) could be calculated
for comparison of gene expression. Additionally, while the original RNA-seq data consisted of paired-end
reads of length 50 nt, for the new data paired-end reads of length 75 nt were generated. This longer
length increased the likelihood of obtained and successfully mapping spliced reads, which are critical for
more robust de novo gene assembly. Analyses of this new RNA-seq data also followed a different
pipeline than originally used. First, STAR was the aligner used, since with this tool more reads were kept
after removing reads not in a proper pair or with a mapping score below 10 (Figure 25a). Retaining more
reads after filtering increased the chances of detecting expression and significant changes in lowly
expressed genes. GenCODE is one of the databases with a more complete index of identified and
predicted non-coding genes (https://www.gencodegenes.org/). Thus, it was included in this analysis,
replacing the original RefSeq annotation used. Despite the extensive list of ncRNAs used, Cufflinks was
again used to assemble new genes not present in the annotation since it has been shown to reliably
predict novel genes, as demonstrated for LN-BP18. After removing small predicted transcripts or with a
single exon, this de novo assembly resulted in the addition of 420 putative new genes into the analysis.
Differential gene analyses was performed with Deseq2, a tool more reliable and sensitive than Cuffdiff
and that also associated a false discovery rate (FDR) value to the calculated fold change between
samples (Love et al. 2014).
Since sample-to-sample distances revealed that WT and Med12flox were the more similar samples, the
latter was used as control for differential gene analysis (Figure 25d). This choice allowed to account for
possible effects from the transformation protocol or the presence of Loxp sites used for generation of
Med12null and Med12hypo mutants, an effect described in previous studies (Qiu et al. 2011, Heffner et al.
2012). With this new pipeline, 150 annotated non-coding genes and 50 Cufflinks predictions were found
misregulated with |log2FC| >= log2 (1.5) and FDR < 0.05. Expression of ncRNAs was more similar
between both mutants than the expression of coding genes (Figure 26b), contrary to the original data
(Figure 8b). The discrepancy between the two datasets could have stemmed from the variability not
accounted for on the data without replicates or from the lower threshold used to classify genes as
misregulated on this section. On one hand, since with the newer data it was possible to have a statistical
confidence associated with the fold change obtained for each gene, a lower threshold could be used. On
the other hand, using smaller thresholds for the data in section 3.1 would have resulted in a big number
of genes being wrongly classified as misregulated when the fold changes observed resulted from the
associated biological or technical variation. Additionally, a new pipeline was used on the new analyses. If
this new pipeline had been applied to the original data, differences original gene expression would also
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have been observed, since different tools generate slightly different results even when used on the same
data. However this new pipeline was performed with more robust and sensitive tools. As such, even
though differences would arise from simply using a different pipeline analysis, a higher confidence in the
newer results would be obtained.
Over 1800 protein coding genes were found significantly misregulated in Med12hypo and/or in
Med12null. Gene ontology (GO) term enrichment analysis in the misregulated coding genes revealed
several terms that were also enriched in the original RNA-seq data, such as axon guidance and
angiogenesis (Table 1 and Figure 26e), supporting the main conclusion of the analysis of the original data.
Downregulation of Wnt targets was observed in the originally data and while some, such as Ccnd1 and
Tbx6, were also found downregulated in the new data, no significant change of expression was observed
for other targets, including T, Axin2 and Sall4. However, Wnt pathway was one of enriched GO terms in
misregulated genes observed for the new data (Figure 26e). These data confirm the observation that in
both RNA-seq datasets, misregulated genes are associated with the same pathways and biological
processes, despite the lack of concordance for some of these genes individually. As such, the new data
supports the conclusions reached after analysing the misregulated coding genes in the original data.The
RNA-seq data for Med12 mutant cells confirmed the downregulation of Wnt targets observed in
embryos generated from these cells.
In a recent study from the Schrewe group (data not published), gastruloids were formed using
Med12flox, Med12hypo and Med12null mutant ESC according to a previously published protocol (Baillie-
Johnson et al. 2015). These gastruloids consisted of ESC aggregates that formed a three dimensional
structure and that were able to differentiated and organize into structures resembling what is found in
embryos (van den Brink et al. 2014). After activating Wnt signalling, the round gastruloids formed from
Med12flox started elongating and germ layer specification into mesoderm was observed in the pole. T
expression was detected in this reagions, similarly to what was verified for embryonic axis elongation.
Although less efficiently, Med12hypo mutant gastruloids were also able to form these elongated
structures. However T expression was severely reduced at the pole. Med12null gastruloids failed to
elongate and were retained in their round structure, with no T expression detect. This behaviour
resembled what was found in Med12null embryos (Rocha et al. 2010), with no expression of T detected,
demonstrating a similar effect for Med12 deficiency both in vivo and in vitro. One of the GO terms found
enriched on misregulated coding genes in Med12 mutant ESC was cell adhesion, a process confirmed to
be disturbed in Med12null gastruloids, which formed multiple smaller aggregates, contrary to the
Med12flox and Med12hypoclones, for which a single aggregate was formed. Data obtained from gastruloids
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not only confirmed the developmental role of Med12 previously observed in mouse embryos, but also
confirmed observations from the analysis of Med12 deficient ESC transcriptome data.
One aspect not analysed in this study was the presence of a Med12 paralog, designated as Med12L.
This gene as not been studied as extensively as Med12. However it is known that its highly similar to
Med12 and that its integration in the Mediator complex is mutually exclusive to that of Med12 (Daniels
et al. 2013). It is possible that their similar protein sequence and similar position within the Mediator
allows some functional overlap between this paralogs. This is supported by a recent study where
mutations in Med12L have been identified in individuals with intellectual disability (Nizon et al. 2019).
These patients showed additionally abnormalities in the corpus callosum and mild defects in facial
morphology, features previously associated with Med12 mutations in humans (Risheg et al. 2007,
Schwartz et al. 2007).
The expression of Med12L was found upregulated over 1 fold in Med12hypo and over 2-fold in Med12null
mutants, consisting with a potential compensation of Med12 deficiency by Med12l. In order to study the
interaction between this two genes and to verify if Med12l does indeed compensate - up to certain
degree - Med12 depletion or Med12 represses Med12l expression, which would result in the increased
expression of Med12L upon Med12 depletion, will required the generation of Med12l deficient mutants
or even double Med12/Med12l deficient mutants.
Go term enrichment analysis revealed two biological processes enriched in the misregulated ncRNAs,
repression of viral genome and regulation of methylation (Figure 26f). Interestingly Ftx, which activates
Xist by preventing DNA methylation at its promoter, was one of the lncRNAs misregulated in Med12null.
However, despite inducing Xist expression, in the Med12null mutant, Xist was not misregulated (Figure
26d), suggesting that Ftx activates Xist through a Med12 dependent mechanism. However, Ftx
upregulation might have had no effect on Xist expression because this lncRNA acts on X chromosome
inactivation in female cells (Penny et al. 1996) and as mentioned before, all the cells used in this study
were male.
Over 200 ncRNAs were significantly misregulated in at least one of the Med12 mutant ESC, confirming
the importance of Med12 in the proper expression of non-coding genes. However, due to Med12 role in
multiple pathways, most of the effects were most likely indirect, resulting from misregulation of
regulators of these lncRNAs. In order to identify lncRNAs in which misregulation was directly mediated
by Med12, ChIP-seq data for this subunit was obtained for ESCs from a previous study (Kagey et al. 2010).
The rationale behind this analysis was if expression of a lncRNA is mediated directly by Med12, then this
subunit should be binding at their promoter and/or gene body, which can be identified through ChIP-seq.
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It was possible that Med12 regulated expression by bounding to a distal enhancer, however, in regions
with several genes in close proximity of this potential enhancer, assigning the enhancer to the proper
target gene would not be trivial. The majority of the identified Med12 binding regions were assigned to
coding genes, with almost 500 regions assigned to different non-coding genes (Figure 27b). Despite the
majority of ncRNAs with Med12 bound at either their promoter or gene body were not misregulated,
around 10% of misregulated ncRNAs contained at least one Med12 binding region (Figure 27d). This
suggested that Med12 mediated their expression. Interestingly, while analysing all classes of
misregulated genes with Med12 binding at their gene body, these genes were found either up or
downregulated with similar frequencies. However, almost 70% of genes with Med12 at promoter where
found downregulated, a similar fraction as when analysing only misregulated ncRNAs (Figure 27e). This
suggested that when Med12 is found at promoter of genes, it frequently mediates activation of their
expression.
Twelve lncRNAs were identified as good candidates for direct targets of Med12. They were significant
misregulated in Med12 deficient ESC and ChIP-seq data confirmed Med12 bind at their promoter and/or
gene body. Among these, four were Cufflinks predicted transcripts that showed no coding potential as
assessed by CPAT (data not shown). In order to evaluate these lncRNAs expression in vivo, RNA-seq data
generated from different embryonic tissues and across multiple developmental stages was analysed.
Knowing the temporal and spatial expression for these genes allows for better design the systems in
which to analyse them in future studies. Furthermore, since a number of lncRNAs act by regulating the
expression of their closest neighbours (Anderson et al. 2016, Paralkar et al. 2016), genes up to 100kb
away from the candidates Med12 targets were identified and their log2FC for both mutants plotted
(Figure 28). Misregulated genes within this window represent a starting point for identification of
possible targets of the lncRNAS. Interestingly, most of these lncRNAs are enriched in ESCs and for several
no expression was detected in analysed tissues. Cufflinks predictions, identified by their name “XLOC...”
were found exclusively in ESCs and even is these cells their expression was quite low which might explain
why they have not been previously identified. Among the twelve potential Med12 targets, some lncRNAs
have been preciously studied. Pltr26 has been associated with pluripotency in mESCs, an association
supported by the expression profile of this gene (Bergmann et al. 2015). However, despite its enrichment
in ESCs, its expression was also identified, even though lower levels, in embryonic heart. In this organ,
Platr26 expression as not been describe before and might represent a different function performed by
this lncRNA. Besides this lncRNA and Malat1, none of the identified genes have been previously studied,
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Various LN-BP18 mutant embryonic stem cells (ESCs) have been generated during this study.
Expression analysis of these ESCs might allow the identification of possible functions of this lncRNA. As
shown, LN-BP18 was lowly expressed in ESCs but showed a higher expression in embryonic tissues such
as pronephros, neural tube and limbs. Due to its higher expression in these tissues, perturbation of its
expression could provide important information regarding its expression and function tissues. As such,
analysis of LN-BP18 TSS1 mutant embryos generated by tetraploid complementation assay, should result
in embryos where no LN-BP18 is expressed (homozygous KO clones) or is downregulated (heterozygous
KO clones), allowing to assess its function.
With the same method, embryos were generated from the LN-BP18-β-gal reporter ESCs and the in
vivo expression of this lncRNA could be determined in a more sensitive way. Sectioning of these embryos
would allow generating a more detailed expression pattern for LN-BP18 in the developing embryo.
Additionally, by analysing the expression of LN-BP18 in additional mutant embryos, such as the
generated Sall1-KO mutants, specifically in the tissues where expression of LN-BP18 was observed using
the LN-BP18-β-gal reporter, the functional relation between these two genes could be determined
In mutants where LN-BP18 TSS1 transcripts were downregulated, an upregulation of Nanog and Oct4
was observed. If expression of LN-BP18 TSS1 isoforms is inversely correlated with expression of these
important pluripotency regulators, then upon upregulation of these non-coding transcripts, a
downregulation of the pluripotency regulators is expected. In order to confirm this hypothesis,
transformation of ESC with constructs on which different LN-BP18 isoforms are under the control of a
strong promoter, would allow an overexpression of these transcripts and assessment of their effect in
the expression of Nanog, Oct4 and additional pluripotency regulators, as well as other potential
interactors such as Sall1. Additionally, generation of embryos form cells overexpressing these isoforms
would allow detecting possible consequences of abnormally high levels of LN-BP18 in mouse
development. Furthermore, since generated data indicated that LN-BP18 TSS2 activity is restricted in ESC
and since no effect was observed on the expression of pluripotency markers upon its downregulation, it
is possible that upregulation of these transcripts would have quantifiable effects on pluripotency
associated genes. As such, embryo generating from cells overexpressing TSS2 transcripts would allow
assessing the impact of ectopic expression of LN-BP18 TSS2 transcripts in embryonic development. In
order to detect potential target genes of LN-BP18, chromatin isolation by RNA purification (CHIRP-seq)
could be used. By generating a biotin tagged version of LN-BP18, RNA-DNA complexes can be crosslinked,
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fragmented and purified using the biotin tag on LN-BP18 to identify binding sites for this lncRNA, which
would represent putative targets.
In the final section of this study, 12 different annotated and novel lncRNAs were identified as
misregulated upon Med12 depletion in ESCs and Med12 binding sites were identified in their
promoter/gene body, strongly suggesting that the expression of these genes was mediated by Med12.
The majority of these genes are predictions based on automatic gene assembly, and as such have not
been studied. Thus, similarly to what was performed to LN-BP18, their expression pattern and gene
structure needs to be identified. Then different mutations need to be generated in order to study their
function. Their expression pattern has been assessed in different embryonic tissues, representing a
starting point for future experiments analysing their expression pattern but also to further confirm any
identified expression domains. The neighbours of these candidate genes that were also misregulated in
Med12 deficient cells have been identified and assessing their expression upon perturbation of
candidate genes expression can confirm if these neighbours are indeed target genes.
These candidate genes represent lncRNAs which normal expression is dependent of Med12. On the
other hand, the detection of lncRNAs that interact with Med12 has not been addressed in this study. To
identify such non-coding transcripts, a method such as RNA Immunoprecipitation (RIP) can be used. A
previous attempt in performing RIP against Med12 was not successful, since the available anti-Med12
antibodies are not specific enough for this kind of method. To overcome this problem, different ESC and
mouse lines expressing Med12-tagged versions have been generated by the Schrewe group and




The function of the Mediator subunit Med12 on gene regulation has been widely studied and its
interaction and regulation of protein coding genes broadly documented. However, only recently has its
interaction with non-coding genes been verified. Analysis of transcriptome data from Med12 deficient
embryonic stem cells (ESCs) revealed hundreds of misregulated protein coding genes, including multiple
Wnt targets and genes involved in the developmental processes that were found affected in embryos
previously generated with these cells.
In addition to the protein coding genes, multiple misregulated non-coding genes were found during
the analysis of transcriptome data generated from Med12 mutant cells, including several putative novel
transcripts. Among these, an uncharacterized long non-coding (lnc)RNA was found to be differentially
expressed cells, tissues and mouse embryos. This gene, designated as LN-BP18, encodes for antisense
transcripts of Sall1, a gene also misregulated in the analysed cells. In humans, mutations in this gene are
associated with Townes-Brocks syndrome (TBS), which shows several overlapping characteristics with
MED12-associated X-linked intellectual disability syndromes. These features led to the deeper
characterization of LN-BP18.
Detailed gene and transcript analyses of this novel lncRNA led to the identification of two distinct
transcription start sites (TSSs), termed TSS1 and TSS2. While TSS1 was active in all analysed tissues, TSS2
was found active only in ESCs. In vitro differentiation of ESCs confirmed this observation, with expression
of transcripts originating from TSS1 increasing throughout the differentiation protocol, while the
opposite dynamic occurring for TSS2 transcripts. Characterization of the gene structure revealed a
complex splicing pattern, with its 7 exons spliced into 9 different isoforms, including spliced variants for
three of the exons. Multiple analyses confirmed the lack of coding potential of all identified isoforms.
BLAST searches revealed no homologous transcripts in other species, however, a non-conserved
predicted lncRNA was described in human, which was also present in a divergent configuration relative
to SALL1, suggesting a potential functional similarity to LN-BP18 despite the low sequence similarity.
Expression analyses of the different mutant ESCs generated revealed a dynamic expression of LN-
BP18. TSS2 transcripts, which were only detected in ESCs and not in embryonic tissues, showed a
positive correlation with different pluripotency markers. This correlation, together with the ESC-specific




Sall1 and LN-BP18 TSS1 transcripts were downregulated in Med12 depleted ESCs. Additionally, in
Sall1-depleted cells, LN-BP18 was downregulated, with a strong effect observed for the TSS1 transcripts
compared to TSS2. These observations, together with the co-expression of these two genes in embryonic
tissues, suggested LN-BP18, specifically the TSS1, as a target of Sall1 activation. This activation is
potentially Med12-dependent, since the effect on LN-BP18 expression was stronger upon Med12
depletion than in Sall1 deplete cells.
A heterozygous LN-BP18-β-galactosidase reporter mutant ESC line was generated to detect
expression of LN-BP18 in a more sensitive way. Expression of the reporter gene identified in addition to
embryonal limb and caudal end expression seen by whole mount in situ hybridization (WISH), a clear
expression in the pronephros, somites, neural tube, forebrain/midbrain- and midbrain/hindbrain-
boundaries, demonstrating the importance of this reporter line for studying LN-BP18 expression and
function during development.
Finally, RNA-seq data from Med12 depleted ESC mutant cells was analysed together with public
Med12 chromatin immunoprecipitation sequencing (ChIP-seq) data from ESCs. This analysis allowed
identifying 12 lncRNAs, both annotated as well as new predictions, representing candidate lncRNAs
whose expression is mediated by Med12. Compiled information for these genes presented here, offer
insight into possible systems to analyse these genes in future studies as well as putative targets.
Data from this thesis describe the genetic structure and expression of a previously uncharacterized
lncRNA. These data, together with the different mutants generated of this gene establish the ground





Die Funktion der “Mediator” Untereinheit Med12, bei der Genregulation wurde intensiv erforscht
und die Interaktionen von Med12 und seine Rolle bei der Regulation von proteinkodierenden Genen
sind gut dokumentiert. Erst kürzlich aber wurde die Interaktion von Med12 mit nicht -
proteinkodierenden (non-coding) Genen gefunden. Die Analyse von Transkriptomdaten von Med12
defizienten embryonalen Stammzellen (embryonic stem cells, ESC) zeigten hunderte von deregulierten
proteinkodierenden Genen, darunter zahlreiche Wnt Zielgene und Gene, die an bestimmten
Entwicklungsprozessen beteiligt sind, die auch in Med12 defizienten Embryonen beeinträchtigt sind.
Neben diesen proteinkodierenden Genen wurden auch zahlreiche non-coding Gene gefunden, darunter
auch einige mit bisher unbekannten Transkripten. Eine bisher uncharakterisierte lange nichtcodierende
RNA (long noncoding RNA, lncRNA) war in Zellen, Geweben und Mausembryonen differentiell exprimiert.
Dieses Gen, LN-BP18, generiert ein antisense Transkript zum Gen Sal1 welches in Med12 Mutanten
ebenfalls misreguliert ist. Im Menschen sind Mutationen in Sal1 mit dem Townes-Brocks Syndrom (TBS)
assoziiert, das mehrere Merkmale von mit Med12 assoziierten Syndromen X-chromosomaler mentaler
Retardierung aufweist. Diese Umstände waren ausschlaggebend für eine nähere Charakterisierung von
LN-BP18.
Eine detaillierte Analyse des Gens und seiner Transkripte führte zur Identifizierung von zwei
unterschiedlichen Transkriptionsstarts (transcription start sites, TSS), die als TSS1 und TSS2 bezeichnet
wurden. Währen TSS1 in allen analysierten Geweben aktiv war, zeigte TSS2 nur in ES-Zellen Aktivität. Die
Untersuchung von in vitro differenzierten ES-Zellen bestätigte diesen Befund. Hier zeigten sich, dass die
Aktivität der TSS1 während der Differenzierung zunahm, während TSS2 reduzierte Aktivität zeigte. Die
Charakterisierung des Gens zeigte ein komplexes Splicingmuster, die 7 Exons werden zu 9 verschiedene
Isoformen kombiniert. Ausserdem gibt es Spleißvarianten von drei Exons. Verschiedene Analysen
bestätigten die Abwesenheit einer proteinkodierenden Sequenz in allen identifizierten Isoformen. BLAST
Analysen zeigten keine homologen Transkripte in anderen Spezies. Allerdings wurde eine nicht
konservierte lncRNA im Menschen beschrieben, die ebenfalls in entgegengesetzter Richtung zu Sal1
transkribiert wird, was trotz der geringen Sequenzähnlichkeit auf eine mögliche funktionelle
Gemeinsamkeit mit LN-BP18 hinweisen könnte.
Die Expressionsanalyse der verschiedenen mutanten ES-Zellinien zeigte ein dynamisches
Expressionsmuster von LN-BP18. TSS2 Transkripte, die nur in ES-Zellen, nicht aber in embryonalen
Geweben detektiert wurden zeigten eine positive Korelation mit verschiedenen Markern für Pluripotenz.
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Dies, sowie die ES-zellspezische Aktivierung dieser TSS deutete auf eine mögliche Rolle dieser Transkripte
im Pluripotenz-Netzwerk hin.
Sal1 und LN-BP18 zeigten verringerte Expression in Med12 defizienten ES-Zellen. Außerdem war LN-
BP18 in Sal1 defizienten Zellen herunterreguliert. Dies war für TSS1 Transkripte ausgeprägter als für TSS2
Transkripte. Dies, und die Co-Expression der beiden Gene in embryonalen Geweben deutete darauf hin,
dass die TSS1 von LN-BP18 durch Sal1 reguliert wird. Diese Aktivierung ist möglicherweise Med12
abhängig, da der Effekt auf die LN-BP18 expression bei Med12 defizienten Zellen stärker war als bei Sal1
Defizienz.
Um die Expression von LN-BP18 genauer zu untersuchen, wurde eine heterozygote LN-BP18-β-
Galactosidase Reporterlinie generiert. In Mäusen dieser Linie zeigte sich die Expression des Reportergens
außer in den embryonalen Gliedmaßen und dem kaudalen Ende, die auch bei in situ Hybridisierung
sichtbar war, im Pronephros, den Somiten, dem Neuralrohr, der Vorderhirn-Mittelhirn- sowie der
Mittelhirn-Hinterhirngrenze. Dies zeigt die Nützlichkeit dieser Reporterlinie bei der Untersuchung der LN-
BP18 Expression und seiner Funktion während der Entwicklung.
Schließlich wurden RNA-seq Daten von Med12 defizienten ES-Zellen zusammen mit öffentlich
zugänglichen Med12 „chromatin immunoprecipitation sequencing“ (ChIP-seq) Daten analysiert. Hier
wurden 12 LncRNAs gefunden, die teilweise noch nicht annotiert waren. Diese sind möglicherweise
durch Med12 reguliert. Hier durchgeführte erste Untersuchungen dieser Gene ermöglichen eine
Eingrenzung Ihres Funktionszusammenhanges für eine zukünftige funktionelle Analyse.
Diese Arbeit beschreibt die Genstruktur und Expression einer bisher uncharakterisierten lncRNA. Diese
Analysen und die verschiedenen Mutanten, die in dieser Arbeit erzeugt wurden legen den Grundstein für
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Supplementary Figure 1 - Misregulated novel putative new lncRNAs.
Browser view of experimentally obtained gene structure for the identified misregulated putative lncRNAs
predicted by Cufflinks. Mapped reads from the 3 samples, red track; structure obtained for the genes





Supplementary Table 1 - Primers used to generate gRNA for CRISPR-Cas9 targeted DSB generation.
In red are the bases added in order to generate compatible ends for proper ligation into vector. In green
are the bases added so that the first base after the U6 promoter that drives gRNA expression is a
guanidine, since transcription from this promoter is more efficient if the first base is a guanidine.
Target location Forward primer Reverse primer
Sall1 intron 2 CACCGAAACTAATTTGTAGTCGTTC AAACGAACGACTACAAATTAGTTTC
Sall1 exon 4 CACCGCCGGATTAAGACCGCCTAGC AAACGCTAGGCGGTCTTAATCCGGC
LN-BP18 exon 4 CACCGCGGAGATCAGCTGCAGCTCA AAACTGAGCTGCAGCTGATCTCCGC
LN-BP18 5’ of TSS1 CACCGTCAAAATTACGGAAATCGAG AAACCTCGATTTCCGTAATTTTGAC
LN-BP18 Intron 1 CACCGTTTCCGACACTTGCTACGTG AAACCACGTAGCAAGTGTCGGAAAC
Ln-BP18 intron 2 CACCGTGGCTTGCAATGGCCAGTTT AAACAAACTGGCCATTGCAAGCCAC
LN-BP18 Intron 3 CACCGAAGCTCTCGACCGTTTCATC AAACGATGAAACGGTCGAGAGCTTC
Supplementary Table 2 - Primers used for screening engineered mutations
Supplementary Table 3 - PCR reaction
Taq polymerase Takara polymerase
Component µl Component µl
Buffer 10x 2.50 5X PrimeSTAR Buffer (Mg2+ Plus) 5
MgCl2 (50mM) 0.75 NTP Mixture (2.5 mM each) 2
dNTPs (10mM) 0.50 Primer Fwd (100uM) 0.1
Primer Fwd (100uM) 0.05 Primer Rev (100uM) 0.1
Primer Rev (100uM) 0.05 PrimeSTAR HS DNA Polymerase 0.25
Taq 0.15 H2O 17.05
Template 0.50
H2O 20.5
Genomic Feature Forward primer Reverse primer
1 5’ Β-gal insertion border ATGCTGCCTCCTGAAATGGT GAATCTCCACTCGCCGTTCA
2 LN-BP18 Exon 4 WT ATGCTGCCTCCTGAAATGGT GCCATACAACCTCAATGGGGA
3 LN-BP18 3’ border Deletion TSS1 GCCTGGCTCGGAGATCCTTC ACCCGGAAGAGGGAGTACAG
4 LN-BP18 TSS1 flanking deletion CTTCGGGGTCGGATTGGAAA ACCCGGAAGAGGGAGTACAG
5 LN-BP18 3’ border Deletion TSS2 CCCCTACACCTCTCCCAACT ATCCCGCTTTACACTCGTCG
6 LN-BP18 TSS2 flanking deletion GCCATGTACGTGTCCTGGTT ATCCCGCTTTACACTCGTCG
7 Sall1 5’ Border deletion WT TGTGAGGGATAACCATCCTGC CTTGCTCTTAGTGGGGCGAC
8 Sall1 flanking deletion TGTGAGGGATAACCATCCTGC CCTCTAAAGAATTCTGCGTGC
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Supplementary Table 4 - PCR run method
Step Temperature Time Cycles
Initial denaturation 94°C 5min 1
Denaturation 94°C 30sec 40
Annealing 60°C 30sec 40
Elongation 72°C 30sec 40
Final elongation 72°C 7min 1
Supplementary Table 5 - qPCR run method
Step Temperature Time Cycles
Initial denaturation 95°C 2min 1
Denaturation 95°C 15sec 40
Elongation 60°C 30sec 40
Melt Curve 95°C 15sec 1
60°C 15sec 1
95°C 15sec 1
Supplementary Table 6 - Primers used for qPCR quantification





















Supplementary Table 7 - Primers used for putative new lncRNAs isolation

























Supplementary Table 8 - Primers used during RACE protocol
Primer Gene Location Primer sequence
1 LN-BP18 exon7 #1 CTGCGACGGTTCATGTGATT
2 LN-BP18 exon7 #2 GCCATGCTGCAGTCTTGAA
3 LN-BP18 exon4 CACGGTGCCATAGCAGCTC
4 LN-BP18 exon1 #1 GAGTGGAGAACTCTGGGCGA
5 LN-BP18 exon1 #2 GGCTGCTTTCTGGTAGCTCT
6 LN-BP18 exon1 #3 GAACACTCACGAAATGGGGC
7 LN-BP18 exon3 #1 CTGCAGAACAAACGCTGTGG
8 LN-BP18 exon3 #2 TGTCCATAACTCAGGGCAACA
9 LN-BP18 exon4 #1 GTAAAAAGGCAGAGACTGCTGG
10 LN-BP18 exon4 #2 GAGCTGCTATGGCACCGTGA
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Supplementary Table 9 - Antibodies used for Western Blot
Antibody Host Supplier Dilution
α-Sall1 Rabbit ab31526; Abcam 1:700
α-β-actin Mouse A5441, Sigma-Aldrich 1:20000
α-H3 Rabbit ab1791, Abcam 1:5000
α-GapdH Rabbit 5174, Cell Signaling 1:1000
α-Rabbit-HRP Goat 111-035-003, Jackson ImmunoResearch 1:5000
α-Mouse-HRP Goat 115-035-003, Jackson ImmunoResearch 1:5000
Supplementary Table 10 - Transcriptome data downloaded from the Encode database to assess tissue
expression of lncRNAs
Tissue Sample Tissue Sample Tissue Sample
Liver E11.5 ENCFF734KYK Limb E14.5 ENCFF888CQF forebrain E12.5 ENCFF604YPA
Liver E12.5 ENCFF527RRL Limb E15.5 ENCFF214NGX forebrain E13.5 ENCFF652LRB
Liver E13.5 ENCFF039JSB Lung E14.5 ENCFF674RZX forebrain E14.5 ENCFF242VUV
Liver E14.5 ENCFF915IMF Lung E15.5 ENCFF099TSL forebrain E15.5 ENCFF370MZR
Liver E15.5 ENCFF257DUT Lung E16.5 ENCFF765KXH forebrain E16.5 ENCFF130CQI
Liver E16.5 ENCFF487NRJ Lung day0 ENCFF471KGO forebrainday0 ENCFF190EHR
Liver day0 ENCFF774ZXX neural tube E11.5 ENCFF485QMJ midbrain E11.5 ENCFF739IFQ
Heart E10.5 ENCFF655GAO neural tube E12.5 ENCFF413LWR midbrain E12.5 ENCFF107QWR
Heart E11.5 ENCFF276KTU neural tube E13.5 ENCFF358GZH midbrain E13.5 ENCFF750QEC
Heart E12.5 ENCFF716KQU neural tube E14.5 ENCFF403FVS midbrain E14.5 ENCFF112LWR
Heart E13.5 ENCFF709XPI neural tube E15.5 ENCFF351DAS midbrain E15.5 ENCFF287UJS
Heart E14.5 ENCFF808WIM neural tube day0 ENCFF685ICX midbrain E16.5 ENCFF864PZZ
Heart E15.5 ENCFF457OAN stomach E14.5 ENCFF643WID midbrain day0 ENCFF398USF
Heart E16.5 ENCFF527FHQ stomach E15.5 ENCFF545CDS hindbrain E10.5 ENCFF844SJF
Heart day0 ENCFF081UNH stomach E16.5 ENCFF929PNC hindbrain E11.5 ENCFF622NTO
Kidney E14.5 ENCFF913EKF stomach day0 ENCFF563UZS hindbrain E12.5 ENCFF961UYK
Kidney E15.5 ENCFF850SDV thymus day0 ENCFF014KTI hindbrain E13.5 ENCFF372BPJ
Kidney E16.5 ENCFF635AXY intestine E14.5 ENCFF694HJE hindbrain E14.5 ENCFF484FNM
Kidney day0 ENCFF769XWI intestine E15.5 ENCFF790QQF hindbrain E15.5 ENCFF215SES
Limb E10.5 ENCFF752XWD intestine E16.5 ENCFF281HBX hindbrain E16.5 ENCFF804RYC
Limb E11.5 ENCFF076RLX intestine day0 ENCFF596ATI hindbrain day0 ENCFF852ZHY
Limb E12.5 ENCFF946JHJ forebrain E10.5 ENCFF046NCT
Limb E13.5 ENCFF759OCS forebrain E11.5 ENCFF275ARE
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Supplementary Table 12 - Go terms enriched in misregulated protein coding genes.
Cluster Go term p-value
1 translation 1.26E-07
ribosomal small subunit assembly 1.34E-05
oxidation-reduction process 3.01E-04
cytoplasmic translation 3.49E-04
ribosomal small subunit biogenesis 1.58E-02
carbohydrate metabolic process 2.12E-02
protein homotetramerization 2.70E-02
monocyte chemotaxis 3.56E-02
lipid metabolic process 3.60E-02
immune response 3.61E-02
cardiac muscle contraction 4.19E-02
2 negative regulation of transcription from RNA
polymerase II promoter
8.98E-10
positive regulation of transcription, DNA-templated 4.60E-06




positive regulation of cell proliferation 2.48E-04
regulation of cell proliferation 4.39E-04
response to mechanical stimulus 5.33E-04
mammary gland development 9.04E-04
heart development 1.21E-03
transcription, DNA-templated 1.38E-03
regulation of transcription, DNA-templated 1.43E-03
mammary gland duct morphogenesis 2.12E-03
response to corticosterone 3.59E-03
cellular response to peptide 6.45E-03
axon guidance 6.63E-03
palate development 7.35E-03
3 outer dynein arm assembly 9.46E-04
inflammatory response 1.05E-03
positive regulation of phagocytosis 4.28E-03










outflow tract septum morphogenesis 5.17E-02
4 regulation of transcription, DNA-templated 2.14E-17
transcription, DNA-templated 3.63E-17
positive regulation of transcription from RNA
polymerase II promoter
5.79E-13
positive regulation of transcription, DNA-templated 9.96E-10
negative regulation of transcription from RNA
polymerase II promoter
6.15E-06
regulation of gene expression 8.24E-06
axon guidance 6.27E-05
covalent chromatin modification 2.24E-04
positive regulation of cell proliferation 4.05E-04
circadian rhythm 4.29E-04
patterning of blood vessels 5.99E-04
embryonic hemopoiesis 1.06E-03
negative regulation of keratinocyte proliferation 1.06E-03
negative regulation of transcription, DNA-templated 1.25E-03
multicellular organism development 1.30E-03






positive regulation of gene expression 4.51E-03
hepatocyte apoptotic process 4.96E-03
negative regulation of apoptotic process 1.12E-02
meiotic cell cycle 2.10E-02
positive regulation of sequence-specific DNA binding
transcription factor activity
2.20E-02
negative regulation of peptidase activity 2.67E-02
positive regulation of tumor necrosis factor
production
2.86E-02




collagen-activated tyrosine kinase receptor signaling
pathway
3.88E-02
regulation of nucleocytoplasmic transport 3.88E-02
brain development 4.08E-02




negative regulation of RNA polymerase II regulatory
region sequence-specific DNA binding
5.76E-02
negative regulation of glycolytic process 6.69E-02
positive regulation of angiogenesis 7.21E-02
phagocytosis, engulfment 7.60E-02
positive regulation of calcium ion import 7.60E-02








CAGE Cap analysis gene expression
ChIP chromatin Immunoprecipitation
cDNA complementary DNA
DSB double strand break
E embryonic day
FDR false discovery rate
FACS fluorescence-activated cell sorting
FC fold change
FPKM fragments per kilo base per million mapped reads
GO gene ontology
GSP gene specific primer
kb kilo bases
lncRNA long non-coding RNA
mRNA messenger RNA
mESC mouse embryonic stem cells
ncRNA non-coding RNA
ncRNA-a non-coding RNA-activating
ORF open reading frame
pA polyadenylation
PCR polymerase chain reaction
PIC pre-initiation complex
PAM protospacer adjacent motif
qPCR quantitative real-time PCR
RACE Rapid Amplification of cDNA Ends
Pol II RNA polymerase II
RT room temperature
TBS Townes-Brocks syndrome
TES transcription end site
TSS transcription start site
WISH whole-mount in situ hybridization
WT wild type
XCI X chromosome inactivation
XLID X chromosome linked intellectual disability syndromes
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174
93 1 2 for “strong was” read “strong signal was ”;
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